RECOMBINANT PROTEIN PRODUCTION IN BOVINE ADENOVIRUS EXPRESSION VECTOR SYSTEM

Abstract: The present invention relates to novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.

Description: 5 RECOMBINANT PROTEIN PRODUCTION IN BOVINE ADENOVIRUS EXPRESSION VECTOR SYSTEM Technical Field The present invention relates novel bovine 10 adenovirus (BAV) expression vector systems in which one or both of the early region 1 (El) and the early region 3 (E3) gene deletions are replaced by a foreign gene and novel recombinant mammalian cell lines stably transformed with BAV El sequences, and therefore, 15 expresses El gene products, to allow a bovine adenovirus with an El gene deletion replaced by a foreign gene to replicate therein. These materials are used in production of recombinant BAV expressing heterologous (antigenic) polypeptides or fragments for 20 the purpose of live recombinant virus or subunit vaccines or for other therapies. Background of the Invention The adenoviruses cause enteric or 25 respiratory infection in humans as well as in domestic and laboratory animals. The bovine adenoviruses (BAVs) comprise at least nine serotypes divided into two subgroups. These subgroups have been characterized based on 30 enzyme-linked immunoassays (ELISA) , serologic studies with immunofluorescence assays, virus-neutralization r J j tests, immunoelectron microscopy, by their host ' specificity and clinical syndromes. Subgroup 1 viruses include BAV 1, 2, 3 and 9 and grow relatively 35 well in established bovine cells compared to subgroup 2 which includes BAV 4, 5, 6, 7 and 8. BAV3 was first isolated in 1965 and is the best characterized of the BAV genotypes and contains a genome of approximately 35 kb (Kurokawa et al (1978) J. Virol. 8:212-218) . The locations of hexon (Hu et al (1984) J. Viol. 4_9:604-608) and proteinase (Cai et al., (1990) Nuc. Acids Res.. JL8_:5568), genes in the BAV3 genome have been identified and sequenced. However, the location and sequences of other genes such as early region 1 (El) and 3 (E3) in the BAV genome have not been reported. In the human adenovirus (HAd) genome there are two important regions: El and E3 in which foreign genes can be inserted to generate recombinant adenoviruses (Berkner and Sharp (1984) Nuc. Acid Res. , 11:1925-1941 and Haj-Ahmad and Graham (1986) J. Virol. , 57:267-274). El proteins are essential for virus replication in tissue culture, however, conditional-helper adenovirus recombinants containing foreign DNA in the El region, can be generated in a cell line which constitutively expresses El (Graham et al., (1977) J. Gen. Virol.. 36:59-72). In contrast, E3 gene products of HAd 2 and HAd 5 are not required for in vitro or in vivo infectious virion production, but have an important role in host immune responses to virus infection (Andersson et al (1985) Cell 43:215- 222; Burgert et al (1987) EMBO J. 6 :2019-2026; Carlin et al (1989) Cell 5_7:135-144; Ginsberg et al (1989) PNAS. USA 86:3823-3827; Gooding et al (1988) Cell 5_3:341-346; Tollefson et al (1991) J. Virol. 65:3095- 3105; Wold and Gooding (1989) Mol. Biol. Med. .6:433- 452 and Wold and Gooding (1991) Virology 184:1-8) . The E3-19kiloDalton (kDa) glycoprotein (gpl9) of human adenovirus type 2 (HAd2) binds to the heavy chain of a number of class 1 major histocompatibility complex (MHC) antigens in the endoplasmic reticulum thus inhibiting their transport to the plasma membrane (Andersson et al. (1985) Cell 4_3:215-222; Burgert and Kvist, (1985) Cell 41:987-997; Burgert and Kvist, (1987) EMBO J. 6:2019-2026.. The E3-14.7kDa protein of HAd2 or HAd5 prevents lysis of virus-infected mouse cells by tumor necrosis factor (TNF) (Gooding et al. (1988) cell 53:341-346) . In addition, the E3-10.4kDa and E3-14.5kDa proteins form a complex to induce endosomal-mediated internalization and degradation of the epidermal growth factor receptor (EGF-R) in virus- infected cells (Carlin et al. Cell 5_7:135-144; Tollefson et al. (1991) J. Virol. £5:3095-3105). The helper-independent recombinant adenoviruses having foreign genes in the E3 region replicate and express very well in every permissive cell line (Chanda et al (1990) Virology 175:535-547; Dewar et al (1989) J. Virol. £3:129-136; Johnson et al (1988) Virology 164:1-14; Lubeck et al (1989) PNAS, USA 8£:6763-6767; McDermott et al (1989) Virology 169:244-247; Mittal et al (1993) Virus Res. 18:67-90; Morin et al (1987) PNAS. USA 81:4626-4630; Prevec et al (1990) J. Inf. Pis. 161:27-30; Prevec et al (1989) J. Gen. Virol. 20:429-434; Schneider et al (1989) J. Gen. Virol. 20:417-427 and Yuasa et al (1991) J. Gen. Virol. 22:1927-1934). Based on the above studies and the suggestion that adenoviruses can package approximately 105% of the wild-type (wt) adenovirus genome (Bett et al (1993) J. Virol. £2:5911-5921 and Ghosh-Choudhury et al (1987) EMBO. J. £:1733-1739) , an insertion of up to 1.8 kb foreign DNA can be packaged into adenovirus particles for use as an expression vector for foreign proteins without any compensating deletion. It is assumed that an indigenous adenovirus vector would be better suited for use as a live recombinant virus vaccine in different animal species compared to an adenovirus of human origin. Non-human adenovirus-based expression vectors have not been reported so far. If like HAds E3, the E3 regions in other adenoviruses are not essential for virus replication in cultured cells, adenovirus recombinants containing foreign gene inserts in the E3 region could be generated. BAV3 is a common pathogen of cattle usually resulting in subclinical infection though occasionally associated with a more serious respiratory tract infection (Darbyshire et al., 1966 Res. Vet Sci 2:81- 93; Mattson et al., 1988 J. Vet Res 49_:67-69). BAV3 can produce tumors when injected into hamsters (Darbyshire, 1966 Nature 211:102) and viral DNA can efficiently effect morphological transformation of mouse, hamster or rat cells in culture (Tsukamoto and Sugino, 1972 J. Virol. 9:465-473: Motoi et al., 1972 Gann £3 . :415-418; M. Hitt, personal communication). Cross hybridization was observed between BAV3 and human adenovirus type 2 (HAd2) (Hu et al., 1984 J. Virol. 19_:604-608) in most regions of the genome including some regions near but not at the left end of the genome. The E1A gene products of the group C human adenoviruses have been very extensively studied and shown to mediate transactivation of both viral and cellular genes (Berk et al., 1979 Cell 17:935-944; Jones and Shenk, 1979 Cell 1£:683-689; Nevins, 1981 Cell 2£:213-220; Nevins, 1982 Cell 29:913-919; reviewed in Berk, 1986 Ann. Res. Genet 10.:45-79), to effect transformation of cells in culture (reviewed in Graham, F.L. (1984) "Transformation by and oncogenicity of human adenoviruses. In:The Adenoviruses." H.S. Ginsberg, Editor. Plenum Press, New York; Branton et al., 1985 Biochim. Biophys. Acta 780:67-94) and induce cell DNA synthesis and mitosis (Zerler et al., 1987 Mol. Cell Biol. 2:821-929; Bellet et al., 1989 J. Virol. £3:303-310; Howe et al., 1990 PNAS. USA 82:5883-5887; Howe and Bayley, 1992 Virology 186:15-24) . The E1A transcription unit comprises two coding sequences separated by an intron region which is deleted from all processed E1A transcripts. In the two largest mRNA species produced from the E1A transcription unit, the first coding regions is further subdivided into exon 1, a sequence found in both the 12s and 13s mRNA species, and the unique region, which is found only in the 13s mRNA species. By comparisons between E1A proteins of human and simian adenoviruses three regions of somewhat conserved protein sequence (CR) have been defined (Kimelman et al., 1985 J. Virol. 53.:399-409) . CR1 and CR2 are encoded in exon 1, while CR3 is encoded in the unique sequence and a small portion of exon 2. Binding sites for a number of cellular proteins including the retinoblasto a protein Rb, cyclin A and an associated protein kinase p33 cd2 , and other, as yet unassigned, proteins have been defined in exon 1 encoded regions of E1A proteins (Yee and Branton, 1985 Virology 112:142-153; Harlow et al., 1986 Mol. Cell Biol. £:1579-1589; Barbeau et al., 1992 Biochem. Cell Biol. 20:1123-1134). Interaction of E1A with these cellular proteins has been implicated as the mechanism through which E1A participates in immortalization and oncogenic transformation (Egan et al, 1989 Oncogene 1:383-388; Whyte et al., 1988 Nature 131:124-129; Whyte et al, 1988 J. Virol. £2:257-265). While E1A alone may transform or immortalize cells in culture, the coexpression of both E1A and either the ElB-19k protein or the ElB-55k protein separately or together is usually required for high frequency transformation of rodent cells in culture (reviewed in Graham, 1984 supra; Branton et al., 1985 supra; McLorie et al. , 1991 J. Gen Virol. 72:1467-1471). Transactivation of other viral early genes in permissive infection of human cells is principally mediated by the amino acid sequence encoded in the CR3 region of E1A (Lillie et al., 1986 Cell 46:1043-1051) . Conserved cysteine residues in a CysX 2 CysX 13 CysX 2 Cys sequence motif in the unique region are associated with metal ion binding activity (Berg, 1986 supra) and are essential for transactivation activity (Jelsma et al., 1988 Virology 163:494-502: Culp et al., 1988 PNAS. USA £5:6450-6454) . As well, the amino acids in CR3 which are immediately amino (N)-terminal to the metal binding domain have been shown to be important in transcription activation, while those immediately carboxy (C)-terminal to the metal binding domain are important in forming associations with the promoter region (Lillie and Green, 1989 Nature 338:39-44; see Fig. 3). The application of genetic engineering has resulted in several attempts to prepare adenovirus expression systems for obtaining vaccines. Examples of such research include the disclosures in U.S. patent 4,510,245 on an adenovirus major late promoter for expression in a yeast host; U.S. patent 4,920,209 on a live recombinant adenovirus type 7 with a gene coding for hepatitis-B surface antigen located at a deleted early region 3; European patent 389 286 on a non-defective human adenovirus 5 recombinant expression system in human cells for HCMV major envelope glycoprotein; WO 91/11525 on live non- pathogenic immunogenic viable canine adenovirus in a cell expressing Ela proteins; French patent 2 642 767 on vectors containing a leader and/or promoter from the E3 of adenovirus 2. The selection of a suitable virus to act as a vector for foreign gene expression, and the identification of a suitable non-essential region as a site for insertion of the gene pose a challenge. In particular, the insertion site must be non-essential for the viable replication of the virus and its effective operation in tissue culture and also in vivo. Moreover, the insertion site must be capable of accepting new genetic material, whilst ensuring that the virus continues to replicate. An essential region of a virus genome can also be utilized for foreign gene insertion if the recombinant virus is grown in a cell line which complements the function of that particular essential region in trans. The present inventors have now identified suitable regions in the BAV genome and have succeeded in inserting foreign genes to generate BAV reco binants. Disclosure of the Invention The present invention relates to novel bovine adenovirus expression vector systems in which part or all of one or both of the El and E3 gene regions are deleted and to recombinant mammalian cell lines of bovine origin transformed with the BAV El sequences, and thus, constitutively express the El gene products to allow bovine adenovirus, having a deletion of part or all of the El gene region replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof, to replicate therein and use of these materials in production of heterologous (antigenic) polypeptides or fragments thereof. The invention also related to a method of preparing a live recombinant virus or subunit vaccines for producing antibodies or cell mediated immunity to an infectious organism in a mammal, such as bovine, which comprises inserting into the bovine adenovirus genome the gene or fragment coding for the antigen which corresponds to said antibodies or induces said cell mediated immunity, together with or without an effective promoter therefore, to produce BAV recombinants. Generally, the foreign gene construct is cloned into a nucleotide sequence which represents only a part of the entire viral genome having one or more appropriate deletions. This chimeric DNA sequence is usually present in a plasmid which allows successful cloning to produce many copies of the sequence. The cloned foreign gene construct can then be included in the complete viral genome, for example, by in vivo recombination following a DNA-mediated cotransfection technique. Multiple copies of a coding sequence or more than one coding sequences can be inserted so that the recombinant vector can express more than one foreign protein. The foreign gene can have additions, deletions or substitutions to enhance expression and/or immunological effects of the expressed protein. The invention also includes an expression system comprising an bovine adenovirus expression vector wherein heterologous nucleotide sequences with or without any exogenous regulatory elements, replace the El gene region and/or part or all of the E3 gene region. The invention also includes (A) a recombinant vector system comprising the entire BAV DNA and a plasmid or two plasmids capable of generating a recombinant virus by in vivo recombination following cotransfection of a suitable cell line comprising BAV DNA representing the entire wild-type BAV genome and a plasmid comprising a bovine adenovirus left or right end sequences containing the El or E3 gene regions, respectively, with a heterologous nucleotide sequence encoding a foreign gene or fragment thereof substituted for part or all of the El or E3 gene regions; (B) a live recombinant bovine adenovirus vector (BAV) system selected from the group consisting of: (a) a system wherein part or all of the El gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof; (b) a system wherein a part or all of the E3 gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof; and (c) a system wherein part or all of the El gene region and part or all of the E3 gene region are deleted and a heterologous nucleotide sequence encoding a foreign gene or fragment thereof is inserted into at least one of the deletions;. (C) a recombinant bovine adenovirus (BAV) comprising a deletion of part or all of El gene region, a deletion of part or all of E3 gene region or deletion of both, and inserted into at least one deletion a heterologous nucleotide sequence coding for an antigenic determinant of a disease causing organism; (D) a recombinant bovine adenovirus expression system comprising a deletion of part or all of El, a deletion of part or all of E3, or both deletions, and inserted into at least one deletion a heterologous nucleotide sequence coding for a foreign gene or fragment thereof under control of an expression promoter: or (E) a recombinant bovine adenovirus (BAV) for producing an immune response in a mammalian host comprising: (1) BAV recombinant containing a heterologous nucleotide sequence coding for an antigenic determinant needed to obtain the desired immune response in association with or without (2) an effective promoter to provide expression of said antigenic determinant in immunogenic quantities for use as a live recombinant virus or recombinant protein or subunit vaccine; (F) a mutant bovine adenovirus (BAV) comprising a deletion of part or all of El and/or a deletion of part or all of E3. Recombinant mammalian cell lines stably transformed with BAV El gene region sequences, said recombinant cell lines thereby capable of allowing replication therein of a bovine adenovirus comprising a deletion of part or all of the El or E3 gene regions replaced by a heterologous or homologous nucleotide sequence encoding a foreign gene or fragment thereof. The invention also includes production, isolation and purification of polypeptides or fragments thereof, such as growth factors, receptors and other cellular proteins from recombinant bovine cell lines expressing BAV El gene products. The invention also includes a method for providing gene therapy to a mammal in need thereof to control a gene deficiency which comprises administering to said mammal a live recombinant bovine adenovirus containing a foreign nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in a target organ or tissue. Another aspect of the invention provides a virus vaccine composition which comprises the recombinant virus or recombinant protein in association with or without a pharmaceutically acceptable carrier. The recombinant virus vaccine can be formulated for administration by an oral dosage (e.g. as an enteric coated tablet) , by injection or otherwise. More specifically, these include a vaccine for protecting a mammalian host against infection comprising a live recombinant adenovirus or recombinant protein produced by the recombinant adenovirus of the invention wherein the foreign gene or fragment encodes an antigen and formulated with or without a pharmaceutically acceptable carrier. The invention also includes methods of producing antibodies or cell mediated immunity in a mammal including (1) a method for eliciting an immune response in a mammalian host against an infection comprising: administering a vaccine comprising a live BAV recombinant of the invention wherein the foreign gene or fragment encodes an antigen with or without a pharmaceutically acceptable carrier, and (2) a method for eliciting an immune response in a mammalian host against an infection comprising: administering a vaccine comprising a recombinant antigen prepared by culturing a BAV recombinant wherein the foreign gene or fragment encodes the desired antigen with or without a pharmaceutically acceptable carrier. The following disclosure will render these and other embodiments of the present invention readily apparent to those of skill in the art. While the disclosure often refers to bovine adenovirus type 3 (BAV3) , it should be understood that this is for the purpose of illustration and that the same features apply to bovine adenovirus of the other type, l, 2, 4, 5, 6, 7 8, and 9 and the invention described and claimed herein is intended to cover all of these bovine adenovirus types. Brief Description of the Drawings Figure 1. Sequence and major open reading frames of the left 11% of the BAV3 genome. The region comprises the El and protein IX transcription region. The 195 nucleotide inverted terminal repeat sequence identified by Shinagawa et al., 1987 Gene 5_5:85-93 is shown in italics . The amino acid sequence for the largest ElA protein, two E1B proteins and protein IX are presented. The probable splice donor ([), splice acceptor (]) and intron sequence (underlined italics) within the ElA region are marked. A 35 base pair repeat sequence between ElA and E1B is indicated in bold underline. Possible transcription promoter TATA sequences and possible poly A addition sequences AATAA are also indicated. Figure 2. Regions of homology in the ElA proteins of BAV3 and human adenovirus type 5 (HAd5) . The amino acid residue of each serotype is indicated. A. Conserved region 3 (CR3) of HAd5 subdivided into three functional regions as defined by Lillie et al (1989) Nature 338:39-44 and described in the Background of the Invention. The intron sequence of BAV3 ElA occurs within the serine amino acid codon at position 204. B. A portion of conserved region 2 (CR2) of HAd5, showing the residues thought to be important in the binding of retinoblastoma protein Rb (Dyson et al., 1990 J. Virol. £1:1353-1356), and the comparable sequence from BAV3. Figure 3. Homology regions between the HAd5 and E1B 19k (176R) protein and the corresponding BAV3 (157R) protein. The amino acid residue number for each of the viruses is indicated. Figure 4. The C-terminal 346R of HAd5 E1B 56k (496R) and the corresponding BAV3 protein (42OR) . The HAd5 protein comparison begins at residue 150 and the BAV3 (in italics) at residue 74. The amino terminal regions of these proteins which are not presented show no significant homology. Figure 5. Homology comparison of the amino acid sequence of HAd5 protein IX and the corresponding protein of BAV3 (in italics) . Figure 6. The genome of BAV3 showing the location of .EσoRI, XJal and BAMHI sites and the structure of the 5100bp segment from 77 to 92 .u. ORFs for the upper strand which can encode 60 amino acids or more are represented by bars. Shaded portions indicate regions of similarity to pVIII, 14.7K E3 and fibre proteins of HAd2 or -5. The first methionine followed by a stretch of amino acids of at least 50 is shown by an open triangle. Termination codons for ORFs likely to code for viral proteins are shown by closed triangles. Figure 7. Nucleotide sequence of BAV3 between 77 and 92 m.u. showing ORFs that have the potential to encode polypeptides of at least 50 amino acids after the initiating methionine. The nucleotide sequence was analyzed using the program DISPCOD (PC/GENE) . Potential N-glycosylation sites (N-X-T/S) and polyadenylation signals are underlined and the first methionine of each ORF is shown in bold. Figure 8. Comparison between the predicted amino acid sequences for the ORFs of BAV3 and known proteins of HAd2 or -5 using the computer program PALIGN (PC/GENE) , with comparison matrix structural- genetic matrix; open gap cost 6; unit gap cost 2. Identical residues are indicated by a colon and similar residues by a dot. (a) Comparison between the predicted amino acid sequence encoded by the 3' end of BAV3 ORF 1 and the HAd2 hexon-associated pVIII precursor. (b) Comparison between the ORF 4 and the HAd5 14.7K E3 protein. (c) Comparison between the predicted amino acid sequence encoded by BAV3 ORF 6 and the HAd2 fibre protein. Figure 9. Construction of BAV3 E3 transfer vector containing the firefly luciferase gene. The 3.0 kb BamHI 'D' fragment of the BAV3 genome which falls between m.u. 77.8 and 86.4, contains almost the entire E3 region (Mittal et al (1992) J. Gen. Virol. 21:3295-3000) . This 3.0 kb fragment was isolated by digesting BAV3 DNA with BamHI and cloned into pUC18 at the BamHI site to obtain pSM14. Similarly, the 4.8 kb BamHI 'C fragment of BAV3 DNA which extends between m.u. 86.4 and 100 was isolated and inserted into pUClδ to produce pSM17. To delete a 696 bp Xhol-Ncol fragment, pSM14 was cleaved with Xhol and Ncol, the larger fragment was purified and the ends were made blunt with Klenow fragment of DNA polymerase I and a Nrul-Sall linker was inserted to generate pSM14del2. A 2.3 kb BamHI fragment containing BAV3 sequences, an E3 deletion and Nrul and Sail cloning sites, was inserted into pSM17 at the BamHI site to obtain pSM41, however, this step was not required for construction of a BAV3 E3 transfer vector. A 1716 bp fragment containing the firefly luciferase gene (de Wet et al (1987) Mol. Cell. Biol. 2:725-737) was isolated by digesting pSVOA/L (provided by D. R. Helinski, University of California at San Diego, CA) with BsmI and Sspl as described (Mittal et al (1993) Virus Res. 18:67-90), and the ends were made blunt with Klenow. The luciferase gene was inserted into pSM41 at the Sail site by blunt end ligation. The resultant plasmid was named pSM41-Luc which contained the luciferase gene in the same orientation as the E3 transcription unit. The plasmid pKN30 was digested with Xbal and inserted into pSM41-Luc (partially cleaved with Xbal) at a Xbal site present within the luciferase gene to obtain pSM41-Luc-Kan. The plasmid pSM14 was digested with BamHI and a 3.0 kb fragment was isolated and inserted into pSM17 at the BamHI site to generate pSM43. The 18.5 kb Xbal 'A' fragment of the BAV3 genome which falls between m.u. 31.5 and 84.3 was cloned into pUC18 at the Xbal site to result pSM21. A 18.5 kb Xbal fragment was purified from pSM21 after cleavage with Xbal and inserted into pSM43 at the Xbal site and the resultant plasmid was named pSM51. A 7.7 kb BamHI fragment containing the luciferase gene and kan r gene was isolated after digesting pSM41-Luc- Kan with BamHI and ligated to pSM51, partially digested with BamHI, to isolate pSM51-Luc-Kan in the presence of ampicillin and kanamycin. Finally the kan r gene was deleted from pSM51-Luc-Kan by partial cleavage with Xbal and religation to obtain pSM51-Luc. Figure 10. Generation of BAV3 recombinants containing the firefly luciferase in the E3 region. The plasmid pSM51-Luc contains the BAV3 genome between m.u. 77.8-84.3 and 31.5-100, a 696 bp deletion in E3 and the luciferase gene in E3 in the E3 parallel orientation. The BAV3 genome digested with Pvul and uncut pSM51-Luc were used for cotransfection of MDBK cells transformed with a plasmid containing BAV3 El sequences to rescue the luciferase gene in E3 of the BAV3 genome by in vivo recombination. The resulting BAV3-luciferase recombinants (BAV3-Luc) isolated from two independent experiments were named BAV3-Luc (3.1) and BAV3-Luc (3.2). The BamHI restriction map of the BAV3-Luc genome is shown. The position and orientation of the firefly luciferase gene is shown as a hatched arrow. Figure 11. Southern blot analyses of restriction enzymes digested DNA fragments of the wt BAV3 or recombinant genomes by using a 696 bp Xhol- Ncol fragment from pSM14 (Fig. 9) and a DNA fragment containing the luciferase gene as probes. 100 ng DNA isolated from the mock (lanes 1, 2, 3), BAV3-Luc (3.1) (lanes 4, 5, 6), BAV3-Luc (3.2) (lanes 7, 8, 9) or wt BAV3 (lanes 10, 11 12)-infected MDBK cells were digested with BamHI (lanes 1, 4, 7, 10), EcoRI (lanes 2, 5, 8, 11) or Xbal (lanes 3, 6, 9, 12) and analyzed by agarose gel electrophoresis. The DNA fragments from the gel were transferred onto a GeneScreenPlus™ membrane and hybridized with a 696 bp Xhol-Ncol fragment from pSM14 (Fig. 9) labeled with 32 P using Pharmacia Oligolabeling Kit (panel A) . Panel B blot represents duplicate samples as in panel A but was probed with a 1716 bp Bsml-Sspl fragment containing the luciferase gene (Fig. 9) . The sizes of bands visualized following hybridization are shown in kb on the right in panel A and on the left in panel B. B: BamHI, E: EcoRI, Xb: Xbal, 3.1: BAV3-LUC (3.1), 3.2: BAV3-Luc (3.2) and wt: wild-type BAV3. Figure 12. Single step growth curve for wt BAV3 and BAV3-Luc. Confluent monolayers of MDBK cells in 25 mm multi-well culture plates were inoculated with the wt BAV3, BAV3-LUC (3.1) or BAV3-LUC (3.2) at a .o.i. of 10 p.f.u. per cell. The virus was allowed to adsorb for 1 h at 37°C, cell monolayers were washed 3 times with PBS ++ (0.137 M NaCl, 2.7 ! KC1, 8 mM Na 2 HP0 4 , 1.5 mM KH 2 P0 4 , containing 0.01% CaCl 2 .2H 2 0 & 0.01% MgCl 2 .6H 2 0) and incubated at 37°C in 1 ml maintenance medium containing 2% horse serum. At various times post-infection, cells were harvested along with the supernatant, frozen and thawed three times and titrated on MDBK cells by plaque assay. Results are the means of duplicate samples. Figure 13. Kinetics of luciferase expression in MDBK cells-infected with BAV3-Luc. Confluent MDBK cell monolayers in 25 mm multi-well culture plates were infected with BAV3-Luc (3.1) or BAV3-Luc (3.2) at a m.o.i. of 50 p.f.u. per cell. At indicated time points post-infection, virus-infected cells were harvested and assayed in duplicate for luciferase activity. Figure 14. Luciferase expression in the presence of 1-0-D-arabinofluranosyl cytosine (AraC) in MDBK cells-infected with BAV3-Luc. Confluent MDBK cell monolayers in 25 mm multi-well culture plates were infected with A) BAV3-Luc (3.1) or B) BAV3-Luc (3.2) at a m.o.i. of 50 p.f.u. per cell and incubated in the absence or presence of 50 μg AraC per ml of maintenance medium. At indicated time points post- infection, virus-infected cells were harvested and assayed in duplicate for luciferase activity. Figure 15. Transcription maps of the wt BAV3 and BAV3-Luc genomes in the E3 region. The genome of wt BAV3 between m.u. 77 and 82 is shown which represents the E3 region. The location of Xhol and Ncol sites which were used to make an E3 deletion are shown. (a) The three frames (Fl, F2 and F3) representing the open reading frames (ORFs) in the upper strand of the wt BAV3 genome in the E3 region are represented by bars. The shaded portions indicate regions of similarities to pVIII and E3-14.7 kDa proteins of HAd5. The positions of the initiation and termination codons for ORFs likely to code for viral proteins are shown by open and closed triangles, respectively. (b) The predicted ORFs for the upper strand in E3 of the BAV3-Luc genome are shown after a 696 bp Xhol-Ncol E3 deletion replaced by the luciferase gene. The ORFs for pVIII and E3-14.7 kDa proteins are intact. The transcription map of the wt BAV3 E3 was adapted from the DNA sequence submitted to the GenBank database under accession number D16839. Figure 16. Western blot analysis of virus- infected MDBK cells using an anti-luciferase antibody. Confluent monolayers of MDBK cells were mock-infected (lane 1) or infected with the wt BAV3 (lane 2) , BAV3- Luc (3.1) (lane 3) and BAV3-Luc (3.2) (lane 4) at a m.o.i. of 50 p.f.u. per cell, harvested at 18 h post- infection, cell extracts prepared and analyzed by SDS- PAGE and Western blotting using a rabbit anti- luciferase antibody. Purified firefly luciferase was used as a positive control (lane 5) . The lane 5 was excised to obtain a shorter exposure. The protein molecular weight markers in kDa are shown on the left. The arrow indicates the 62 kDa luciferase bands reacted with the anti-luciferase antibody, wt: wild-type BAV3, 3.1: BAV3-LUC (3.1) and 3.2: BAV3- Luc (3.2) . Figure 17. Construction of pSM71-neo. A 8.4 kb Sail fragment of the BAV3 genome which falls between m.u. 0 and 24 was isolated and inserted into pUC19 at the Sall-Smal site to generate pSM71. The plasmid, pRSDneo (Fitzpatrick et al (1990) Virology 176:145-157. contains the neomycin-resistant (neo r gene flanked with the simian virus 40 (SV40) regulatory sequences originally from the plasmid, pSV2neo (Southern et al (1982) J. Mol. APPI. Genet 1:327-341) after deleting a portion of the SV40 sequences upstream of the neo r gene to remove several false initiation codons. A 2.6 kb fragment containing the neo r gene under the control of the SV40 regulatory sequences, was obtained from the plasmid, pRSDneo after digestion with BamHI and Bglll, and cloned into pSM71 at the Sail site by blunt end ligation to obtain pSM71-neo containing the neo r gene in the El parallel orientation. Figure 18. Construction of pSM61-kan 1 and pSM61-kan2. A 11.9 kb Bglll fragment of the BAV3 genome which extends between m.u. 0 and 34 was purified and introduced into pUC19 at the BamHI-HincII site to obtain pSM61. The plasmid, pKN30 contains the neo' gene along with SV40 promoter and polyadenylation sequences from the plasmid pSV2neo without any modification. The entire pKN30 plasmid was inserted into pSM61 at the Sail site to generate pSM61-kanl having the neo r gene in the El anti-parallel orientation and pSM61-kan2 when the neo r gene is in the El parallel orientation. Figure 19. Construction of an El transfer plasmid containing the beta-galactosidase gene. The plasmid, pSM71 which contains the BAV3 genome between m.u. 0 and 24, was cleaved with Clal and partially with Avrll to delete a 2.6 kb Avrll-Clal fragment (between m.u. 1.3 and 8.7) which falls within the El region. A 0.5 kb fragment containing the SV40 promoter and polyadenylation sequences was obtained from pFG144K5-SV by digesting with Xbal and inserted into pSM71 to replace the 2.6 kb deletion to generate pSM71-dell-SV. A 3.26 kb fragment containing the bacterial beta-galactosidase gene was isolated from pDUC/Z (Liang et al (1993) Virology 195:42-50. after cleavage with Ncol and Hindlll and cloned into pSM71- dell-SV at the BamHI site to put the beta- galactosidase gene under the control of the SV40 regulatory sequences to obtain pSM71-Z. Modes of Carrying Out the Invention The practice of the present invention will employ, unless otherwise indicated, conventional microbiology, immunology, virology, molecular biology, and recombinant DNA techniques which are within the skill of the art. These techniques are fully explained in the literature. See, e.g.. Maniatis et al. , Molecular Cloning: A Laboratory Manual (1982); DNA Cloning: A Practical Approach, vols. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed. (1984)); Nucleic Acid Hybridization (B. Hames & S. Higgins, eds. (1985)); Transcription and Translation (B. Hames & S. Higgins, eds. (1984)); Animal Cell Culture (R. Freshney, ed. (1986)); Perbal, A Practical Guide to Molecular Cloning (1984). Sambrook et al.. Molecular Cloning: A Laboratory Manual (2nd Edition) ; VOls. I, II & III (1989). A. Definitions In describing the present invention, the following terminology, as defined below, will be used. A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., is capable of replication under its own control. A "vector" is a replicon, such as a plasmid, phage, cosmid or virus, to which another DNA segment may be attached so as to bring about the replication of the attached segment. By "live virus" is meant, in contradistinction to "killed" virus, a virus which is capable of producing identical progeny in tissue culture and inoculated animals. A "helper-free virus vector" is a vector that does not require a second virus or a cell line to supply something defective in the vector. A "double-stranded DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its normal, double- stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments of DNA from viruses, plasmids, and chromosomes) . In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA) . A DNA "coding sequence" is a DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, viral DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence. A "transcriptional promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bound at the 3' terminus by the translation start codon (ATG) of a coding sequence and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease SI) , as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eucaryotic promoters will often, but not always, contain "TATA" boxes and "CAAT" boxes. Procaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences. DNA "control sequences" refer collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the transcription and translation of a coding sequence in a host cell. A coding sequence or sequence encoding is "operably linked to" or "under the control of" control sequences in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence. A "host cell" is a cell which has been transformed, or is capable of transformation, by an exogenous DNA sequence. A cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA may or may not be integrated (covalently linked) to chromosomal DNA making up the genome of the cell. In procaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. A stably transformed cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. For mammalian cells, this stability is demonstrated by the ability of the cell to establish cell lines or clones comprised of a population of daughter cell containing the exogenous DNA. A "clone" is a population of daughter cells derived from a single cell or common ancestor. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations. Two polypeptide sequences are "substantially homologous" when at least about 80% (preferably at least about 90%, and most preferably at least about 95%) of the amino acids match over a defined length of the molecule. Two DNA sequences are "substantially homologous" when they are identical to or not differing in more that 40% of the nucleotides, more preferably about 20% of the nucleotides, and most preferably about 10% of the nucleotides. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g.. Maniatis et al., supra; DNA Cloning, vols. I & II, supra: Nucleic Acid Hybridization, supra. A "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature. Thus, when the heterologous region encodes a viral gene, the gene will usually be flanked by DNA that does not flank the viral gene in the genome of the source virus or virus-infected cells. Another example of the heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene) . Allelic variation or naturally occurring mutational events do not give rise to a heterologous region of DNA, as used herein. "Bovine host" refers to cattle of any breed, adult or infant. The term "protein" is used herein to designate a polypeptide or glycosylated polypeptide, respectively, unless otherwise noted. The term "polypeptide" is used in its broadest sense, i.e., any polymer of amino acids (dipeptide or greater) linked through peptide bonds. Thus, the term "polypeptide" includes proteins, oligopeptides, protein fragments, analogs, muteins, fusion proteins and the like. "Fusion protein" is usually defined as the expression product of a gene comprising a first region encoding a leader sequence or a stabilizing polypeptide, and a second region encoding a heterologous protein. It involves a polypeptide comprising an antigenic protein fragment or a full length BAV protein sequence as well as (a) heterologous sequence(s), typically a leader sequence functional for secretion in a recombinant host for intracellularly expressed polypeptide, or an N- terminal sequence that protects the protein from host cell proteases, such as SOD. An antigenic protein fragment is usually about 5-7 amino acids in length. "Native" proteins or polypeptides refer to proteins or polypeptides recovered from BAV or BAV- infected cells. Thus, the term "native BAV polypeptide" would include naturally occurring BAV proteins and fragments thereof. "Non-native" polypeptides refer to polypeptides that have been produced by recombinant DNA methods or by direct synthesis. "Recombinant" polypeptides refers to polypeptides produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide. A "substantially pure" protein will be free of other proteins, preferably at least 10% homogeneous, more preferably 60% homogeneous, and most preferably 95% homogeneous. An "antigen" refers to a molecule containing one or more epitopes that will stimulate a host's immune system to make a humoral and/or cellular antigen-specific response. The term is also used interchangeably with "immunogen." A "hapten" is a molecule containing one or more epitopes that does not stimulate a host's immune system to make a humoral or cellular response unless linked to a carrier. The term "epitope" refers to the site on an antigen or hapten to which a specific antibody molecule binds or is recognized by T cells. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site." An "immunological response" to a composition or vaccine is the development in the host of a cellular and/ or antibody-mediated immune response to the composition or vaccine of interest. Usually, such a response consists of the subject producing antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells directed specifically to an antigen or antigens included in the composition or vaccine of interest. The terms "immunogenic polypeptide" and "immunogenic amino acid sequence" refer to a polypeptide or amino acid sequence, respectively, which elicit antibodies that neutralize viral infectivity, and/or mediate antibody-complement or antibody dependent cell cytotoxicity to provide protection of an immunized host. An "immunogenic polypeptide" as used herein, includes the full length (or near full length) sequence of the desired protein or an immunogenic fragment thereof. By "immunogenic fragment" is meant a fragment of a polypeptide which includes one or more epitopes and thus elicits antibodies that neutralize viral infectivity, and/or mediates antibody-complement or antibody dependent cell cytotoxicity to provide protection of an immunized host. Such fragments will usually be at least about 5 amino acids in length, and preferably at least about 10 to 15 amino acids in length. There is no critical upper limit to the length of the fragment, which could comprise nearly the full length of the protein sequence, or even a fusion protein comprising fragments of two or more of the antigens. The term "treatment" as used herein refers to treatment of a mammal, such as bovine or the like, either (i) the prevention of infection or reinfection (prophylaxis) , or (ii) the reduction or elimination of symptoms of an infection. The vaccine comprises the recombinant BAV itself or recombinant antigen produced by recombinant BAV. By "infectious" is meant having the capacity to deliver the viral genome into cells. B. General Method The present invention identifies and provides a means of deleting part or all of the nucleotide sequence of bovine adenovirus El and/or E3 gene regions to provide sites into which heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof can be inserted to generate bovine adenovirus recombinants. By "deleting part of" the nucleotide sequence is meant using conventional genetic engineering techniques for deleting the nucleotide sequence of part of the El and/or E3 region. Various foreign genes or coding sequences (prokaryotic, and eukaryotic) can be inserted in the bovine adenovirus nucleotide sequence, e.g.,DNA, in accordance with the present invention, particularly to provide protection against a wide range of diseases and many such genes are already known in the art. The problem heretofore having been to provide a safe, convenient and effective vaccine vector for the genes or coding sequences. It is also possible that only fragments of nucleotide sequences of genes can be used (where these are sufficient to generate a protective immune response) rather than the complete sequence as found in the wild-type organism. Where available, synthetic genes or fragments thereof can also be used. However, the present invention can be used with a wide variety of genes, fragment and the like, and is not limited to those set out above. In some cases the gene for a particular antigen can contain a large number of introns or can be from an RNA virus, in these cases a complementary DNA copy (cDNA) can be used. In order for successful expression of the gene to occur, it can be inserted into an expression vector together with a suitable promoter including enhancer elements and polyadenylation sequences. A number of eucaryotic promoter and polyadenylation sequences which provide successful expression of foreign genes in mammalian cells and how to construct expression cassettes, are known in the art, for example in U.S. patent 5,151,267, the disclosures of which are incorporated herein by reference. The promoter is selected to give optimal expression of immunogenic protein which in turn satisfactorily leads to humoral, cell mediated and mucosal immune responses according to known criteria. The foreign protein produced by expression in vivo in a recombinant virus-infected cell may be itself immunogenic. More than one foreign gene can be inserted into the viral genome to obtain successful production of more than one effective protein. Thus with the recombinant virus of the present invention, it is possible to provide protection against a wide variety of diseases affecting cattle. Any of the recombinant antigenic determinant or recombinant live virus of the invention can be formulated and used in substantially the same manner as described for the antigenic determinant vaccines or an live vaccine vectors. The antigens used in the present invention can be either native or recombinant antigenic polypeptides or fragments. They can be partial sequences, full-length sequences, or even fusions (e.g., having appropriate leader sequences for the recombinant host, or with an additional antigen sequence for another pathogen) . The preferred antigenic polypeptide to be expressed by the virus systems of the present invention contain full-length (or near full-length) sequences encoding antigens. Alternatively, shorter sequences that are antigenic (i.e., encode one or more epitopes) can be used. The shorter sequence can encode a "neutralizing epitope," which is defined as an epitope capable of eliciting antibodies that neutralize virus infectivity in an in vitro assay. Preferably the peptide should encode a "protective epitope" that is capable of raising in the host an "protective immune response;" i.e., an antibody- and/or a cell-mediated immune response that protects an immunized host from infection. The antigens used in the present invention, particularly when comprised of short oligopeptides, can be conjugated to a vaccine carrier. Vaccine carriers are well known in the art: for example, bovine serum albumin (BSA) , human serum albumin (HSA) and keyhole limpet hemocyanin (KLH) . A preferred carrier protein, rotavirus VP6, is disclosed in EPO Pub. No. 0259149, the disclosure of which is incorporated by reference herein. Genes for desired antigens or coding sequences thereof which can be inserted include those of organisms which cause disease in mammals, particularly bovine pathogens such as bovine rotavirus, bovine coronavirus, bovine herpes virus type 1, bovine respiratory syncytial virus, bovine parainfluenza virus type 3 (BPI-3) , bovine diarrhea virus, Pasteurella haemolvtica. Haemophilus somnus and the like. The vaccines of the invention carrying foreign genes or fragments can also be orally administered in a suitable oral carrier, such as in an enteric-coated dosage form. Oral formulations include such normally-employed excipients as, for example, pharmaceutical grades of annitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral vaccine compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, containing from about 10% to about 95% of the active ingredient, preferably about 25% to about 70%. An oral vaccine may be preferable to raise mucosal immunity in combination with systemic immunity, which plays an important role in protection against pathogens infecting the gastrointestinal tract. In addition, the vaccine be formulated into a suppository. For suppositories, the vaccine composition will include traditional binders and carriers, such as polyalkaline glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w) , preferably about 1% to about 2%. Protocols for administering to animals the vaccine composition(s) of the present invention are within the skill of the art in view of the present disclosure. Those skilled in the art will select a concentration of the vaccine composition in a dose effective to elicit an antibody and/or T-cell mediated immune response to the antigenic fragment. Within wide limits, the dosage is not believed to be critical. Typically, the vaccine composition is administered in a manner which will deliver between about 1 to about 1,000 micrograms of the subunit antigen in a convenient volume of vehicle, e.g., about 1-10 cc. Preferably, the dosage in a single immunization will deliver from about 1 to about 500 micrograms of subunit antigen, more preferably about 5-10 to about 100-200 micrograms (e.g., 5-200 micrograms) . The timing of administration may also be important. For example, a primary inoculation preferably may be followed by subsequent booster inoculations if needed. It may also be preferred, although optional, to administer a second, booster immunization to the animal several weeks to several months after the initial immunization. To insure sustained high levels of protection against disease, it may be helpful to readminister a booster immunization to the animals at regular intervals, for example once every several years. Alternatively, an initial dose may be administered orally followed by later inoculations, or vice versa. Preferred vaccination protocols can be established through routine vaccination protocol experiments. The dosage for all routes of administration of in vivo recombinant virus vaccine depends on various factors including, the size of patient, nature of infection against which protection is needed, carrier and the like and can readily be determined by those of skill in the art. By way of non-limiting example, a dosage of between 10 3 pfu and 10 8 pfu and the like can be used. As with in vitro subunit vaccines, additional dosages can be given as determined by the clinical factors involved. In one embodiment of the invention, a number of recombinant cell lines are produced according to the present invention by constructing an expression cassette comprising the BAV El region and transforming host cells therewith to provide cell lines or cultures expressing the El proteins. These recombinant cell lines are capable of allowing a recombinant BAV, having an El gene region deletion replaced by heterologous nucleotide sequence encoding for a foreign gene or fragment, to replicate and express the desired foreign gene or fragment thereof which is encoded within the recombinant BAV. These cell lines are also extremely useful in generating recombinant BAV, having an E3 gene deletion replaced by heterologous nucleotide sequence encoding for a foreign gene or fragment, by m vivo recombination following DNA-mediated cotransfection. In one embodiment of the invention, the recombinant expression cassette can be obtained by cleaving the wild-type BAV genome with an appropriate restriction enzyme to produce a DNA fragment representing the left end or the right end of the genome comprising El or E3 gene region sequences, respectively and inserting the left or right end fragment into a cloning vehicle, such as plasmid and thereafter inserting at least one DNA sequence encoding a foreign protein, into El or E3 deletion with or without the control of an exogenous promoter. The recombinant expression cassette is contacted with the wild-type BAV DNA through homologous recombination or other conventional genetic engineering method within an El transformed cell line to obtain the desired recombinant. The invention also includes an expression system comprising an bovine adenovirus expression vector wherein a heterologous nucleotide, e.g. DNA, replaces part or all of the E3 region and/or part or all of the El region. The expression system can be used wherein the foreign nucleotide sequences, e.g. DNA, is with or without the control of any other heterologous promoter. The BAV El gene products of the adenovirus of the invention transactivate most of the cellular genes, and therefore, cell lines which constitutively express El proteins can express cellular polypeptides at a higher level than normal cell lines. The recombinant mammalian, particularly bovine, cell lines of the invention can be used to prepare and isolate polypeptides, , including those such as (a) proteins associated with adenovirus ElA proteins: e.g. p300, retinoblastoma(Rb) protein, cyclins, kinases and the like.; (b) proteins associated with adenovirus E1B protein: e.g. p53 and the like.; (c) growth factors, such as epidermal growth factor (EGF) , transforming growth factor (TGF) and the like; (d) receptors such as epidermal growth factor receptor (EGF-R) , fibroblast growth factor receptor (FGF-R) , tumor necrosis factor receptor (TNF-R) , insulin-like growth factor receptor (IFG-R) , major histocompatibility complex class I receptor and the like; (e) proteins encoded by proto-oncogenes such as protein kinases (tyrosine-specific protein kinases and protein kinases specific for serine or threonine) , p21 proteins (guanine nucleotide-binding proteins with GTPase activity and the like; (f) other cellular proteins such as actins, collagens, fibronectins, integrins, phospholipids, proteoglycans, histones and the like, and (g) proteins involved in regulation of transcription such as TATA-box-binding protein (TBP) , TBP-associated factors (TAFs) . SPl binding protein and the like. The invention also includes a method for providing gene therapy to a mammal in need thereof to control a gene deficiency which comprises administering to said mammal a live recombinant bovine adenovirus containing a foreign nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in the target organ or tissue. These kinds of techniques are recently being used by those of skill in the art to replace a defective gene or portion thereof. Examples of foreign genes nucleotide sequences or portions thereof that can be incorporated for use in a conventional gene therapy include, cystic fibrosis transmembrane conductance regulator gene, human minidystrophin gene, alpha1-antitrypsin gene and the like. Examples Described below are examples of the present invention. These examples are provided only for illustrative purposes and are not intended to limit the scope of the present invention in any way. In light of the present disclosure, numerous embodiments within the scope of the claims will be apparent to those of ordinary skill in the art. The contents of the references cited in the specification are incorporated by reference herein. Cells and viruses Cell culture media and reagents were obtained from GIBCO/BRL Canada (Burlington, Ontario, Canada) . Media were supplemented with 25 mM Hepes and 50 μg/ml gentamicin. MDBK cells or MDBK cells transformed with a plasmid containing BAV3 El sequences were grown in MEM supplemented with 10% Fetal bovine serum. The wild-type BAV3 ((strain WBR- 1) (Darbyshire et al, 1965 J. Comparative Pathology 7_5_:327) was kindly provided by Dr. B. Darbyshire, University of Guelph, Guelph, Canada) and BAV3- luciferase recombinants working stocks and virus titrations were done in MDBK cells. Enzymes, bacteria and plasmids Restriction endonucleases, polymerase chain reaction (PCR) and other enzymes required for DNA manipulations were purchased from Pharmacia LKB Biotechnology (Canada) Ltd. (Dorval, Quebec, Canada) , Boehringer-Mannheim, Inc. (Laval or Montreal, Quebec, Canada) , New England BioLabs (Beverly, MA) , or GIBCO/BRL Canada (Burlington, Ontario, Canada) and used as per manufacturer's instructions. Restriction enzyme fragments of BAV3 DNA were inserted into pUC18 or pUC19 (Yanich-Penon et al (1985) Gene 3_3:103-109) following standard procedures (Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbour Laboratory, New York) . E. coli strain DH5 (supE44 λsc?R17 reσAl endAl gryrA96 thi-l relAl) was transformed with recombinant plasmids by electroporation (Dower et al. (1988) Nuc. Acids Res.. 16:6127-6145). Plasmid DNA was prepared using the alkaline lysis procedure (Bernboim and Doly (1978) Nuc. Acids Res.. 7:1513-1523). The plasmid, pSVOA/L containing the entire cDNA encoding firefly luciferase (de Wet et al (1987) Mol. Cell. Biol. 2:725-737), was a gift from D.R. Helinski, University of California, San Diego, La Jolla, CA. Construction of recombinant BAV3 MDBK cells transformed with a plasmid containing BAV3 El sequences were cotransfected with the wt BAV3 DNA digested with Pvul and the plasmid, pSM51-Luc (Figs. 9 and 10) using the lipofection- mediated cotransfection protocol (GIBCO/BRL, Life Technologies, Inc., Grand Island, NY). The virus plaques produced following cotransfection were isolated, plaque purified and the presence of the luciferase gene in the BAV3 genome was detected by agarose gel electrophoresis of recombinant virus DNA digested with appropriate restriction enzymes. Southern blot and hybridization Mock or virus-infected MDBK cells were harvested in lysis buffer (500 μg/ml pronase in 0.01 M Tris, pH 7.4, 0.01 M EDTA, 0.5% SDS) and DNA was extracted (Graham et al (1991) Manipulation of adenovirus vectors In: Methods and Molecular Biology, :Gene Transfer and Expression Techniques (Eds. Murray and Walker) Humana Press, Clifton, N.J. pp. 109-128) . 100 ng DNA was digested either with BamHI, EcoRI or Xbal and resolved on a 1% agarose gel by electrophoresis. DNA bands from the agarose gel were transferred to a GeneScreenPlus™ membrane (Du Pont Canada Inc. (NEN Products) , Lachine, Quebec, Canada) by the capillary blot procedure (Southern, E.M. (1975) J. Mol. Biol. 98 . :503-517) . Probes were labeled with 32 P using an Oligolabeling Kit (Pharmacia LKB Biotechnology (Canada) Ltd., Dorval, Quebec, Canada) and the unincorporated label was removed by passing the labeled probe through a sephadex G-50 column (Sambrook et al (1989) supra) . Probes were kept in a boiling water bath for 2 min and used in hybridization experiments following GeneScreenPlus™ hybridization protocol. The DNA bands which hybridized with the probe were visualized by autoradiography. Luciferase assays The protocol was essentially the same as described (Mittal et al (1993) Virus Res. 28:67-90) . Briefly, MDBK cell monolayers in 25 mm multi-well dishes (Corning Glass Works, Corning, NY) were infected in duplicate either with BAV3-Luc (3.1) or BAV3-Luc (3.2) at a m.o.i. of 50 p.f.u. per cell. At indicated time points post-infection, recombinant virus-infected cell monolayers were washed once with PBS (0.137 M NaCl, 2.7 mM KC1, 8 mM Na 2 HP0 4/ 1.5 mM KH 2 P0 4 ) and harvested in 1 ml luciferase extraction buffer (100 mM potassium phosphate, pH 7.8, 1 mM dithiothreitol) . The cell pellets were resuspended in 200 μl of luciferase extraction buffer and lysed by three cycles of freezing and thawing. The supernatants were assayed for luciferase activity. For the luciferase assay, 20 μl of undiluted or serially diluted cell extract was mixed with 350 μl of luciferase assay buffer (25 mM glycylglycine, pH 7.8, is m MgCl 2 , 5 mM ATP) in a 3.5 ml tube (Sarstedt Inc., St-Laurent, Quebec, Canada) . Up to 48 tubes can be kept in the luminometer rack and the equipment was programed to inject 100 μl of luciferin solution (1 mM luciferin in 100 mM potassium phosphate buffer, pH 7.8) in the tube present in the luminometer chamber to start the enzyme reaction. The Luminometer (Packard Picolite Luminometer, Packard Instrument Canada, Ltd., Mississauga, Ontario, Canada) used in the present study produced 300 to 450 light units of background count in a 10 sec reaction time. Known amounts of the purified firefly luciferase were used in luciferase assays to calculate the amount of active luciferase present in each sample. Western blotting Mock or virus-infected MDBK cells were lysed in 1:2 diluted 2X loading buffer (80 mM Tris-HCl, pH 6.8, 0.67 M urea, 25% glycerol, 2.5% SDS, 1 M mercaptoethanol, 0.001% bromophenol blue), boiled for 3 min and then centrifuged to pellet cell debris. Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 0.1% SDS-10% polyacrylamide gels (Laemmli, et al (1970) Nature 227:680-685) . After the end of the run, polypeptide bands in the gel were electrophoretically transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Richmond, CA) . The membrane was incubated at room temperature for 2 h with 1:4000 diluted rabbit anti- luciferase antibody (Mittal et al (1993) supra) . The binding of anti-luciferase antibody to the specific protein band/s on the membrane was detected with 1:5000 diluted horseradish peroxidase conjugated-goat anti-rabbit IgG (Bio-Rad Laboratories, Richmond, CA) and with an ECL Western blotting detection system (Amersham Canada Ltd., Oakville, Ontario). Example 1 Cloning of BAV3 El Region DNA for sequencing To complement the restriction site (Kurokawa et al, 1978 J. Virol.. 2^:212-218; Hu et al, 1984 J. Virol. 4):604-608) other restriction enzyme sites in the BAV3 genome were defined. The 8.4 kilobase pair (kb) Sail B fragment which extends from the left end of the genome to approximately 24% was cloned into the Smal-Sall sites of pUC18 essentially as described previously (Graham et al, 1989 EMBO Journal . 8:2077- 2085) . Beginning at the left end of the BAV3 genome, the relevant restriction sites used for subsequent subcloning and their approximate positions are: SacI (2%), EcoRI (3.5%), Hindlll (5%), SacI (5.5%), Smal (5.6%) and Hindlll (11%). Through the use of appropriate restriction enzymes, the original plasmid was collapsed to contain smaller inserts which could be sequenced using the pUC universal primers. Some fragments were also subcloned in both pUClδ and pUC19 to allow confirmational sequencing in both directions. These procedures, together with the use of twelve different oligonucleotide primers hybridizing with BAV3 sequences, allowed to sequence the BAV3 genome from its left end to the Hindlll site at 11%. To ensure that some features of the sequence obtained were not unique to the initial clone selected for sequencing, two more pUC19 clones were prepared containing the Sail fragment from a completely independent DNA preparation. These clones were used to confirm the original sequence for the region from approximately 3% to 5.5% of the BAV3 genome. DNA sequencing reactions were based on the chain-termination method (Sanger et al. 1977 PNAS. USA 21:5463-5467) and manual sequencing followed the DNA sequencing protocol described in the Sequenase™ kit produced by US Biochemical. [α- 35 S]dATPs was obtained from Amersham Canada Ltd. All oligonucleotides used as primers were synthesized by the Central Facility of the Molecular Biology and Biotechnology Institute (MOBIX) at McMaster University, Hamilton, Ontario. The entire region (0 to 11%) of the BAV3 genome was sequenced by at least two independent determinations for each position by automated sequencing on a 373A DNA Sequencer (Applied Biosystems) using Taq-Dye terminators. Over half of the region was further sequenced by manual procedures to confirm overlaps and other regions of interest. DNA sequence analysis and protein comparisons were carried out on a MICROGENIE program. Example 2 Coding Sequences of the BAV3 El Region BAV3 genomic DNA, from the left end of the genome to the Hindlll site at approximately 11%, was cloned into plasmids and sequenced by a combination of manual and automated sequencing. An examination of the resultant BAV3 El genomic sequence (Fig 1) revealed a number of interesting features relevant both to transactivation and to other functions associated with adenovirus El proteins. On the basis of open reading frames (ORFs) it was possible to assign potential coding regions analogous to those defined in human Ad5 (HAd5) . As shown in Fig 1, ORFs corresponding roughly to the first exon and unique region of HAd5 ElA as well are ORFs corresponding to the 19k and 58k proteins of E1B and the ORF corresponding to protein IX were all defined in this sequence. The open reading frame defining the probable ElA coding region begins at the ATG at nt 606 and continues to a probable splice donor site at position 1215. The first consensus splice acceptor site after this is located after nt 1322 and defines an intron of 107 base pairs with an internal consensus splice branching site at position 1292. The putative BAV3 ElA polypeptide encoded by a message corresponding to these splice sites would have 211 amino acids and a unmodified molecular weight of 23,323. The major homology of the protein encoded by this ORF and HAd5 ElA is in the residues corresponding to CR3 (shown in Fig 2) . The homology of amino acid sequences on both sides of the putative intron strengthens the assignment of probable splice donor and acceptor sites. The CR3 has been shown to be of prime importance in the transactivation activity of HAd5 EIA gene products. As seen in Fig. 2A the homology of this sequence in the BAV3 protein to the corresponding region of the 289R ElA protein of HAd5 includes complete conservation of the CysX 2 CysXι 3 CysX 2 Cys sequence motif which defines the metal binding site of this protein (Berg, 1986 Science 232:485-487) as well as conservation of a number of amino acids within this region and within the promoter binding region as defined by Lillie and Green 1989 Nature 338:39-44) . The only other region of significant homology between the BAV3 ElA protein and that of HAd5 was a stretch of amino acids known to be important in binding of the cellular Rb protein to the HAd5 ElA protein (Dyson et al, 1990 J. Virol. 64_:1353-1356) . As shown in Fig 2B, this sequence, which is located between amino acids 120 and 132 in the CR2 region of HAd5 ElA, is found near the amino (N-) terminus of the BAV3 protein between amino acids 26 and 37. An open reading frame from the ATG at nt 1476 to the termination signal at 1947 defines a protein of 157 amino acids with two regions of major homology to the HAd5 E1B 19k protein. As shown in Fig 3 both the BAV3 and the HAd5 proteins have a centrally located hydrophobic amino acid sequence. The sequence in BAV3, with substitutions of valine for alanine and leucine for valine, should result in a somewhat more hydrophobic pocket than the corresponding HAd5 region. The other portion of HAd5 19k that may be conserved in the BAV3 protein is the serine rich sequence found near the N-terminus (residues 20 to 26) in HAd5 19k and near the C-terminus (residues 136 to 142) in the BAV3 protein (also shown in Fig 3) . On ORF beginning at the ATG at nt 1850 and terminating at nt 3110 overlaps the preceding BAV3 protein reading frame and thus has the same relationship to it as does the HAd5 E1B 56k protein to E1B 19k protein. As shown in Fig 4 this BAV3 protein of 42OR and the corresponding HAd5 E1B 56k protein of 496R show considerable sequence homology over their C- terminal 346 residues. The N-terminal regions of these proteins (not depicted in the figure) show no significant homology and differ in overall length. Following the E1B ORFs, the open reading frame beginning at nt 3200 and ending at the translation terminator TAA at nt 3575 defines a protein of 125R with an unmodified molecular weight of 13,706. As seen in Fig 5 this protein shares some homology with the structural protein IX of HAd5 particularly in N-terminal sequences. Possible Transcription Control Regions in BAV3 El The inverted terminal repeats (ITR) at the ends of the BAV3 genome have been shown to extend to 195 nt (Shinagawa et al, 1987 Gene £55:85-93). The GC- rich 3' portion of the ITR contains a number of consensus binding sites for the transcription stimulating protein SPl (Dynan and Tijan (1983) Cell 3_5:79-87) and possible consensus sites for the adenovirus transcription factor (ATF) (Lee et al. (1987) Nature 3_25:368-372) occur at nts 60 and 220. While there are no exact consensus sites for the factors EF-1A (Bruder and Healing (1989) Mol. Cell Biol. 9_:5143-5153) or E2F (Kovesdi et al, 1987 PNAS. USA J4:2180-2184) upstream of the ATG at nt 606, there are numerous degenerate sequences which may define the enhancer region comparable to that seen in HAd5 (Hearing and Shenk, 1986 Cell 45:229-236) . The proposed BAV3 ElA coding sequence terminates at a TGA residue at nt 1346 which is located within a 35 base pair sequence which is immediately directly repeated (see Fig 1) . Two repeats of this sequence were detected in three independently derived clones for a plaque purified stock of BAV3. The number of direct repeats can vary in any BAV3 population though plaque purification allows for isolation of a relatively homogeneous population of viruses. That direct repeats in the sequences can function as promoter or enhancer elements for E1B transcription is being tested. There are no strong polyA addition consensus sites between the ElA and the E1B coding sequences and in fact no AATAA sequence is found until after the protein IX coding sequences following E1B. The TATAAA sequence beginning at nt 1453 could function as the proximal promoter for E1B but it is located closer to the ATG at 1476 than is considered usual (McKnight et al, 1982 Science 217:316-322) . The TATA sequence located further upstream immediately before the proposed ElA intron sequence also seems inappropriately positioned to serve as a transcription box for the E1B proteins. There are clearly some unique features in this region of the BAV3 genome. The transcriptional control elements for the protein IX transcription unit are conventional and well defined. Almost immediately following the open reading frame for the larger E1B protein there is, at nt 3117, a SPl binding sequence. This is followed at 3135 by a TATAAAT sequence which could promote a transcript for the protein IX open reading frame beginning at the ATG at 3200 and ending with the TAA at 3575. One polyA addition sequence begins within the translation termination codon and four other AATAA sequences are located at nts 3612, 3664, 3796 and 3932. In keeping with the general organization of the ElA region of other adenoviruses, the BAV3 ElA region contains an intron sequence with translation termination codons in all three reading frames and which is therefore probably deleted by splicing from all ElA mRNA transcripts. The largest possible protein produced from the BAV3 ElA region will have 211 amino acid residues and is the equivalent of the 289 amino acid protein translated from the 13s mRNA of HAd5. Two striking features in a comparison of these proteins are the high degree of homology in a region corresponding to CR3 and the absence in BAV3 of most of amino acids corresponding to the second exon of HAd5. In fact the only amino acids encoded in the second exon of BAV3 are, those which are considered to constitute part of CR3. A great deal of work carried out with HAd5 has identified the importance of the CR3 sequences in transactivation of other HAd5 genes. While a detailed analysis of the corresponding BAV3 region and its possible role in transactivation of BAV3 genes needs to be carried out, it is none-the- less interesting to note a couple of possibly pertinent features. The HAd5 CR3 region has been operationally subdivided into three regions (Lillie et al, 1989 Nature 338:39-44; see Fig 8); an N-terminal region from 139 to 153 which has four acidic residues and is thought to be important in transcription activation, a central, metal-binding, region defined by the Cys-X 2 -Cys-X 13 -CysX 2 -Cys sequence which is essential for both promoter binding and activation, and a C-terminal region (residues 175-189) which is essential for promoter binding. Since, in most instances, ElA protein is thought not to interact directly with DNA (Ferguson et al 1985) , the promoter binding regions may be involved in forming associations with proteins which then allow association with DNA. In Fig 2a the BAV3 ElA protein contains the central, metal binding domain and has considerable homology in the carboxy portion of this region. The BAV3 ElA protein also shows identity of sequence with HAd5 in the carboxy 6 amino acids of the promoter binding domain. These features may allow the BAV3 ElA protein to interact with the same transcription activating factors required for HAd5 ElA function. In contrast, except for a Glu-Glu pair there is little homology between the bovine and human viruses in the activation domain. The fact that this domain can be functionally substituted by a heterologous acidic activation sequence (Lillie et al, 1989 supra) suggests that protein specificity is not required in this region and this may allow the BAV3 ElA protein to function in the activation of BAV3 genes. The BAV3 ElA activation region contains six acidic residues in the 18 residues amino to the metal binding domain. The other interesting feature of BAV3 ElA, which is undoubtedly relevant to the oncogenic potential of this virus, is the presence of the sequence Asp27-Leu-Glu-Cys-His-Glu which conforms to, a core sequence known to be important in the binding of cellular Rb and related proteins by the transforming proteins of a number of DNA tumour viruses (Dyson et al, 1990 supra) . From deletion mutant analysis there is a clear association between the potential of HAd5 ElA proteins to bind Rb and the ability of the protein to induce morphological transformation in appropriate cells (see references in Dyson et al, 1990 supra) . The BAV3 ElA protein is distinct from its HAd5 counterpart in the relative position of this Rb binding sequence which is in the CR2 of HAd5 ElA and near the N-terminus of the BAV3 ElA protein. Through the use of alternative splice sites HAd5 ElA transcripts can give rise to at least 5 distinct mRNA species (Berk et al, 1978 Cell 14:695- 711; Stephens et al, 1987 EMBO Journal 6 :2027-2035) . Whether BAV3, like HAd5, can generate a number of different mRNA species through the use of alternative splice sites in the ElA transcripts remains to be determined. For example a potential splice donor site which could delete the sequence equivalent to the unique sequence of HAd5 is present immediately after nt 1080 but it is not known if this site is actually used. HAd5 E1B encodes two proteins (19k and 56k) either of which can cooperate with ElA, by pathways which are additive and therefore presumably independent (McLorie et al, 1991 J. Gen. Virol. 22.:1467-1471) , to produce morphological transformation of cells in culture (see for example: Branton et al, 1985 supra; Graham, 1984 supra) . The significance of the conservation of the hydrophobic stretch of amino acids in the central portion of the shorter E1B proteins of HAd5 and BAV3 is not clear as yet. A second short region of homology Gln-Ser-Ser-X-Ser-Thr- Ser at residue 136 near the C-terminus of the BAV3 protein is located near the N-terminus at residue 20 in the HAd5 19k protein. The major difference in both length and sequence of the larger (42OR) E1B protein of BAV3 from the corresponding HAd5 protein (496R) is confined to the N-terminus of these proteins. The two proteins show considerable evolutionary homology in the 345 amino acids that extend to their C-termini. A similar degree of homology extends into the N-terminal halves of protein IX of BAV3 and HAd5. Taken together these analyses suggest that while BAV3 and the human adenoviruses have diverged by simple point mutational events in some regions, more dramatic genetic events such as deletion and recombination may have been operating in other regions particularly those defining the junction between ElA and E1B. Example 3 Cloning and seguencing of the BAV3 E3 and fibre genes The general organization of adenovirus genomes seems to be relatively well conserved so it was possible to predict, from the locations of a number of HAd E3 regions, that BAV E3 should lie between map units (m.u.) 77 to 86. To prepare DNA for cloning and sequencing, BAV3 (strain WBR-1) was grown in Madin-Darby bovine kidney (MDBK) cells, virions were purified and DNA was extracted (Graham, F.L. & Prevec, L. (1991) Methods in Molecular Biology, vol. 7, Gene Transfer and Expression Protocols, pp. 109- 146. Edited by E.J. Murray, Clifton, New Jersey; Humana Press.). Previously published restriction maps for .EcoRI and BajπHI (Kurokawa et al., 1978) were confirmed (Fig. 6) . The BamHI D and .EcoRI F fragments of BAV3 DNA were isolated and inserted into pUC18 and pUC19 vectors, and nested sets of deletions were made using exonuclease III and SI nuclease (Henikoff, S. (1984) Gene, 8.:351-359) . The resulting clones were sequenced by the dideoxynucleotide chain termination technique (Sanger, F. , Nicklen, S. & Coulson, A.R. (1977) Proceedings of the National Academy of Sciences. U.S.A.. 24:5463-5467) . The nucleotide sequence from positions 1 to 287 was obtained from the right end of the BamHI B fragment (Fig. 6) . The sequence of the regions spanning (i) the BamHI site at nucleotide 3306 and the EcoRI site at nucleotide 3406, and (ii) the EcoRI site at nucleotide 4801 and the nucleotide 5100 was obtained from a plasmid containing the Xbal C fragment (m.u. 83 to 100; not shown) using primers hybriding to BAV3 sequences. Analysis of the sequence was performed with the aid of the PC/GENE sequence analysis package developed by Amos Bairoch, Department of Medical Biochemistry, University of Geneva, Switzerland. The 5100 nucleotide sequence which extends between 77 and 92 m.u. of the BAV3 genome is shown in Fig. 7. The upper strand contains 14 open reading frames (ORFs) which could encode polypeptides of 60 amino acid residues or more (Fig. 6 and 7) . The lower strand contains no ORF encoding a protein of longer than 50 amino acids after an initiation codon. The predicted amino acid sequence for each ORF on the upper strand was analyzed for homology with predicted amino acid sequences from several sequenced Ads: HAd2 (Hέrisse, J. , Courtois, G. & Galibert, F. (1980) Nucleic Acids Research. 8.:2173-2192; Herisse, J. , Courtois, G. & Galibert, F. (1981) Nucleic Acids Research. 9_:1229-1249) , -3(Signas, C. , Akusjarvi, G. & Pettersson, U. (1985) Journal of Virology. 53:672- 678.), -5(Cladaras, C. & Wold, W.S.M. (1985) Virology. 140:28-43) . -7 (Hong, J.S., Mullis, K.G. & Engler, J.A. (1988) Virology. 167:545-553) and -35(Flomenberg, P.R., Chen, M. & Horwitz, M.S. (1988) Journal of Virology. 62.:4431-4437) , and murine Adl (MAdl) (Raviprakash, K.S., Grunhaus, A., El Kholy, M.A. & Horwitz, M.S. (1989) Journal of Virology. 63:5455- 5458) and canine Adl (CAdl) (Dragulev, B.P., Sira, S., Abouhaidar, M.G. & Campbell, J.B. (1991) Virology. 181:298-305). Three of the BAV3 ORFs exhibited homology with characterized HAd proteins pVIII, fibre and the 14.7K E3 protein. The amino acid sequence predicted from BAV3 ORF 1 shows overall identity of approximately 55% when compared to the C-terminal 75% of HAd2 pVIII (Cladaras & Wold, 1985, supra) (Fig. 8a) , indicating that ORF 1 encodes the right end of BAd3 pVIII. Near the C-terminal end of BAd3 pVIII there is a 67 amino acid stretch (residues 59 to 125; Fig. 8a) which has 75% identity with HAd2 pVIII. This region has previously been shown to be highly conserved among different Ads (Cladaras & Wold, 1985, supra; Signas, C, Akusjarvi, G. & Pettersson, U. (1986) Gene. 50:173-184,; Raviprakash et al., 1989, supra; Dragulev et al., 1991, supra). The fibre protein is present on the surface of the virion as long projections from each vertex of the icosahedral capsid and is involved in a number of Ad functions including attachment of the virus to the cell surface during infection, assembly of virions and antigenicity (Philipson, L. (1983) Current Topics in Microbiology and Immunology. 109:1-52) . On the basis of the primary structure of HAd2 fibre protein, it has been proposed that the shaft region (between amino acid residues 40 and 400) is composed of a number of repeating structural motifs containing about 15 hydrophobic residues organized in two short jS-sheets and two 0-bends (Green, N.M. , Wrigley, N.G., Russell, W.C., Martin, S.R. & McLachlan, A.D. (1983) EMBO Journal. 1:1357-1365). The amino acid sequences at the N terminus of the BAV3 ORF 6-encoded protein share about 60% identity with the HAd2 fibre protein tail, but there is little or no similarity in the knob region, and about 45% identity overall (Fig. 8c) . The BAd3 fibre gene would encode a protein of 976 residues if no splicing occurs, i.e. 394 amino acid residues longer than the HAd2 fibre protein. The number of repeating motifs in the shaft region of the fibre protein from different Ads varies between 28 and 23 (Signas et al., 1985, supra; Chroboczek, J. & Jacrot, B. (1987) Virology. 16_l:549-554; Hong et al. , 1988, supra; Raviprakash et al., 1989, supra; Dragulev et al., 1991, supra). The BAV3 fibre protein can be organized into 52 such repeats in this region (not shown) , which would account for most of the difference in size compared to those of HAd2, HAd3, HAD5, HAd7, CAdl and MAdl (Signas et al., 1985,supra; Herisse et al., 1980,supra; Herisse & Galibert, 1981, supra; Hong et al., 1988,supra; Raviprakash et al., 1989, supra; Dragulev et al., 1991, supra). HAd2 and HAd5 E3 lies between the pVIII and the fibre genes an encodes at least 10 polypeptides (Cladaras & Wold, 1985,supra) . The promoter for E3 of these two serotypes lies within the sequences encoding pVIII, about 320 bp 5' of the termination codon. No consensus TATA box is found in the corresponding region of the BAV3 sequences. A non-canonical polyadenylation signal (ATAAA) for E3 transcripts is located at position 1723, between the end of the putative E3 region and the beginning of ORF 6, encoding the fibre protein, and two consensus signals are located within ORF 6 at positions 2575 and 3565. The polyadenylation signal for the fibre protein is located at nucleotide 4877. Six ORFs were identified in the BAV3 genome between the pVIII and the fibre genes, but only four (ORFs 2, 3, 4 and 5) have the potential to encode polypeptides of at least 50 amino acids after an initiation codon (Fig. 7) . The amino acid sequence predicted to be encoded by ORF 2 is 307 residues long and contains eight potential N- glycosylation sites (Fig. 7) as well as a hydrophobic sequence which may be a potential transmembrane domain (PLLFAFVLCTGCAVLLTAFGPSILSGT) between residues 262 and 289. This domain may be a part of the protein homologous to the HAd2 and HAd5 19K E3 glycoprotein (Cladaras & Wold, 1985, supra) , and the proposed CAdl 22.2K protein (Dragulev et al., 1991, supra), but ORF 2 does not show appreciable homology with these proteins. The ORF 4 shows approximately 44% identity with the 14.7K E3 protein of HAd5 (Fig. 6 and 8b), which has been shown to prevent lysis of virus- infected mouse cells by tumour necrosis factor (Gooding, L.R., Elmore, L.W. , Tollefson, A.E., Brody, H.A. & Wold, W.S.M. (1988) Cell. 52:341-346; Wold, W.S.M. & Gooding, L.R. (1989) Molecular Biology and Medicine, (5:433-452). Analysis of the 14.7K protein sequence from HAd2, -3, -5 and -7 has revealed a highly conserved domain, which in HAd5 lies between amino acid residues 41 and 56 (Horton, T.M. , Tollefson, A.E., Wold, W.S.M. & Gooding, L.R. (1990) Journal of Virology. 64.:1250-1255) . The corresponding region in the BAV3 ORF 4-encoded protein, between amino acids 70 and 85, contains 11 amino acids identical to those of the HAd5 14.7K protein conserved domain (Fig. 8b) . The BAV3 E3 region appears to be approximately 1.5kbp long, about half the size of those of HAd2 and -5 (Cladaras & Wold, 1985, supra) , and novel splicing events in BAV3 E3 would be required to generate more homologues to the HAd3 E3 proteins. A similarly short E3 region has been reported for MAdl (RAviprakash et al., 1989, supra) and CAdl (Dragulev et al., 1991,supra). Example 4 Construction of BAV3-luciferase recombinants Adenovirus-based mammalian cell expression vectors have gained tremendous importance in the last few years as a vehicle for recombinant vaccine delivery, and also in gene therapy. BAV3-based expression vectors have a greater potential for developing novel recombinant vaccines for veterinary use. To show that BAV3 E3 gene products are not essential for virus growth in cultured cells and this locus could be used to insert foreign DNA sequences, a 1.7 kb fragment containing the firefly luciferase gene was introduced in the 696 bp deletion of the E3 region of the BAV3 genome in the E3 parallel orientation to generate a BAV3 recombinant. The rationale of using the luciferase gene is that it acted as a highly sensitive reporter gene when introduced in the E3 region of the HAd5 genome to generate HAd5-Luc recombinants (Mittal et al (1993) Virus Res. 18:67-90) . To facilitate the insertion of the firefly luciferase gene into the E3 region of the BAV3 genome, a BAV3 E3 transfer vector containing the luciferase gene was constructed (Fig. 9) . The BAV3 E3 region falls approximately between m.u. 77 and 82. In our first series of vectors we replaced a 696 bp Xhol- Ncol E3 deletion (between m.u. 78.8 and 80.8) with a Nrul-Sall cloning sites for insertion of foreign genes to obtain pSM14del2. A 1716 bp Bsml-Sspl fragment containing the luciferase gene was isolated and first inserted into an intermediate plasmid, pSM41, in the E3 locus at the Sail site by blunt end ligation to generate pSM41-Luc. The luciferase gene without any exogenous regulatory sequences, was inserted into the E3 locus in the same orientation as the E3 transcription unit. The kan r gene was inserted into pSM41-Luc at the Xbal site present within the luciferase gene to generate an amp r /kan r plasmid, pSM41-Luc-Kan. A 7.7 kb fragment containing the BAV3 sequences along with the luciferase gene and the kan r gene was obtained from pSM41-Luc-Kan by digestion with BamHI and inserted into an amp r plasmid, pSM5l partially digested with BamHI to replace a 3.0 kb BamHI fragment (lies between m.u. 77.8 and 86.4) to generate a doubly resistant (kan r & amp r ) plasmid, pSM51-Luc-Kan. The kan r gene was deleted from pSM51- Luc-Kan by partial cleavage with Xbal to generate pSM51-Luc containing the luciferase gene in the E3- parallel orientation. MDBK cells transformed with a plasmid containing the BAV3 El sequences was cotransfected with the wt BAV3 DNA digested with Pvul, which make two cuts within the BAV3 genome at m.u 65.7 and 71.1, and the plasmid, pSM51-Luc to rescue the luciferase gene in E3 of the BAV3 genome by in vivo recombination (Fig. 10) . The digestion of the wt BAV3 DNA with Pvul was helpful in minimizing the generation of the wt virus plaques following cotransfection. The left end of the wt BAV3 genome represented by Pvul 'A' fragment falls between m.u. 0 and 65.7, and pSM51-Luc which extends between m.u. 31.5 and 100 (except for E3 deletion replaced with the luciferase gene) have sufficient overlapping BAV3 DNA sequences to generate recombinant viruses. Two virus plaques were obtained in two independent cotransfection experiments which were grown in MDBK cells. The viral DNA from both plaques was extracted and analyzed by agarose gel electrophoresis after digesting either with BamHI, EcoRI or Xbal to identify the presence and orientation of the luciferase gene in the viral genome (data not shown) . In the genomes of both recombinants, the luciferase gene was present in the E3 region in the E3 parallel orientation. The BAV3-luciferase recombinants were plaque purified and named BAV3-Luc (3.1) and BAV3-Luc (3.2) to represent plaques obtained from two independent experiments. Since both recombinant virus isolates were identical they will be referred to as BAV3-Luc. The presence of the luciferase gene in BAV3-Luc isolates are further confirmed by Southern blot analyses and luciferase assays using extracts from recombinant virus-infected cells. Characterization of BAV3-recombinants Southern blot analyses of the wt BAV3 and recombinants genomic DNA digested either with BamHI, EcoRI or Xbal, were carried out to confirm the presence and orientation of the luciferase gene in the E3 locus and the deletion of the 696 bp Xhol-Ncol fragment from E3 of the BAV3-Luc genome (Fig. 11) . When the blot was probed with a 696 Xhol-Ncol fragment of E3 of the BAV3 genome (panel A, lanes 4 to 9) no hybridization signal was detected with the DNA fragments from the recombinant viruses, however, the expected bands (3.0 kb BamHI, 8.1 kb EcoRI, and 18.5 kb Xbal) of the wt BAV3 DNA fragments (panel A, lanes 10 to 12) showed hybridization, confirming that the 696 bp Xhol-Ncol fragment of the E3 region was indeed deleted in the BAV3-Luc genomic DNA. In panel B, when an identical blot was probed with the luciferase gene, there were strong hybridization signals with the DNA fragments from the recombinant viruses (4.0 kb BamHI (lane 4 S 7), 6.0 kb & 3.2 kb EcoRI (lanes 5 & 8) , 16.7 kb & 2.9 kb Xbal (lanes 6 & 9)). These results confirmed that the BAV3-Luc contains the luciferase gene in the E3 parallel orientation with a 696 bp Xhol-Ncol E3 deletion. The growth characteristics of the recombinant viruses was compared with the wt BAV3 in a single step growth curve (Fig. 12) . Virus titers in MDBK cells-infected with the wt BAV3 started increasing at 12 h post-infection reaching a maximum at 36-48 h post-infection and then declined thereafter. Virus titers of the recombinant viruses also started increasing at 12 h postinfection reaching a maximum at 48 h post-infection and then declined, however, the titers of recombinant viruses remained approximately one log lower than the wt virus. The plaque size of the recombinant viruses were also comparatively smaller than the wt virus (data not shown) . Kinetics of luciferase expression by BAV3-Luc Luciferase activity in BAV3-Luc-infected MDBK cells was monitored at different times post¬ infection by luciferase assays (Fig. 13) . A low level of luciferase activity was first observed at 12 h post-infection reaching a peak at 30 h post-infection and then dropped subsequently. At 30 h post- infection, approximately 425 pg luciferase was detected in 4xl0 5 BAV3-Luc (3.1)-infected MDBK cells. In MDBK cells-infected with the wt BAV3, luciferase expression was not detected (data not shown) . The kinetics of luciferase expression by BAV3-Luc (3.1) and BAV3-Luc (3.2) appears very much similar. The kinetics of luciferase expression also showed that the majority of enzyme expression in virus-infected cells seemed to occur late in infection. To determine luciferase expression in the absence of viral DNA replication, BAV3-Luc-infected MDBK cells were incubated in the presence of an inhibitor of DNA synthesis, 1-jS-D-arabinofuranosyl cytosine (AraC) and luciferase activity was measured in virus-infected cell extracts at various times post-infection and compared to luciferase expression obtained in the absence of AraC (Fig. 14) . When the recombinant virus-infected cells were incubated in the presence of AraC, luciferase expression at 18, 24 and 30 h post- infection was approximately 20-30% of the value obtained in the absence of AraC. These results indicated that the majority of luciferase expression in MDBK cells infected with BAV3-Luc took place after the onset of viral DNA synthesis. To confirm this MDBK cells-infected with the BAV3-Luc were grown in the absence or presence of AraC, harvested at 18 h, 24 h, and 30 h post-infection, viral DNA extracted and analyzed by dot bot analysis using pSM51-Luc (see Fig. 9) as a probe (data not shown) . In the presence of AraC, viral DNA synthesis was severely reduced compared to viral DNA synthesis in the absence of AraC. Western blot analysis of BAV3-Luc-infected cells Luciferase was expressed as an active enzyme as determined by luciferase assays using extracts from MDBK cells-infected with BAV3-Luc (see Fig. 13) . The luciferase gene without any exogenous regulatory sequences was inserted into E3 of the BAV3 genome, therefore, there was a possibility of luciferase expression as a fusion protein with part of an E3 protein if the luciferase gene was in the same frame, Such as, Fl and F3 which represent open reading frames (ORFs) for E3 proteins (Fig. 15) or the fusion protein may arise due to recognition of an upstream initiation codon in the luciferase ORF. To explore this possibility we sequenced the DNA at the junction of the luciferase gene and the BAV3 sequences with the help of a plasmid, pSM51-Luc and a synthetic primer design to bind luciferase coding sequences near the initiation codon (data not shown) . The luciferase coding region fell in frame F2. The luciferase initiation codon was the first start codon in this frame, however, the ORF started at 84 nucleotides upstream of the luciferase start codon. To further confirm that luciferase protein is of the same molecular weight as purified firefly luciferase, unlabeled mock-infected, wt BAV3-infected or BAV3-Luc- infected MDBK cell extracts were reacted with an anti- luciferase antibody in a Western blot (Fig. 16) . A 62 kDa polypeptide band was visible in the BAV3-Luc (lane 3 and 4)-infected cell extracts which were of the same molecular weight as pure firefly luciferase (lane 5) . We are not sure whether a band of approximately 30 kDa which also reacted with the anti-luciferase antibody in lanes 3 and 4 represented a degraded luciferase protein. The majority of luciferase expression is probably driven from the major late promoter (MLP) to provide expression paralleling viral late gene expression, moreover, the enzyme expression seen in the presence of AraC may be taking place from the E3 promoter. In HAd5 vectors, foreign genes without any exogenous regulatory sequences when inserted in E3 also displayed late kinetics and were inhibited by AraC. The BAV3 recombinant virus replicated relatively well in cultured cells but not as good as the wt BAV3. This is not surprising as infectious virus titers of a number of HAd5 recombinants were slightly lower than the wt HAd5 (Bett et al (1993) J Virol. .62:5911-5921). This may be because of reduced expression of fiber protein in recombinant adenoviruses having inserts in the E3 region compared to the wt virus (Bett et al, supra and Mittal et al (1993) Virus Res. 28:67-90). The E3 of BAV3 is approximately half the size of the E3 region of HAd2 or HAd5 and thus has the coding potential for only half the number of proteins compared to E3 of HAd2 or HAd5 (Cladaras et al (1985) Virology 140:28-43: Herisse et al (1980) Nuc. Acids Res. 8 :2173-2192; Herisse et al (1981) Nuc. Acids Res. 2:1229-1249 and Mittal et al (1993 J. Gen. Virol. 21:3295-3000). BAV3 E3 gene products have been shown to be not required for virus growth in tissue culture. However, presently it is known that BAV3 E3 gene products also evade immune surveillance in vivo like HAds E3 proteins. One of the BAV3 E3 open reading frames (ORFs) has been shown to have amino acid homology with the 14.7 kDa E3 protein of HAds (Mittal et al (1993) supra). The 14.7 kDa E3 protein of HAds prevents lysis of virus-infected mouse cells by tumour necrosis factor (Gooding et al (1988) Cell 53:341-346 and Horton et al (1990) J. Virol. 64:1250-1255) . The study of pathogenesis and immune responses of a series of BAV3 E3 deletion mutants in cattle provides very useful information regarding the role of E3 gene products in modulating immune responses in their natural host. The BAV3-based vector has a 0.7 kb E3 deletion which can hold an insert up to 2.5 kb in size. The BAV3 E3 deletion can extend probably up to 1.4 kb which in turn would also increase the insertion capacity of this system. The role of the MLP and the E3 promoter is examined to determine their ability to drive expression of a foreign gene inserted into E3 when a proper polyadenylation signal is provided. Exogenous promoters, such as, the simian virus 40 (SV40) promoter (Subramant et al (1983) Anal. Biochem. 135:1-15) . the human cytomegalovirus immediate early promoter (Boshart et al (1985) Cell 43:215-222) , and the human beta-actin promoter (Gunning et al (1987) PNAS. USA 11:4831-4835) are tested to evaluate their ability to facilitate expression of foreign genes when introduced into E3 of the BAV3 genome. Recently HAd-based expression vectors are under close scrutiny for their potential use in human gene therapy (Ragot et al (1993) Nature 361:647-650; Rosenfeld et al (1991) Science 252:431-434; Rosenfeld et al (1992) Cell 68:141-155 and Stratford-Perricaudet et al (1990) Hum. Gene. Ther. 1:241-256). A preferable adenovirus vector for gene therapy would be one which maintains expression of the required gene for indefinite or for a long period in the target organ or tissue. It may be obtained if the recombinant virus vector genome is incorporate into the host genome or maintained its independent existence extrachromosomally without active virus replication. HAds replicate very well in human, being their natural host. HAds can be made defective in replication by deleting the El region, however, how such vectors would maintain the expression of the target gene in a required fashion is not very clear. Moreover, the presence of anti-HAds antibodies in almost every human being may create some problems with the HAd-based delivery system. The adenovirus genomes have a tendency to form circles in non-permissive cells. BAV-based vectors could provide a possible alternative to HAd-based vectors for human gene therapy. As BAV3 does not replicate in human, the recombinant BAV3 genomes may be maintained as independent circles in human cells providing expression of the essential protein for a long period of time. The foreign gene insertion in animal adenoviruses is much more difficult than HAds because it is hard to develop a cell line which is also good for adenovirus DNA-mediated transfection. This may be one of the major reasons that the development of an animal adenovirus-based expression system has not been reported so far. It took us more than a year to isolate a cell line suitable for BAV3 DNA-mediated transfection. However, the rapid implementation of BAV-based expression vectors for the production of live virus recombinant vaccines for farm animals, is very promising. BAVs grow in the respiratory and gastrointestinal tracts of cattle, therefore, recombinant BAV-based vaccines have use to provide a protective mucosal immune response, in addition to humoral and cellular immune responses, against pathogens where mucosal immunity plays a major role in protection. Example 5 Generation of cell lines transformed with the BAV3 El sequences MDBK cells in monolayer cultures were transfected with pSM71-neo, pSM61-kanl or pSM61-kan2 by a lipofection-mediated transfection technique (GIBCO/BRL, Life Technologies, Inc., Grand Island, NY) . At 48 h after transfection, cells were maintained in the MEM supplemented with 5% fetal bovine serum and 700 μg/ml G418. The medium was changed every 3rd day. In the presence of G418, only those cells would grow which have stably incorporated the plasmid DNA used in transfection experiments into their genomes and are expressing the neo r gene. The cells which have incorporated the neo r gene might also have taken up the BAV3 El sequences and thus expressing BAV3 El protein/s. A number of neo r (i.e., G418-resistant) colonies were isolated, expended and tested for the presence of BAV3 El message/s by Northern blot analyses using a DNA probe containing only the BAV3 El sequences. Expression of BAV3 El protein/s were confirmed by a complimentation assay using a HAd5 deletion mutant defective in El function due to an El deletion. Fetal bovine kidney cells in monolayers were also transfected with pSM71-neo, pSM61kan-l or pSM61- kan2 by the lipofection-mediated transfection technique, electroporation (Chu et al (1987) Nucl. Acids Res. 15:1311-1326), or calcium phosphate precipitation technique (Graham et al (1973) Virology 51:456-467). Similarly, a number of G418-resistant colonies were isolated, expended and tested for the presence of BAV3 El gene products as mentioned above. Example 6 Generation of a BAV3 recombinant containing the beta-galactosidase gene as an El insert As El gene products are essential for virus replication, adenovirus recombinants containing El inserts will grow only in a cell line which is transformed with the adenovirus El sequences and expresses El. A number of cell line which are transformed with the BAV3 El sequences were isolated as described earlier. The technique of foreign gene insertions into the El regions is similar to the gene insertion into the E3 region of the BAV3 genome, however, for insertion into El there is a need of an El transfer plasmid which contains DNA sequences from the left end of the BAV3 genome, an appropriate deletion and a cloning site for the insertion of foreign DNA sequences. G418-resistant MDBK cell monolayers were cotransfected with the wild-type (wt) BAV3 DNA and pSM71-Z following the lipofection- mediated transfection procedure (GIBCO/BRL, Life Technologies, Inc., Grand Island, NY). The monolayers were incubated at 37°C under an agarose overlay. After a week post-incubation an another layer of overlay containing 300 ug/ml Blu-gal™ (GIBCO/BRL Canada, Burlington, Ontario, Canada) was put onto each monolayer. The blue plaques were isolated, plaque purified and the presence of the beta-galactosidase gene in the BAV3 genome was identified by agarose gel electrophoresis of recombinant virus DNA digested with suitable restriction enzymes and confirmed by beta- galactosidase assays using extracts from recombinant . virus infected cells. Deposit of Biological Materials The following materials were deposited and are maintained with the Veterinary Infectious Disease Organization (VIDO) , Saskatoon, Saskatchewan, Canada. The nucleotide sequences of the deposited materials are incorporated by reference herein, as well as the sequences of the polypeptides encoded thereby. In the event of any discrepancy between a sequence expressly disclosed herein and a deposited sequence, the deposited sequence is controlling. Material Internal Accession No. Deposit Date Recombinant plasmids pSM51 pSM51 Dec 6 , 1993 pSM71 pSM71 Dec 6 , 1993 Recombinant cell lines MDBK cells transformed with BAV3 El sequences (MDBK-BAVE1 ) Dec 6 , 1993 Fetal bovine kidney cells transformed with BAV3 El sequences (FBK- BAV-E1 ) Dec 6 , 1993 While the present invention has been illustrated above by certain specific embodiments, the specific examples are not intended to limit the scope of the invention as described in the appended claims . SEQUENCE LISTING (1 ) GENERAL INFORMATION: (i) APPLICANT: UNIVERSITY OF SASKATCHEWAN (ii) TITLE OF INVENTION: RECOMBINANT PROTEIN PRODUCTION IN BOVINE ADENOVIRUS EXPRESSION VECTOR SYSTEM (iii) NUMBER OF SEQUENCES: 34 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: SCOTT & AYLEN (B) STREET: 60 QUEEN STREET (C) CITY: OTTAWA (D) PROVINCE: ONTARIO (E) COUNTRY: CANADA (F)POSTAL CODE: K1 P 5Y7 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: JOAN M. VAN ZANT (B) REFERENCE/DOCKET NUMBER: PAT 21976TW-90 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 1-416-368-2400 (B) TELEFAX: 1-416-363-7246 (2) INFORMATION FOR SEQ ID Nθ:1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join(606..1215, 1323..1345) (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:1: CATCATCAATAATCTACAGTACACTGATGG CAGCGGTCCAACTGCCAATCATTTTTGCCA 60 CGTCATTTATGACGCAACGA CGGCGAGCGTGGCGTGCTGA CGTAACTGTG GGGCGGAGCG 120 CGTCGCGGAG GCGGCGGCGCTGGGCGGGGCTGAGGGCGGC GGGGGCGGCG CGCGGGGCGG 180 CGCGCGGGGCGGGGCGAGGG GCGGAGTTCC GCACCCGCTA CGTCATTTTCAGACATTTTT 240 TAGCAAATTTGCGCCTTTTG CAAGCATTTTTCTCACATTT CAGGTATTTAGAGGGCGGAT 300 TTTTGGTGTTCGTACTTCCG TGTCACATAG TTCACTGTCAATCTTCATTA CGGCTTAGAC 36.0 AAATTTTCGG CGTCTTTTCCGGGTTTATGTCCCCGGTCAC CTTTATGACTGTGTGAAACA 420 CACCTGCCCA TTGTTTACCC TTGGTCAGTT TTTTCGTCTC CTAGGGTGGG AACATCAAGA 480 ACAAATTTGC CGAGTAATTG TGCACCTTTT TCCGCGTTAG GACTGCGTTT CACACGTAGA 540 CAGACTTTTT CTCATTTTCT CACACTCCGT CGTCCGCTTC AGAGCTCTGC GTCTTCGCTG 600 CCACC ATG AAG TAC CTG GTC CTC GTT CTC AAC GAC GGC ATG AGT CGA 647 Met Lys Tyr Leu Val Leu Val Leu Asn Asp Gly Met Ser Arg 1 5 10 ATT GAA AAA GCT CTC CTG TGC AGC GAT GGT GAG GTG GAT TTA GAG TGT 695 He Glu Lys Ala Leu Leu Cys Ser Asp Gly Glu Val Asp Leu Glu Cys 15 20 25 30 CAT GAG GTA CTT CCC CCT TCT CCC GCG CCT GTC CCC GCT TCT GTG TCA 743 His Glu Val Leu Pro Pro Ser Pro Ala Pro Val Pro Ala Ser Val Ser 35 40 45 CCC GTG AGG AGT CCT CCT CCT CTG TCT CCG GTG TTT CCT CCG TCT CCG 791 Pro Val Arg Ser Pro Pro Pro Leu Ser Pro Val Phe Pro Pro Ser Pro 50 55 60 CCA GCC CCG CTT GTG AAT CCA GAG GCG AGT TCG CTG CTG CAG CAG TAT 839 Pro Ala Pro Leu Val Asn Pro Glu Ala Ser Ser Leu Leu Gin Gin Tyr 65 70 75 CGG AGA GAG CTG TTA GAG AGG AGC CTG CTC CGA ACG GCC GAA GGT CAG 887 Arg Arg Glu Leu Leu Glu Arg Ser Leu Leu Arg Thr Ala Glu Gly Gin 80 85 90 CAG CGT GCA GTG TGT CCA TGT GAG CGG TTG CCC GTG GAA GAG GAT GAG 935 Gin Arg Ala Val Cys Pro Cys Glu Arg Leu Pro Val Glu Glu Asp Glu 95 100 105 110 TGT CTG AAT GCC GTA AAT TTG CTG TTT CCT GAT CCC TGG CTA AAT GCA 983 Cys Leu Asn Ala Val Asn Leu Leu Phe Pro Asp Pro Trp Leu Asn Ala 115 120 125 GCT GAA AAT GGG GGT GAT ATT TTT AAG TCT CCG GCT ATG TCT CCA GAA 1031 Ala Glu Asn Gly Gly Asp He Phe Lys Ser Pro Ala Met Ser Pro Glu 130 135 140 CCG TGG ATA GAT TTG TCT AGC TAC GAT AGC GAT GTA GAA GAG GTG ACT 1079 Pro Trp He Asp Leu Ser Ser Tyr Asp Ser Asp Val Glu Glu Val Thr 145 150 155 AGT CAC TTT TTT CTG GAT TGC CCT GAA GAC CCC AGT CGG GAG TGT TCA 1127 Ser His Phe Phe Leu Asp Cys Pro Glu Asp Pro Ser Arg Glu Cys Ser 160 165 170 TCT TGT GGG TTT CAT CAG GCT CAA AGC GGA ATT CCA GGC ATT ATG TGC 1175 Ser Cys Gly Phe His Gin Ala Gin Ser Gly He Pro Gly He Met Cys 175 180 185 190 AGT TTG TGC TAC ATG CGC CAA ACC TAC CAT TGC ATC TAT A GTAAGTACAT 1225 Ser Leu Cys Tyr Met Arg Gin Thr Tyr His Cys He Tyr 195 200 TCTGTAAAAG AACATCTTGG TGATTTCTAG GTATTGTTTA GGGATTAACT GGGTGGAGTG 1285 ATCTTAATCC GGCATAACCA AATACATGTT TTCACAG GT CCA GTT TCT GAA GAG 1339 Ser Pro Val Ser Glu Glu 205 GAA ATG TGAGTCATGT TGACTTTGGC GCGCAAGAGG AAATGTGAGT CATGTTGACT 1395 Glu Met 210 TTGGCGCGCC CTACGGTGAC TTTAAAGCAA TTTGAGGATC ACTTTTTTGT TAGTCGCTAT 1455 AAAGTAGTCA CGGAGTCTTC ATGGATCACT TAAGCGTTCT TTTGGATTTG AAGCTGCTTC 1515 GCTCTATCGT AGCGGGGGCT TCAAATCGCA CTGGAGTGTG GAAGAGGCGG CTGTGGCTGG 1575 GACGCCTGAC TCAACTGGTC CATGATACCT GCGTAGAGAA CGAGAGCATA TTTCTCAATT 1635 CTCTGCCAGG GAATGAAGCT TTTTTAAGGT TGCTTCGGAG CGGCTATTTT GAAGTGTTTG 1695 ACGTGTTTGT GGTGCCTGAG CTGCATCTGG ACACTCCGGG TCGAGTGGTC GCCGCTCTTG 1755 CTCTGCTGGT GTTCATCCTC AACGATTTAG ACGCTAATTC TGCTTCTTCA GGCTTTGATT 1815 CAGGTTTTCT CGTGGACCGT CTCTGCGTGC CGCTATGGCT GAAGGCCAGG GCGTTCAAGA 1875 TCACCCAGAG CTCCAGGAGC ACTTCGCAGC CTTCCTCGTC GCCCGACAAG ACGACCCAGA 1935 CTACCAGCCA GTAGACGGGG ACAGCCCACC CCGGGCTAGC CTGGAGGAGG CTGAACAGAG 1995 CAGCACTCGT TTCGAGCACA TCAGTTACCG AGACGTGGTG GATGACTTCA ATAGATGCCA 2055 TGATGTTTTT TATGAGAGGT ACAGTTTTGA GGACATAAAG AGCTACGAGG CTTTGCCTGA 2115 GGACAATTTG GAGCAGCTCA TAGCTATGCA TGCTAAAATC AAGCTGCTGC CCGGTCGGGA 2175 GTATGAGTTG ACTCAACCTT TGAACATAAC ATCTTGCGCC TATGTGCTCG GAAATGGGGC 2235 TACTATTAGG GTAACAGGGG AAGCCTCCCC GGCTATTAGA GTGGGGGCCA TGGCCGTGGG 2295 TCCGTGTGTA ACAGGAATGA CTGGGGTGAC TTTTGTGAAT TGTAGGTTTG AGAGAGAGTC 2355 AACAATTAGG GGGTCCCTGA TACGAGCTTC AACTCACGTG CTGTTTCATG GCTGTTATTT 2415 TATGGGAATT ATGGGCACTT GTATTGAGGT GGGGGCGGGA GCTTACATTC GGGGTTGTGA 2475 GTTTGTGGGC TGTTACCGGG GAATCTGTTC TACTTCTAAC AGAGATATTA AGGTGAGGCA 2535 GTGCAACTTT GACAAATGCT TACTGGGTAT TACTTGTAAG GGGGACTATC GTCTTTCGGG 2595 AAATGTGTGT TCTGAGACTT TCTGCTTTGC TCATTTAGAG GGAGAGGGTT TGGTTAAAAA 2655 CAACACAGTC AAGTCCCCTA GTCGCTGGAC CAGCGAGTCT GGCTTTTCCA TGATAACTTG 2715 TGCAGACGGC AGGGTTACGC CTTTGGGTTC CCTCCACATT GTGGGCAACC GTTGTAGGCG 2775 TTGGCCAACC ATGCAGGGGA ATGTGTTTAT CATGTCTAAA CTGTATCTGG GCAACAGAAT 2835 AGGGACTGTA GCCCTGCCCC AGTGTGCTTT CTACAAGTCC AGCATTTGTT TGGAGGAGAG 2895 GGCGACAAAC AAGCTGGTCT TGGCTTGTGC TTTTGAGAAT AATGTACTGG TGTACAAAGT 2955 GCTGAGACGG GAGAGTCCCT CAACCGTGAA AATGTGTGTT TGTGGGACTT CTCATTATGC 3015 AAAGCCTTTG ACACTGGCAA TTATTTCTTC AGATATTCGG GCTAATCGAT ACATGTACAC 3075 TGTGGACTCA ACAGAGTTCA CTTCTGACGA GGATTAAAAG TGGGCGGGGC CAAGAGGGGT 3135 ATAAATAGGT GGGGAGGTTG AGGGGAGCCG TAGTTTCTGT TTTTCCCAGA CTGGGGGGGA 3195 CAACATGGCC GAGGAAGGGC GCATTTATGT GCCTTATGTA ACTGCCCGCC TGCCCAAGTG 3255 GTCGGGTTCG GTGCAGGATA AGACGGGCTC GAACATGTTG GGGGGTGTGG TACTCCCTCC 3315 TAATTCACAG GCGCACCGGA CGGAGACCGT GGGCACTGAG GCCACCAGAG ACAACCTGCA 3375 CGCCGAGGGA GCGCGTCGTC CTGAGGATCA GACGCCCTAC ATGATCTTGG TGGAGGACTC 3435 TCTGGGAGGT TTGAAGAGGC GAATGGACTT GCTGGAAGAA TCTAATCAGC AGCTGCTGGC 3495 AACTCTCAAC CGTCTCCGTA CAGGACTCGC TGCCTATGTG CAGGCTAACC TTGTGGGCGG 3555 CCAAGTTAAC CCCTTTGTTT AAATAAAAAT ACACTCATAC AGTTTATTAT GCTGTCAATA 3615 AAATTCTTTA TTTTTCCTGT GATAATACCG TGTCCAGCGT GCTCTGTCAA TAAGGGTCCT 3675 ATGCATCCTG AGAAGGGCCT CATATACCCA TGGCATGAAT ATTAAGATAC ATGGGCATAA 3735 GGCCCTCAGA AGGGTTGAGG TAGAGCCACT GCAGACTTTC GTGGGGAGGT AAGGTGTTGT 3795 AAATAATCCA GTCATACTGA CTGTGCTGGG CGTGGAAGGA AAAGATGTCT TTTAGAAGAA 3855 GGGTGATTGG CAAAGGGAGG CTCTTAGTGT AGGTATTGAT AAATCTGTTC AGTTGGGAGG 3915 GATGCATTCG GGGGCTAATA AGGTGGAGTT TAGCCTGAAT CTTAAGGTTG GCAATGTTGC 3975 CCCCTAGGTC TTTGCGAGGA TTCATGTTGT GCAGTACCAC AAAAACAGAG TAGCCTGTGC 4035 ATTTGGGGAA TTTATCATGA AGCTT 4060 (2) INFORMATION FOR SEQ ID NO:2: Ci) SEQUENCE CHARACTERISTICS: (A) LENGTH: 211 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2: Met Lys Tyr Leu Val Leu Val Leu Asn Asp Gly Met Ser Arg He Glu 1 5 10 15 Lys Ala Leu Leu Cys Ser Asp Gly Glu Val Asp Leu Glu Cys His Glu 20 25 30 Val Leu Pro Pro Ser Pro Ala Pro Val Pro Ala Ser Val Ser Pro Val 35 40 45 Arg Ser Pro Pro Pro Leu Ser Pro Val Phe Pro Pro Ser Pro Pro Ala 50 55 60 Pro Leu Val Asn Pro Glu Ala Ser Ser Leu Leu Gin Gin Tyr Arg Arg 65 70 75 80 Glu Leu Leu Glu Arg Ser Leu Leu Arg Thr Ala Glu Gly Gin Gin Arg 85 90 95 Ala Val Cys Pro Cys Glu Arg Leu Pro Val Glu Glu Asp Glu Cys Leu 100 105 110 Asn Ala Val Asn Leu Leu Phe Pro Asp Pro Trp Leu Asn Ala Ala Glu 115 120 125 Asn Gly Gly Asp He Phe Lys Ser Pro Ala Met Ser Pro Glu Pro Trp 130 135 140 He Asp Leu Ser Ser Tyr Asp Ser Asp Val Glu Glu Val Thr Ser His 145 150 155 160 Phe Phe Leu Asp Cys Pro Glu Asp Pro Ser Arg Glu Cys Ser Ser Cys 165 170 175 Gly Phe His Gin Ala Gin Ser Gly He Pro Gly He Met Cys Ser Leu 180 185 190 Cys Tyr Met Arg Gin Thr Tyr His Cys He Tyr Ser Pro Val Ser Glu 195 200 205 Glu Glu Met 210 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1476..1946 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3: CATCATCAAT AATCTACAGT ACACTGATGG CAGCGGTCCA ACTGCCAATC ATTTTTGCCA 60 CGTCATTTAT GACGCAACGA CGGCGAGCGT GGCGTGCTGA CGTAACTGTG GGGCGGAGCG 120 CGTCGCGGAG GCGGCGGCGC TGGGCGGGGC TGAGGGCGGC GGGGGCGGCG CGCGGGGCGG 180 CGCGCGGGGC GGGGCGAGGG GCGGAGTTCC GCACCCGCTA CGTCATTTTC AGACATTTTT 240 TAGCAAATTT GCGCCTTTTG CAAGCATTTT TCTCACATTT CAGGTATTTA GAGGGCGGAT 300 TTTTGGTGTT CGTACTTCCG TGTCACATAG TTCACTGTCA ATCTTCATTA CGGCTTAGAC 360 AAATTTTCGG CGTCTTTTCC GGGTTTATGT CCCCGGTCAC CTTTATGACT GTGTGAAACA 420 CACCTGCCCA TTGTTTACCC TTGGTCAGTT TTTTCGTCTC CTAGGGTGGG AACATCAAGA 480 ACAAATTTGC CGAGTAATTG TGCACCTTTT TCCGCGTTAG GACTGCGTTT CACACGTAGA 540 CAGACTTTTT CTCATTTTCT CACACTCCGT CGTCCGCTTC AGAGCTCTGC GTCTTCGCTG 600 CCACCATGAA GTACCTGGTC CTCGTTCTCA ACGACGGCAT GAGTCGAATT GAAAAAGCTC 660 TCCTGTGCAG CGATGGTGAG GTGGATTTAG AGTGTCATGA GGTACTTCCC CCTTCTCCCG 720 CGCCTGTCCC CGCTTCTGTG TCACCCGTGA GGAGTCCTCC TCCTCTGTCT CCGGTGTTTC 780 CTCCGTCTCC GCCAGCCCCG CTTGTGAATC CAGAGGCGAG TTCGCTGCTG CAGCAGTATC 840 GGAGAGAGCT GTTAGAGAGG AGCCTGCTCC GAACGGCCGA AGGTCAGCAG CGTGCAGTGT 900 GTCCATGTGA GCGGTTGCCC GTGGAAGAGG ATGAGTGTCT GAATGCCGTA AATTTGCTGT 960 TTCCTGATCC CTGGCTAAAT GCAGCTGAAA ATGGGGGTGA TATTTTTAAG TCTCCGGCTA 1020 TGTCTCCAGA ACCGTGGATA GATTTGTCTA GCTACGATAG CGATGTAGAA GAGGTGACTA 1080 GTCACTTTTT TCTGGATTGC CCTGAAGACC CCAGTCGGGA GTGTTCATCT TGTGGGTTTC 1140 ATCAGGCTCA AAGCGGAATT CCAGGCATTA TGTGCAGTTT GTGCTACATG CGCCAAACCT 1200 ACCATTGCAT CTATAGTAAG TACATTCTGT AAAAGAACAT CTTGGTGATT TCTAGGTATT 1260 GTTTAGGGAT TAACTGGGTG GAGTGATCTT AATCCGGCAT AACCAAATAC ATGTTTTCAC 1320 AGGTCCAGTT TCTGAAGAGG AAATGTGAGT CATGTTGACT TTGGCGCGCA AGAGGAAATG 1380 TGAGTCATGT TGACTTTGGC GCGCCCTACG GTGACTTTAA AGCAATTTGA GGATCACTTT 1440 TTTGTTAGTC GCTATAAAGT AGTCACGGAG TCTTC ATG GAT CAC TTA AGC GTT 1493 Met Asp His Leu Ser Val 1 5 CTT TTG GAT TTG AAG CTG CTT CGC TCT ATC GTA GCG GGG GCT TCA AAT 1541 Leu Leu Asp Leu Lys Leu Leu Arg Ser He Val Ala Gly Ala Ser Asn 10 15 20 CGC ACT GGA GTG TGG AAG AGG CGG CTG TGG CTG GGA CGC CTG ACT CAA 1589 Arg Thr Gly Val Trp Lys Arg Arg Leu Trp Leu Gly Arg Leu Thr Gin 25 30 35 CTG GTC CAT GAT ACC TGC GTA GAG AAC GAG AGC ATA TTT CTC AAT TCT 1637 Leu Val His Asp Thr Cys Val Glu Asn Glu Ser He Phe Leu Asn Ser 40 45 50 CTG CCA GGG AAT GAA GCT TTT TTA AGG TTG CTT CGG AGC GGC TAT TTT 1685 Leu Pro Gly Asn Glu Ala Phe Leu Arg Leu Leu Arg Ser Gly Tyr Phe 55 60 65 70 GAA GTG TTT GAC GTG TTT GTG GTG CCT GAG CTG CAT CTG GAC ACT CCG 1733 Glu Val Phe Asp Val Phe Val Val Pro Glu Leu His Leu Asp Thr Pro 75 80 85 GGT CGA GTG GTC GCC GCT CTT GCT CTG CTG GTG TTC ATC CTC AAC GAT 1781 Gly Arg Val Val Ala Ala Leu Ala Leu Leu Val Phe He Leu Asn Asp 90 95 100 TTA GAC GCT AAT TCT GCT TCT TCA GGC TTT GAT TCA GGT TTT CTC GTG 1829 Leu Asp Ala Asn Ser Ala Ser Ser Gly Phe Asp Ser Gly Phe Leu Val 105 110 115 GAC CGT CTC TGC GTG CCG CTA TGG CTG AAG GCC AGG GCG TTC AAG ATC 1877 Asp Arg Leu Cys Val Pro Leu Trp Leu Lys Ala Arg Ala Phe Lys He 120 125 130 ACC CAG AGC TCC AGG AGC ACT TCG CAG CCT TCC TCG TCG CCC GAC AAG 1925 Thr Gin Ser Ser Arg Ser Thr Ser Gin Pro Ser Ser Ser Pro Asp Lys 135 140 145 150 ACG ACC CAG ACT ACC AGC CAG TAGACGGGGA CAGCCCACCC CGGGCTAGCC 1976 Thr Thr Gin Thr Thr Ser Gin 155 TGGAGGAGGC TGAACAGAGC AGCACTCGTT TCGAGCACAT CAGTTACCGA GACGTGGTGG 2036 ATGACTTCAA TAGATGCCAT GATGTTTTTT ATGAGAGGTA CAGTTTTGAG GACATAAAGA 2096 GCTACGAGGC TTTGCCTGAG GACAATTTGG AGCAGCTCAT AGCTATGCAT GCTAAAATCA 2156 AGCTGCTGCC CGGTCGGGAG TATGAGTTGA CTCAACCTTT GAACATAACA TCTTGCGCCT 2216 ATGTGCTCGG AAATGGGGCT ACTATTAGGG TAACAGGGGA AGCCTCCCCG GCTATTAGAG 2276 TGGGGGCCAT GGCCGTGGGT CCGTGTGTAA CAGGAATGAC TGGGGTGACT TTTGTGAATT 2336 GTAGGTTTGA GAGAGAGTCA ACAATTAGGG GGTCCCTGAT ACGAGCTTCA ACTCACGTGC 2396 TGTTTCATGG CTGTTATTTT ATGGGAATTA TGGGCACTTG TATTGAGGTG GGGGCGGGAG 2456 CTTACATTCG GGGTTGTGAG TTTGTGGGCT GTTACCGGGG AATCTGTTCT ACTTCTAACA 2516 GAGATATTAA GGTGAGGCAG TGCAACTTTG ACAAATGCTT ACTGGGTATT ACTTGTAAGG 2576 GGGACTATCG TCTTTCGGGA AATGTGTGTT CTGAGACTTT CTGCTTTGCT CATTTAGAGG 2636 GAGAGGGTTT GGTTAAAAAC AACACAGTCA AGTCCCCTAG TCGCTGGACC AGCGAGTCTG 2696 GCTTTTCCAT GATAACTTGT GCAGACGGCA GGGTTACGCC TTTGGGTTCC CTCCACATTG 2756 TGGGCAACCG TTGTAGGCGT TGGCCAACCA TGCAGGGGAA TGTGTTTATC ATGTCTAAAC 2816 TGTATCTGGG CAACAGAATA GGGACTGTAG CCCTGCCCCA GTGTGCTTTC TACAAGTCCA 2876 GCATTTGTTT GGAGGAGAGG GCGACAAACA AGCTGGTCTT GGCTTGTGCT TTTGAGAATA 2936 ATGTACTGGT GTACAAAGTG CTGAGACGGG AGAGTCCCTC AACCGTGAAA ATGTGTGTTT 2996 GTGGGACTTC TCATTATGCA AAGCCTTTGA CACTGGCAAT TATTTCTTCA GATATTCGGG 3056 CTAATCGATA CATGTACACT GTGGACTCAA CAGAGTTCAC TTCTGACGAG GATTAAAAGT 3116 GGGCGGGGCC AAGAGGGGTA TAAATAGGTG GGGAGGTTGA GGGGAGCCGT AGTTTCTGTT 3176 TTTCCCAGAC TGGGGGGGAC AACATGGCCG AGGAAGGGCG CATTTATGTG CCTTATGTAA 3236 CTGCCCGCCT GCCCAAGTGG TCGGGTTCGG TGCAGGATAA GACGGGCTCG AACATGTTGG 3296 GGGGTGTGGT ACTCCCTCCT AATTCACAGG CGCACCGGAC GGAGACCGTG GGCACTGAGG 3356 CCACCAGAGA CAACCTGCAC GCCGAGGGAG CGCGTCGTCC TGAGGATCAG ACGCCCTACA 3416 TGATCTTGGT GGAGGACTCT CTGGGAGGTT TGAAGAGGCG AATGGACTTG CTGGAAGAAT 3476 CTAATCAGCA GCTGCTGGCA ACTCTCAACC GTCTCCGTAC AGGACTCGCT GCCTATGTGC 3536 AGGCTAACCT TGTGGGCGGC CAAGTTAACC CCTTTGTTTA AATAAAAATA CACTCATACA 3596 GTTTATTATG CTGTCAATAA AATTCTTTAT TTTTCCTGTG ATAATACCGT GTCCAGCGTG ■ • 3656 CTCTGTCAAT AAGGGTCCTA TGCATCCTGA GAAGGGCCTC ATATACCCAT GGCATGAATA 3716 TTAAGATACA TGGGCATAAG GCCCTCAGAA GGGTTGAGGT AGAGCCACTG CAGACTTTCG 3776 TGGGGAGGTA AGGTGTTGTA AATAATCCAG TCATACTGAC TGTGCTGGGC GTGGAAGGAA 3836 AAGATGTCTT TTAGAAGAAG GGTGATTGGC AAAGGGAGGC TCTTAGTGTA GGTATTGATA 3896 AATCTGTTCA GTTGGGAGGG ATGCATTCGG GGGCTAATAA GGTGGAGTTT AGCCTGAATC 3956 TTAAGGTTGG CAATGTTGCC CCCTAGGTCT TTGCGAGGAT TCATGTTGTG CAGTACCACA 4016 AAAACAGAGT AGCCTGTGCA TTTGGGGAAT TTATCATGAA GCTT 4060 (2) INFORMATION FOR SEQ ID N0:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 157 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Asp His Leu Ser Val Leu Leu Asp Leu Lys Leu Leu Arg Ser He 1 5 10 15 Val Ala Gly Ala Ser Asn Arg Thr Gly Val Trp Lys Arg Arg Leu Trp 20 25 30 Leu Gly Arg Leu Thr Gin Leu Val His Asp Thr Cys Val Glu Asn Glu 35 40 45 Ser He Phe Leu Asn Ser Leu Pro Gly Asn Glu Ala Phe Leu Arg Leu 50 55 60 Leu Arg Ser Gly Tyr Phe Glu Val Phe Asp Val Phe Val Val Pro Glu 65 70 75 80 Leu His Leu Asp Thr Pro Gly Arg Val Val Ala Ala Leu Ala Leu Leu 85 90 95 Val Phe He Leu Asn Asp Leu Asp Ala Asn Ser Ala Ser Ser Gly Phe 100 105 110 Asp Ser Gly Phe Leu Val Asp Arg Leu Cys Val Pro Leu Trp Leu Lys 115 120 125 Ala Arg Ala Phe Lys He Thr Gin Ser Ser Arg Ser Thr Ser Gin Pro 130 135 140 Ser Ser Ser Pro Asp Lys Thr Thr Gin Thr Thr Ser Gin 145 150 155 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1850..3109 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: CATCATCAAT AATCTACAGT ACACTGATGG CAGCGGTCCA ACTGCCAATC ATTTTTGCCA 60 CGTCATTTAT GACGCAACGA CGGCGAGCGT GGCGTGCTGA CGTAACTGTG GGGCGGAGCG 120 CGTCGCGGAG GCGGCGGCGC TGGGCGGGGC TGAGGGCGGC GGGGGCGGCG CGCGGGGCGG 180 CGCGCGGGGC GGGGCGAGGG GCGGAGTTCC GCACCCGCTA CGTCATTTTC AGACATTTTT 240 TAGCAAATTT GCGCCTTTTG CAAGCATTTT TCTCACATTT CAGGTATTTA GAGGGCGGAT 300 TTTTGGTGTT CGTACTTCCG TGTCACATAG TTCACTGTCA ATCTTCATTA CGGCTTAGAC 360 AAATTTTCGG CGTCTTTTCC GGGTTTATGT CCCCGGTCAC CTTTATGACT GTGTGAAACA 420 CACCTGCCCA TTGTTTACCC TTGGTCAGTT TTTTCGTCTC CTAGGGTGGG AACATCAAGA 480 ACAAATTTGC CGAGTAATTG TGCACCTTTT TCCGCGTTAG GACTGCGTTT CACACGTAGA 540 CAGACTTTTT CTCATTTTCT CACACTCCGT CGTCCGCTTC AGAGCTCTGC GTCTTCGCTG 600 CCACCATGAA GTACCTGGTC CTCGTTCTCA ACGACGGCAT GAGTCGAATT GAAAAAGCTC 660 TCCTGTGCAG CGATGGTGAG GTGGATTTAG AGTGTCATGA GGTACTTCCC CCTTCTCCCG 720 CGCCTGTCCC CGCTTCTGTG TCACCCGTGA GGAGTCCTCC TCCTCTGTCT CCGGTGTTTC 780 CTCCGTCTCC GCCAGCCCCG CTTGTGAATC CAGAGGCGAG TTCGCTGCTG CAGCAGTATC 840 GGAGAGAGCT GTTAGAGAGG AGCCTGCTCC GAACGGCCGA AGGTCAGCAG CGTGCAGTGT 900 GTCCATGTGA GCGGTTGCCC GTGGAAGAGG ATGAGTGTCT GAATGCCGTA AATTTGCTGT 960 TTCCTGATCC CTGGCTAAAT GCAGCTGAAA ATGGGGGTGA TATTTTTAAG TCTCCGGCTA 1020 TGTCTCCAGA ACCGTGGATA GATTTGTCTA GCTACGATAG CGATGTAGAA GAGGTGACTA 1080 GTCACTTTTT TCTGGATTGC CCTGAAGACC CCAGTCGGGA GTGTTCATCT TGTGGGTTTC 1140 ATCAGGCTCA AAGCGGAATT CCAGGCATTA TGTGCAGTTT GTGCTACATG CGCCAAACCT 1200 ACCATTGCAT CTATAGTAAG TACATTCTGT AAAAGAACAT CTTGGTGATT TCTAGGTATT 1260 GTTTAGGGAT TAACTGGGTG GAGTGATCTT AATCCGGCAT AACCAAATAC ATGTTTTCAC 1320 AGGTCCAGTT TCTGAAGAGG AAATGTGAGT CATGTTGACT TTGGCGCGCA AGAGGAAATG 1380 TGAGTCATGT TGACTTTGGC GCGCCCTACG GTGACTTTAA AGCAATTTGA GGATCACTTT 1440 TTTGTTAGTC GCTATAAAGT AGTCACGGAG TCTTCATGGA TCACTTAAGC GTTCTTTTGG 1500 ATTTGAAGCT GCTTCGCTCT ATCGTAGCGG GGGCTTCAAA TCGCACTGGA GTGTGGAAGA 1560 GGCGGCTGTG GCTGGGACGC CTGACTCAAC TGGTCCATGA TACCTGCGTA GAGAACGAGA 1620 GCATATTTCT CAATTCTCTG CCAGGGAATG AAGCTTTTTT AAGGTTGCTT CGGAGCGGCT 1680 ATTTTGAAGT GTTTGACGTG TTTGTGGTGC CTGAGCTGCA TCTGGACACT CCGGGTCGAG 1740 TGGTCGCCGC TCTTGCTCTG CTGGTGTTCA TCCTCAACGA TTTAGACGCT AATTCTGCTT 1800 CTTCAGGCTT TGATTCAGGT TTTCTCGTGG ACCGTCTCTG CGTGCCGCT ATG GCT 1855 Met Ala 1 GAA GGC CAG GGC GTT CAA GAT CAC CCA GAG CTC CAG GAG CAC TTC GCA 1903 Glu Gly Gin Gly Val Gin Asp His Pro Glu Leu Gin Glu His Phe Ala 5 10 15 GCC TTC CTC GTC GCC CGA CAA GAC GAC CCA GAC TAC CAG CCA GTA GAC 1951 Ala Phe Leu Val Ala Arg Gin Asp Asp Pro Asp Tyr Gin Pro Val Asp 20 25 30 GGG GAC AGC CCA CCC CGG GCT AGC CTG GAG GAG GCT GAA CAG AGC AGC 1999 Gly Asp Ser Pro Pro Arg Ala Ser Leu Glu Glu Ala Glu Gin Ser Ser 35 40 45 50 ACT CGT TTC GAG CAC ATC AGT TAC CGA GAC GTG GTG GAT GAC TTC AAT 2047 Thr Arg Phe Glu His He Ser Tyr Arg Asp Val Val Asp Asp Phe Asn .55 60 65 AGA TGC CAT GAT GTT TTT TAT GAG AGG TAC AGT TTT GAG GAC ATA AAG 2095 Arg Cys His Asp Val Phe Tyr Glu Arg Tyr Ser Phe Glu Asp He Lys 70 75 80 AGC TAC GAG GCT TTG CCT GAG GAC AAT TTG GAG CAG CTC ATA GCT ATG 2143 Ser Tyr Glu Ala Leu Pro Glu Asp Asn Leu Glu Gin Leu He Ala Met 85 90 95 CAT GCT AAA ATC AAG CTG CTG CCC GGT CGG GAG TAT GAG TTG ACT CAA 2191 His Ala Lys He Lys Leu Leu Pro Gly Arg Glu Tyr Glu Leu Thr Gin 100 105 110 CCT TTG AAC ATA ACA TCT TGC GCC TAT GTG CTC GGA AAT GGG GCT ACT 2239 Pro Leu Asn He Thr Ser Cys Ala Tyr Val Leu Gly Asn Gly Ala Thr 115 120 125 130 ATT AGG GTA ACA GGG GAA GCC TCC CCG GCT ATT AGA GTG GGG GCC ATG 2287 He Arg Val Thr Gly Glu Ala Ser Pro Ala He Arg Val Gly Ala Met 135 140 145 GCC GTG GGT CCG TGT GTA ACA GGA ATG ACT GGG GTG ACT TTT GTG AAT 2335 Ala Val Gly Pro Cys Val Thr Gly Met Thr Gly Val Thr Phe Val Asn 150 155 160 TGT AGG TTT GAG AGA GAG TCA ACA ATT AGG GGG TCC CTG ATA CGA GCT 2383 Cys Arg Phe Glu Arg Glu Ser Thr He Arg Gly Ser Leu He Arg Ala 165 170 175 TCA ACT CAC GTG CTG TTT CAT GGC TGT TAT TTT ATG GGA ATT ATG GGC 2431 Ser Thr His Val Leu Phe His Gly Cys Tyr Phe Met Gly He Met Gly 180 185 190 ACT TGT ATT GAG GTG GGG GCG GGA GCT TAC ATT CGG GGT TGT GAG TTT 2479 Thr Cys He Glu Val Gly Ala Gly Ala Tyr He Arg Gly Cys Glu Phe 195 200 205 210 GTG GGC TGT TAC CGG GGA ATC TGT TCT ACT TCT AAC AGA GAT ATT AAG 2527 Val Gly Cys Tyr Arg Gly He Cys Ser Thr Ser Asn Arg Asp He Lys 215 220 225 GTG AGG CAG TGC AAC TTT GAC AAA TGC TTA CTG GGT ATT ACT TGT AAG 2575 Val Arg Gin Cys Asn Phe Asp Lys Cys Leu Leu Gly He Thr Cys Lys 230 235 240 GGG GAC TAT CGT CTT TCG GGA AAT GTG TGT TCT GAG ACT TTC TGC TTT 2623 Gly Asp Tyr Arg Leu Ser Gly Asn Val Cys Ser Glu Thr Phe Cys Phe 245 250 255 GCT CAT TTA GAG GGA GAG GGT TTG GTT AAA AAC AAC ACA GTC AAG TCC 2671 Ala His Leu Glu Gly Glu Gly Leu Val Lys Asn Asn Thr Val Lys Ser 260 265 270 CCT AGT CGC TGG ACC AGC GAG TCT GGC TTT TCC ATG ATA ACT TGT GCA 2719 Pro Ser Arg Trp Thr Ser Glu Ser Gly Phe Ser Met He Thr Cys Ala 275 280 285 290 GAC GGC AGG GTT ACG CCT TTG GGT TCC CTC CAC ATT GTG GGC AAC CGT 2767 Asp Gly Arg Val Thr Pro Leu Gly Ser Leu His He Val Gly Asn Arg 295 300 305 TGT AGG CGT TGG CCA ACC ATG CAG GGG AAT GTG TTT ATC ATG TCT AAA 2815 Cys Arg Arg Trp Pro Thr Met Gin Gly Asn Val Phe He Met Ser Lys 310 315 320 CTG TAT CTG GGC AAC AGA ATA GGG ACT GTA GCC CTG CCC CAG TGT GCT 2863 Leu Tyr Leu Gly Asn Arg He Gly Thr Val Ala Leu Pro Gin Cys Ala 325 330 335 TTC TAC AAG TCC AGC ATT TGT TTG GAG GAG AGG GCG ACA AAC AAG CTG 2911 Phe Tyr Lys Ser Ser He Cys Leu Glu Glu Arg Ala Thr Asn Lys Leu 340 345 350 GTC TTG GCT TGT GCT TTT GAG AAT AAT GTA CTG GTG TAC AAA GTG CTG 2959 Val Leu Ala Cys Ala Phe Glu Asn Asn Val Leu Val Tyr Lys Val Leu 355 360 365 370 AGA CGG GAG AGT CCC TCA ACC GTG AAA ATG TGT GTT TGT GGG ACT TCT 3007 Arg Arg Glu Ser Pro Ser Thr Val Lys Met Cys Val Cys Gly Thr Ser 375 380 385 CAT TAT GCA AAG CCT TTG ACA CTG GCA ATT ATT TCT TCA GAT ATT CGG 3055 His Tyr Ala Lys Pro Leu Thr Leu Ala He He Ser Ser Asp He Arg 390 395 400 GCT AAT CGA TAC ATG TAC ACT GTG GAC TCA ACA GAG TTC ACT TCT GAC 3103 Ala Asn Arg Tyr Met Tyr Thr Val Asp Ser Thr Glu Phe Thr Ser Asp 405 410 415 GAG GAT TAAAAGTGGG CGGGGCCAAG AGGGGTATAA ATAGGTGGGG AGGTTGAGGG 3159 Glu Asp 420 GAGCCGTAGT TTCTGTTTTT CCCAGACTGG GGGGGACAAC ATGGCCGAGG AAGGGCGCAT 3219 TTATGTGCCT TATGTAACTG CCCGCCTGCC CAAGTGGTCG GGTTCGGTGC AGGATAAGAC 3279 GGGCTCGAAC ATGTTGGGGG GTGTGGTACT CCCTCCTAAT TCACAGGCGC ACCGGACGGA 3339 GACCGTGGGC ACTGAGGCCA CCAGAGACAA CCTGCACGCC GAGGGAGCGC GTCGTCCTGA 3399 GGATCAGACG CCCTACATGA TCTTGGTGGA GGACTCTCTG GGAGGTTTGA AGAGGCGAAT 3459 GGACTTGCTG GAAGAATCTA ATCAGCAGCT GCTGGCAACT CTCAACCGTC TCCGTACAGG 3519 ACTCGCTGCC TATGTGCAGG CTAACCTTGT GGGCGGCCAA GTTAACCCCT TTGTTTAAAT 3579 AAAAATACAC TCATACAGTT TATTATGCTG TCAATAAAAT TCTTTATTTT TCCTGTGATA 3639 ATACCGTGTC CAGCGTGCTC TGTCAATAAG GGTCCTATGC ATCCTGAGAA GGGCCTCATA 3699 TACCCATGGC ATGAATATTA AGATACATGG GCATAAGGCC CTCAGAAGGG TTGAGGTAGA 3759 GCCACTGCAG ACTTTCGTGG GGAGGTAAGG TGTTGTAAAT AATCCAGTCA TACTGACTGT 3819 GCTGGGCGTG GAAGGAAAAG ATGTCTTTTA GAAGAAGGGT GATTGGCAAA GGGAGGCTCT 3879 TAGTGTAGGT ATTGATAAAT CTGTTCAGTT GGGAGGGATG CATTCGGGGG CTAATAAGGT 3939 GGAGTTTAGC CTGAATCTTA AGGTTGGCAA TGTTGCCCCC TAGGTCTTTG CGAGGATTCA 3999 TGTTGTGCAG TACCACAAAA ACAGAGTAGC CTGTGCATTT GGGGAATTTA TCATGAAGCT 4059 T 4060 (2) INFORMATION FOR SEQ ID N0:6: Ci) SEQUENCE CHARACTERISTICS: (A) LENGTH: 420 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Ala Glu Gly Gin Gly Val Gin Asp His Pro Glu Leu Gin Glu His 1 5 10 15 Phe Ala Ala Phe Leu Val Ala Arg Gin Asp Asp Pro Asp Tyr Gin Pro 20 25 30 Val Asp Gly Asp Ser Pro Pro Arg Ala Ser Leu Glu Glu Ala Glu Gin 35 40 45 Ser Ser Thr Arg Phe Glu His He Ser Tyr Arg Asp Val Val Asp Asp 50 55 60 Phe Asn Arg Cys His Asp Val Phe Tyr Glu Arg Tyr Ser Phe Glu Asp 65 70 75 80 He Lys Ser Tyr Glu Ala Leu Pro Glu Asp Asn Leu Glu Gin Leu He 85 90 95 Ala Met His Ala Lys He Lys Leu Leu Pro Gly Arg Glu Tyr Glu Leu 100 105 110 Thr Gin Pro Leu Asn He Thr Ser Cys Ala Tyr Val Leu Gly Asn Gly 115 120 125 Ala Thr He Arg Val Thr Gly Glu Ala Ser Pro Ala He Arg Val Gly 130 135 140 Ala Met Ala Val Gly Pro Cys Val Thr Gly Met Thr Gly Val Thr Phe 145 150 155 160 Val Asn Cys Arg Phe Glu Arg Glu Ser Thr He Arg Gly Ser Leu He 165 170 175 Arg Ala Ser Thr His Val Leu Phe His Gly Cys Tyr Phe Met Gly He 180 185 190 Met Gly Thr Cys He Glu Val Gly Ala Gly Ala Tyr He Arg Gly Cys 195 200 205 Glu Phe Val Gly Cys Tyr Arg Gly He Cys Ser Thr Ser Asn Arg Asp 210 215 220 He Lys Val Arg Gin Cys Asn Phe Asp Lys Cys Leu Leu Gly He Thr 225 230 235 240 Cys Lys Gly Asp Tyr Arg Leu Ser Gly Asn Val Cys Ser Glu Thr Phe 245 250 255 Cys Phe Ala His Leu Glu Gly Glu Gly Leu Val Lys Asn Asn Thr Val 260 265 270 Lys Ser Pro Ser Arg Trp Thr Ser Glu Ser Gly Phe Ser Met He Thr 275 280 285 Cys Ala Asp Gly Arg Val Thr Pro Leu Gly Ser Leu His He Val Gly 290 295 300 Asn Arg Cys Arg Arg Trp Pro Thr Met Gin Gly Asn Val Phe He Met 305 310 315 320 Ser Lys Leu Tyr Leu Gly Asn Arg He Gly Thr Val Ala Leu Pro Gin 325 330 335 Cys Ala Phe Tyr Lys Ser Ser He Cys Leu Glu Glu Arg Ala Thr Asn 340 345 350 Lys Leu Val Leu Ala Cys Ala Phe Glu Asn Asn Val Leu Val Tyr Lys 355 360 365 Val Leu Arg Arg Glu Ser Pro Ser Thr Val Lys Met Cys Val Cys Gly 370 375 380 Thr Ser His Tyr Ala Lys Pro Leu Thr Leu Ala He He Ser Ser Asp 385 390 395 400 He Arg Ala Asn Arg Tyr Met Tyr Thr Val Asp Ser Thr Glu Phe Thr 405 410 415 Ser Asp Glu Asp 420 (2) INFORMATION FOR SEQ ID N0:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D> TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3200..3574 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CATCATCAAT AATCTACAGT ACACTGATGG CAGCGGTCCA ACTGCCAATC ATTTTTGCCA 60 CGTCATTTAT GACGCAACGA CGGCGAGCGT GGCGTGCTGA CGTAACTGTG GGGCGGAGCG 120 CGTCGCGGAG GCGGCGGCGC TGGGCGGGGC TGAGGGCGGC GGGGGCGGCG CGCGGGGCGG 180 CGCGCGGGGC GGGGCGAGGG GCGGAGTTCC GCACCCGCTA CGTCATTTTC AGACATTTTT 240 TAGCAAATTT GCGCCTTTTG CAAGCATTTT TCTCACATTT CAGGTATTTA GAGGGCGGAT 300 TTTTGGTGTT CGTACTTCCG TGTCACATAG TTCACTGTCA ATCTTCATTA CGGCTTAGAC 360 AAATTTTCGG CGTCTTTTCC GGGTTTATGT CCCCGGTCAC CTTTATGACT GTGTGAAACA 420 CACCTGCCCA TTGTTTACCC TTGGTCAGTT TTTTCGTCTC CTAGGGTGGG AACATCAAGA 480 ACAAATTTGC CGAGTAATTG TGCACCTTTT TCCGCGTTAG GACTGCGTTT CACACGTAGA 540 CAGACTTTTT CTCATTTTCT CACACTCCGT CGTCCGCTTC AGAGCTCTGC GTCTTCGCTG 600 CCACCATGAA GTACCTGGTC CTCGTTCTCA ACGACGGCAT GAGTCGAATT GAAAAAGCTC 660 TCCTGTGCAG CGATGGTGAG GTGGATTTAG AGTGTCATGA GGTACTTCCC CCTTCTCCCG 720 CGCCTGTCCC CGCTTCTGTG TCACCCGTGA GGAGTCCTCC TCCTCTGTCT CCGGTGTTTC 780 CTCCGTCTCC GCCAGCCCCG CTTGTGAATC CAGAGGCGAG TTCGCTGCTG CAGCAGTATC 840 GGAGAGAGCT GTTAGAGAGG AGCCTGCTCC GAACGGCCGA AGGTCAGCAG CGTGCAGTGT 900 GTCCATGTGA GCGGTTGCCC GTGGAAGAGG ATGAGTGTCT GAATGCCGTA AATTTGCTGT 960 TTCCTGATCC CTGGCTAAAT GCAGCTGAAA ATGGGGGTGA TATTTTTAAG TCTCCGGCTA 1020 TGTCTCCAGA ACCGTGGATA GATTTGTCTA GCTACGATAG CGATGTAGAA GAGGTGACTA 1080 GTCACTTTTT TCTGGATTGC CCTGAAGACC CCAGTCGGGA GTGTTCATCT TGTGGGTTTC 1140 ATCAGGCTCA AAGCGGAATT CCAGGCATTA TGTGCAGTTT GTGCTACATG CGCCAAACCT 1200 ACCATTGCAT CTATAGTAAG TACATTCTGT AAAAGAACAT CTTGGTGATT TCTAGGTATT 1260 GTTTAGGGAT TAACTGGGTG GAGTGATCTT AATCCGGCAT AACCAAATAC ATGTTTTCAC 1320 AGGTCCAGTT TCTGAAGAGG AAATGTGAGT CATGTTGACT TTGGCGCGCA AGAGGAAATG 1380 TGAGTCATGT TGACTTTGGC GCGCCCTACG GTGACTTTAA AGCAATTTGA GGATCACTTT 1440 TTTGTTAGTC GCTATAAAGT AGTCACGGAG TCTTCATGGA TCACTTAAGC GTTCTTTTGG 1500 ATTTGAAGCT GCTTCGCTCT ATCGTAGCGG GGGCTTCAAA TCGCACTGGA GTGTGGAAGA 1560 GGCGGCTGTG GCTGGGACGC CTGACTCAAC TGGTCCATGA TACCTGCGTA GAGAACGAGA 1620 GCATATTTCT CAATTCTCTG CCAGGGAATG AAGCTTTTTT AAGGTTGCTT CGGAGCGGCT 1680 ATTTTGAAGT GTTTGACGTG TTTGTGGTGC CTGAGCTGCA TCTGGACACT CCGGGTCGAG 1740 TGGTCGCCGC TCTTGCTCTG CTGGTGTTCA TCCTCAACGA TTTAGACGCT AATTCTGCTT 1800 CTTCAGGCTT TGATTCAGGT TTTCTCGTGG ACCGTCTCTG CGTGCCGCTA TGGCTGAAGG 1860 CCAGGGCGTT CAAGATCACC CAGAGCTCCA GGAGCACTTC GCAGCCTTCC TCGTCGCCCG 1920 ACAAGACGAC CCAGACTACC AGCCAGTAGA CGGGGACAGC CCACCCCGGG CTAGCCTGGA 1980 GGAGGCTGAA CAGAGCAGCA CTCGTTTCGA GCACATCAGT TACCGAGACG TGGTGGATGA 2040 CTTCAATAGA TGCCATGATG TTTTTTATGA GAGGTACAGT TTTGAGGACA TAAAGAGCTA 2100 CGAGGCTTTG CCTGAGGACA ATTTGGAGCA GCTCATAGCT ATGCATGCTA AAATCAAGCT 2160 GCTGCCCGGT CGGGAGTATG AGTTGACTCA ACCTTTGAAC ATAACATCTT GCGCCTATGT 2220 GCTCGGAAAT GGGGCTACTA TTAGGGTAAC AGGGGAAGCC TCCCCGGCTA TTAGAGTGGG 2280 GGCCATGGCC GTGGGTCCGT GTGTAACAGG AATGACTGGG GTGACTTTTG TGAATTGTAG 2340 GTTTGAGAGA GAGTCAACAA TTAGGGGGTC CCTGATACGA GCTTCAACTC ACGTGCTGTT 2400 TCATGGCTGT TATTTTATGG GAATTATGGG CACTTGTATT GAGGTGGGGG CGGGAGCTTA 2460 CATTCGGGGT TGTGAGTTTG TGGGCTGTTA CCGGGGAATC TGTTCTACTT CTAACAGAGA 2520 TATTAAGGTG AGGCAGTGCA ACTTTGACAA ATGCTTACTG GGTATTACTT GTAAGGGGGA 2580 CTATCGTCTT TCGGGAAATG TGTGTTCTGA GACTTTCTGC TTTGCTCATT TAGAGGGAGA 2640 GGGTTTGGTT AAAAACAACA CAGTCAAGTC CCCTAGTCGC TGGACCAGCG AGTCTGGCTT 2700 TTCCATGATA ACTTGTGCAG ACGGCAGGGT TACGCCTTTG GGTTCCCTCC ACATTGTGGG 2760 CAACCGTTGT AGGCGTTGGC CAACCATGCA GGGGAATGTG TTTATCATGT CTAAACTGTA 2820 TCTGGGCAAC AGAATAGGGA CTGTAGCCCT GCCCCAGTGT GCTTTCTACA AGTCCAGCAT 2880 TTGTTTGGAG GAGAGGGCGA CAAACAAGCT GGTCTTGGCT TGTGCTTTTG AGAATAATGT 2940 ACTGGTGTAC AAAGTGCTGA GACGGGAGAG TCCCTCAACC GTGAAAATGT GTGTTTGTGG 3000 GACTTCTCAT TATGCAAAGC CTTTGACACT GGCAATTATT TCTTCAGATA TTCGGGCTAA 3060 TCGATACATG TACACTGTGG ACTCAACAGA GTTCACTTCT GACGAGGATT AAAAGTGGGC 3120 GGGGCCAAGA GGGGTATAAA TAGGTGGGGA GGTTGAGGGG AGCCGTAGTT TCTGTTTTTC 3180 CCAGACTGGG GGGGACAAC ATG GCC GAG GAA GGG CGC ATT TAT GTG CCT TAT 3232 Met Ala Glu Glu Gly Arg He Tyr Val Pro Tyr 1 5 10 GTA ACT GCC CGC CTG CCC AAG TGG TCG GGT TCG GTG CAG GAT AAG ACG 3280 Val Thr Ala Arg Leu Pro Lys Trp Ser Gly Ser Val Gin Asp Lys Thr 15 20 25 GGC TCG AAC ATG TTG GGG GGT GTG GTA CTC CCT CCT AAT TCA CAG GCG 3328 Gly Ser Asn Met Leu Gly Gly Val Val Leu Pro Pro Asn Ser Gin Ala 30 35 40 CAC CGG ACG GAG ACC GTG GGC ACT GAG GCC ACC AGA GAC AAC CTG CAC 3376 His Arg Thr Glu Thr Val Gly Thr Glu Ala Thr Arg Asp Asn Leu His 45 50 55 GCC GAG GGA GCG CGT CGT CCT GAG GAT CAG ACG CCC TAC ATG ATC TTG 3424 Ala Glu Gly Ala Arg Arg Pro Glu Asp Gin Thr Pro Tyr Met He Leu 60 65 70 75 GTG GAG GAC TCT CTG GGA GGT TTG AAG AGG CGA ATG GAC TTG CTG GAA 3472 Val Glu Asp Ser Leu Gly Gly Leu Lys Arg Arg Met Asp Leu Leu Glu 80 85 90 GAA TCT AAT CAG CAG CTG CTG GCA ACT CTC AAC CGT CTC CGT ACA GGA 3520 Glu Ser Asn Gin Gin Leu Leu Ala Thr Leu Asn Arg Leu Arg Thr Gly 95 100 105 CTC GCT GCC TAT GTG CAG GCT AAC CTT GTG GGC GGC CAA GTT AAC CCC 3568 Leu Ala Ala Tyr Val Gin Ala Asn Leu Val Gly Gly Gin Val Asn Pro 110 115 120 TTT GTT TAAATAAAAA TACACTCATA CAGTTTATTA TGCTGTCAAT AAAATTCTTT 3624 Phe Val 125 ATTTTTCCTG TGATAATACC GTGTCCAGCG TGCTCTGTCA ATAAGGGTCC TATGCATCCT 3684 GAGAAGGGCC TCATATACCC ATGGCATGAA TATTAAGATA CATGGGCATA AGGCCCTCAG 3744 AAGGGTTGAG GTAGAGCCAC TGCAGACTTT CGTGGGGAGG TAAGGTGTTG TAAATAATCC 3804 AGTCATACTG ACTGTGCTGG GCGTGGAAGG AAAAGATGTC TTTTAGAAGA AGGGTGATTG 3864 GCAAAGGGAG GCTCTTAGTG TAGGTATTGA TAAATCTGTT CAGTTGGGAG GGATGCATTC 3924 GGGGGCTAAT AAGGTGGAGT TTAGCCTGAA TCTTAAGGTT GGCAATGTTG CCCCCTAGGT 3984 CTTTGCGAGG ATTCATGTTG TGCAGTACCA CAAAAACAGA GTAGCCTGTG CATTTGGGGA 4044 ATTTATCATG AAGCTT 4060 (2) INFORMATION FOR SEQ ID N0:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 125 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Ala Glu Glu Gly Arg He Tyr Val Pro Tyr Val Thr Ala Arg Leu 1 5 10 15 Pro Lys Trp Ser Gly Ser Val Gin Asp Lys Thr Gly Ser Asn Met Leu 20 25 30 Gly Gly Val Val Leu Pro Pro Asn Ser Gin Ala His Arg Thr Glu Thr 35 40 45 Val Gly Thr Glu Ala Thr Arg Asp Asn Leu His Ala Glu Gly Ala Arg 50 55 60 Arg Pro Glu Asp Gin Thr Pro Tyr Met He Leu Val Glu Asp Ser Leu 65 70 75 80 Gly Gly Leu Lys Arg Arg Met Asp Leu Leu Glu Glu Ser Asn Gin Gin 85 90 95 Leu Leu Ala Thr Leu Asn Arg Leu Arg Thr Gly Leu Ala Ala Tyr Val 100 105 110 Gin Ala Asn Leu Val Gly Gly Gin Val Asn Pro Phe Val 115 120 125 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i i ) MOLECULE TYPE: peptide (Xi ) SEQUENCE DESCRIPTION: SEQ ID N0:9: Glu Glu Phe Val Leu Asp Tyr Val Glu His Pro Gly His Gly Cys Arg 1 5 10 15 Ser Cys His Tyr His Arg Arg Asn Thr Gly Asp Pro Asp He Met Cys 20 25 30 Ser Leu Cys Tyr Met Arg Thr Cys Gly Met Phe Val Tyr Ser Pro Val 35 40 45 Ser Glu Pro Glu Pro Glu 50 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 0: He Asp Leu Thr Cys His Glu Ala Gly Phe Pro Pro Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i i ) MOLECULE TYPE: peptide (xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 11 : Leu Asp Phe Ser Thr Pro Gly Arg Ala Ala Ala Ala Val Ala Phe Leu 1 5 10 15 Ser Phe He (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0.-12: Gin Ser Ser Asn Ser Thr Ser 1 5 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 347 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Gin Lys Tyr Ser He Glu Gin Leu Thr Thr Tyr Trp Leu Gin Pro Gly 1 5 10 15 Asp Asp Phe Glu Glu Ala He Arg Val Tyr Ala Lys Val Ala Leu Arg 20 25 30 Pro Asp Cys Lys Tyr Lys He Ser Lys Leu Val Asn He Arg Asn Cys 35 40 45 Cys Tyr He Ser Gly Asn Gly Ala Glu Val Glu He Asp Thr Glu Asp 50 55 60 Arg Val Ala Phe Arg Cys Ser Met He Asn Met Trp Pro Gly Val Leu 65 70 75 80 Gly Met Asp Gly Val Val He Met Asn Val Arg Phe Thr Gly Pro Asn 85 90 95 Phe Ser Gly Thr Val Phe Leu Ala Asn Thr Asn Leu He Leu His Gly 100 105 110 Val Ser Phe Tyr Gly Phe Asn Asn Thr Cys Val Glu Ala Trp Thr Asp 115 120 125 Val Arg Val Arg Gly Cys Ala Phe Tyr Cys Cys Trp Lys Gly Val Val 130 135 140 Cys Arg Pro Lys Ser Arg Ala Ser He Lys Lys Cys Leu Phe Glu Arg 145 150 155 160 Cys Thr Leu Gly He Leu Ser Glu Gly Asn Ser Arg Val Arg His Asn 165 170 175 Val Ala Ser Asp Cys Gly Cys Phe Met Leu Val Lys Ser Val Ala Val 180 185 190 He Lys His Asn Met Val Cys Gly Asn Cys Glu Asp Arg Ala Ser Gin 195 200 205 Met Leu Thr Cys Ser Asp Gly Asn Cys His Leu Leu Lys Thr He His 210 215 220 Val Ala Ser His Ser Arg Lys Ala Trp Pro Val Phe Glu His Asn He 225 230 235 240 Leu His Arg Cys Ser Leu His Leu Gly Asn Arg Arg Gly Val Phe Leu 245 250 255 Pro Tyr Gin Cys Asn Leu Ser His Thr Lys He Leu Leu Glu Pro Glu 260 265 270 Ser Met Ser Lys Val Asn Leu Asn Gly Val Phe Asp Met Thr Met Lys 275 280 285 He Trp Lys Val Leu Arg Tyr Asp Glu Thr Arg Thr Arg Cys Arg Pro 290 295 300 Cys Glu Cys Gly Gly Lys His He Arg Asn Gin Pro Val Met Leu Asp 305 310 315 320 Val Thr Glu Glu Leu Arg Pro Asp His Leu Val Leu Ala Cys His Arg 325 330 335 Ala Glu Phe Gly Ser Ser Asp Glu Asp Thr Asp 340 345 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 140 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Met Ser Thr Asn Ser Phe Asp Gly Ser He Val Ser Ser Tyr Leu Thr 1 5 10 15 Thr Arg Met Pro Pro Trp Ala Gly Val Arg Gin Asn Val Met Gly Ser 20 25 30 Ser He Asp Gly Arg Pro Val Leu Pro Ala Asn Ser Thr Thr Leu Thr 35 40 45 Tyr Glu Thr Val Ser Gly Thr Pro Leu Glu Thr Ala Ala Ser Ala Ala 50 55 60 Ala Ser Ala Ala Ala Ala Thr Ala Arg Gly He Val Thr Asp Phe Ala 65 70 75 80 Phe Leu Ser Pro Leu Ala Ser Ser Ala Ala Ser Arg Ser Ser Ala Arg 85 90 95 Asp Asp Lys Leu Thr Ala Leu Leu Ala Gin Leu Asp Ser Leu Thr Arg 100 ' 105 110 Glu Leu Asn Val Val Ser Gin Gin Leu Leu Asp Leu Arg Gin Gin Val 115 120 125 Ser Ala Leu Lys Ala Ser Ser Pro Pro Asn Ala Val 130 135 140 (2) INFORMATION FOR SEQ ID N0:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..418 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: C CTC ATC AAA CAA CCC GTG GTG GGC ACC ACC CAC GTG GAA ATG CCT 46 Leu He Lys Gin Pro Val Val Gly Thr Thr His Val Glu Met Pro 1 5 10 15 CGC AAC GAA GTC CTA GAA CAA CAT CTG ACC TCA CAT GGC GCT CAA ATC 94 Arg Asn Glu Val Leu Glu Gin His Leu Thr Ser His Gly Ala Gin He 20 25 30 GCG GGC GGA GGC GCT GCG GGC GAT TAC TTT AAA AGC CCC ACT TCA GCT 142 Ala Gly Gly Gly Ala Ala Gly Asp Tyr Phe Lys Ser Pro Thr Ser Ala 35 40 45 CGA ACC CTT ATC CCG CTC ACC GCC TCC TGC TTA AGA CCA GAT GGA GTC 190 Arg Thr Leu He Pro Leu Thr Ala Ser Cys Leu Arg Pro Asp Gly Val 50 55 60 TTT CAA CTA GGA GGA GGC TCG CGT TCA TCT TTC AAC CCC CTG CAA ACA 238 Phe Gin Leu Gly Gly Gly Ser Arg Ser Ser Phe Asn Pro Leu Gin Thr 65 70 75 GAT TTT GCC TTC CAC GCC CTG CCC TCC AGA CCG CGC CAC GGG GGC ATA 286 Asp Phe Ala Phe His Ala Leu Pro Ser Arg Pro Arg His Gly Gly He 80 85 90 95 GGA TCC AGG CAG TTT GTA GAG GAA TTT GTG CCC GCC GTC TAC CTC AAC 334 Gly Ser Arg Gin Phe Val Glu Glu Phe Val Pro Ala Val Tyr Leu Asn 100 105 110 CCC TAC TCG GGA CCG CCG GAC TCT TAT CCG GAC CAG TTT ATA CGC CAC 382 Pro Tyr Ser Gly Pro Pro Asp Ser Tyr Pro Asp Gin Phe He Arg His 115 120 125 TAC AAC GTG TAC AGC AAC TCT GTG AGC GGT TAT AGC TGAGATTGTA 428 Tyr Asn Val Tyr Ser Asn Ser Val Ser Gly Tyr Ser 130 135 AGACTCTCCT ATCTGTCTCT GTGCTGCTTT TCCGCTTCAA GCCCCACAAG CATGAAGGGG 488 TTTCTGCTCA TCTTCAGCCT GCTTGTGCAT TGTCCCCTAA TTCATGTTGG GACCATTAGC 548 TTCTATGCTG CAAGGCCCGG GTCTGAGCCT AACGCGACTT ATGTTTGTGA CTATGGAAGC 608 GAGTCAGATT ACAACCCCAC CAtΪGGTTCTG TGGTTGGCTC GAGAGACCGA TGGCTCCTGG 668 ATCTCTGTTC TTTTCCGTCA CAACGGCTCC TCAACTGCAG CCCCCGGGGT CGTCGCGCAC 728 TTTACTGACC ACAACAGCAG CATTGTGGTG CCCCAGTATT ACCTCCTCAA CAACTCACTC 788 TCTAAGCTCT GCTGCTCATA CCGGCACAAC GAGCGTTCTC AGTTTACCTG CAAACAAGCT 848 GACGTCCCTA CCTGTCACGA GCCCGGCAAG CCGCTCACCC TCCGCGTCTC CCCCGCGCTG 908 GGAACTGCCC ACCAAGCAGT CACTTGGTTT TTTCAAAATG TACCCATAGC TACTGTTTAC 968 CGACCTTGGG GCAATGTAAC TTGGTTTTGT CCTCCCTTCA TGTGTACCTT TAATGTCAGC 1028 CTGAACTCCC TACTTATTTA CAACTTTTCT GACAAAACCG GGGGGCAATA CACAGCTCTC 1088 ATGCACTCCG GACCTGCTTC CCTCTTTCAG CTCTTTAAGC CAACGACTTG TGTCACCAAG 1148 GTGGAGGACC CGCCGTATGC CAACGACCCG GCCTCGCCTG TGTGGCGCCC ACTGCTTTTT 1208 GCCTTCGTCC TCTGCACCGG CTGCGCGGTG TTGTTAACCG CCTTCGGTCC ATCGATTCTA 1268 TCCGGTACCC GAAAGCTTAT CTCAGCCCGC TTTTGGAGTC CCGAGCCCTA TACCACCCTC 1328 CACTAACAGT CCCCCCATGG AGCCAGACGG AGTTCATGCC GAGCAGCAGT TTATCCTCAA 1388 TCAGATTTCC TGCGCCAACA CTGCCCTCCA GCGTCAAAGG GAGGAACTAG CTTCCCTTGT 1448 CATGTTGCAT GCCTGTAAGC GTGGCCTCTT TTGTCCAGTC AAAACTTACA AGCTCAGCCT 1508 CAACGCCTCG GCCAGCGAGC ACAGCCTGCA CTTTGAAAAA AGTCCCTCCC GATTCACCCT 1568 GGTCAACACT CACGCCGGAG CTTCTGTGCG AGTGGCCCTA CACCACCAGG GAGCTTCCGG 1628 CAGCATCCGC TGTTCCTGTT CCCACGCCGA GTGCCTCCCC GTCCTCCTCA AGACCCTCTG 1688 TGCCTTTAAC TTTTTAGATT AGCTGAAAGC AAATATAAAA TGGTGTGCTT ACCGTAATTC 1748 TGTTTTGACT TGTGTGCTTG ATTTCTCCCC CTGCGCCGTA ATCCAGTGCC CCTCTTCAAA 1808 ACTCTCGTAC CCTATGCGAT TCGCATAGGC ATATTTTCTA AAAGCTCTGA AGTCAACATC 1868 ACTCTCAAAC ACTTCTCCGT TGTAGGTTAC TTTCATCTAC AGATAAAGTC ATCCACCGGT 1928 TAACATCATG AAGAGAAGTG TGCCCCAGGA CTTTAATCTT GTGTATCCGT ACAAGGCTAA 1988 GAGGCCCAAC ATCATGCCGC CCTTTTTTGA CCGCAATGGC TTTGTTGAAA ACCAAGAAGC 2048 CACGCTAGCC ATGCTTGTGG AAAAGCCGCT CACGTTCGAC AAGGAAGGTG CGCTGACCCT 2108 GGGCGTCGGA CGCGGCATCC GCATTAACCC CGCGGGGCTT CTGGAGACAA ACGACCTCGC 2168 GTCCGCTGTC TTCCCACCGC TGGCCTCCGA TGAGGCCGGC AACGTCACGC TCAACATGTC 2228 TGACGGGCTA TATACTAAGG ACAACAAGCT AGCTGTCAAA GTAGGTCCCG GGCTGTCCCT 2288 CGACTCCAAT AATGCTCTCC AGGTCCACAC AGGCGACGGG CTCACGGTAA CCGATGACAA 2348 GGTGTCTCTA AATACCCAAG CTCCCCTCTC GACCACCAGC GCGGGCCTCT CCCTACTTCT 2408 GGGTCCCAGC CTCCACTTAG GTGAGGAGGA ACGACTAACA GTAAACACCG GAGCGGGCCT 2468 CCAAATTAGC AATAACGCTC TGGCCGTAAA AGTAGGTTCA GGTATCACCG TAGATGCTCA 2528 AAACCAGCTC GCTGCATCCC TGGGGGACGG TCTAGAAAGC AGAGATAATA AAACTGTCGT 2588 TAAGGCTGGG CCCGGACTTA CAATAACTAA TCAAGCTCTT ACTGTTGCTA CCGGGAACGG 2648 CCTTCAGGTC AACCCGGAAG GGCAACTGCA GCTAAACATT ACTGCCGGTC AGGGCCTCAA 2708 CTTTGCAAAC AACAGCCTCG CCGTGGAGCT GGGCTCGGGC CTGCATTTTC CCCCTGGCCA 2768 AAACCAAGTA AGCCTTTATC CCGGAGATGG AATAGACATC CGAGATAATA GGGTGACTGT 2828 GCCCGCTGGG CCAGGCCTGA GAATGCTCAA CCACCAACTT GCCGTAGCTT CCGGAGACGG 2888 TTTAGAAGTC CACAGCGACA CCCTCCGGTT AAAGCTCTCC CACGGCCTGA CATTTGAAAA 2948 TGGCGCCGTA CGAGCAAAAC TAGGACCAGG ACTTGGCACA GACGACTCTG GTCGGTCCGT 3008 GGTTCGCACA GGTCGAGGAC TTAGAGTTGC AAACGGCCAA GTCCAGATCT TCAGCGGAAG 3068 AGGCACCGCC ATCGGCACTG ATAGCAGCCT CACTCTCAAC ATCCGGGCGC CCCTACAATT 3128 TTCTGGACCC GCCTTGACTG CTAGTTTGCA AGGCAGTGGT CCGATTACTT ACAACAGCAA 3188 CAATGGCACT TTCGGTCTCT CTATAGGCCC CGGAATGTGG GTAGACCAAA ACAGACTTCA 3248 GGTAAACCCA GGCGCTGGTT TAGTCTTCCA AGGAAACAAC CTTGTCCCAA ACCTTGCGGA 3308 TCCGCTGGCT ATTTCCGACA GCAAAATTAG TCTCAGTCTC GGTCCCGGCC TGACCCAAGC 3368 TTCCAACGCC CTGACTTTAA GTTTAGGAAA CGGGCTTGAA TTCTCCAATC AAGCCGTTGC 3428 TATAAAAGCG GGCCGGGGCT TACGCTTTGA GTCTTCCTCA CAAGCTTTAG AGAGCAGCCT 3488 CACAGTCGGA AATGGCTTAA CGCTTACCGA TACTGTGATC CGCCCCAACC TAGGGGACGG 3548 CCTAGAGGTC AGAGACAATA AAATCATTGT TAAGCTGGGC GCGAATCTTC GTTTTGAAAA 3608 CGGAGCCGTA ACCGCCGGCA CCGTTAACCC TTCTGCGCCC GAGGCACCAC CAACTCTCAC 3668 TGCAGAACCA CCCCTCCGAG CCTCCAACTC CCATCTTCAA CTGTCCCTAT CGGAGGGCTT 3728 GGTTGTGCAT AACAACGCCC TTGCTCTCCA ACTGGGAGAC GGCATGGAAG TAAATCAGCA 3788 CGGACTTACT TTAAGAGTAG GCTCGGGTTT GCAAATGCGT GACGGCATTT TAACAGTTAC 3848 ACCCAGCGGC ACTCCTATTG AGCCCAGACT GACTGCCCCA CTGACTCAGA CAGAGAATGG 3908 AATCGGGCTC GCTCTCGGCG CCGGCTTGGA ATTAGACGAG AGCGCGCTCC AAGTAAAAGT 3968 TGGGCCCGGC ATGCGCCTGA ACCCTGTAGA AAAGTATGTA ACCCTGCTCC TGGGTCCTGG 4028 CCTTAGTTTT GGGCAGCCGG CCAACAGGAC AAATTATGAT GTGCGCGTTT CTGTGGAGCC 4088 CCCCATGGTT TTCGGACAGC GTGGTCAGCT CACATTTTTA GTGGGTCACG GACTACACAT 4148 TCAAAATTCC AAACTTCAGC TCAATTTGGG ACAAGGCCTC AGAACTGACC CCGTCACCAA 4208 CCAGCTGGAA GTGCCCCTCG GTCAAGGTTT GGAAATTGCA GACGAATCCC AGGTTAGGGT 4268 TAAATTGGGC GATGGCCTGC AGTTTGATTC ACAAGCTCGC ATCACTACCG CTCCTAACAT 4328 GGTCACTGAA ACTCTGTGGA CCGGAACAGG CAGTAATGCT AATGTTACAT GGCGGGGCTA 4388 CACTGCCCCC GGCAGCAAAC TCTTTTTGAG TCTCACTCGG TTCAGCACTG GTCTAGTTTT 4448 AGGAAACATG ACTATTGACA GCAATGCATC CTTTGGGCAA TACATTAACG CGGGACACGA 4508 ACAGATCGAA TGCTTTATAT TGTTGGACAA TCAGGGTAAC CTAAAAGAAG GATCTAACTT 4568 GCAAGGCACT TGGGAAGTGA AGAACAACCC CTCTGCTTCC AAAGCTGCTT TTTTGCCTTC 4628 CACCGCCCTA TACCCCATCC TCAACGAAAG CCGAGGGAGT CTTCCTGGAA AAAATCTTGT 4688 GGGCATGCAA GCCATACTGG GAGGCGGGGG CACTTGCACT GTGATAGCCA CCCTCAATGG 4748 CAGACGCAGC AACAACTATC CCGCGGGCCA GTCCATAATT TTCGTGTGGC AAGAATTCAA 4808 CACCATAGCC CGCCAACCTC TGAACCACTC TACACTTACT TTTTCTTACT GGACTTAAAT 4868 AAGTTGGAAA TAAAGAGTTA AACTGAATGT TTAAGTGCAA CAGACTTTTA TTGGTTTTGG 4928 CTCACAACAA ATTACAACAG CATAGACAAG TCATACCGGT CAAACAACAC AGGCTCTCGA 4988 AAACGGGCTA ACCGCTCCAA GAATCTGTCA CGCAGACGAG CAAGTCCTAA ATGTTTTTTC 5048 ACTCTCTTCG GGGCCAAGTT CAGCATGTAT CGGATTTTCT GCTTACACCT TT 5100 (2) INFORMATION FOR SEQ ID N0:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 139 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (Xi) SEQUENCE DESCRIPTION: SEQ ID N0:16: Leu He Lys Gin Pro Val Val Gly Thr Thr His Val Glu Met Pro Arg 1 5 10 15 Asn Glu Val Leu Glu Gin His Leu Thr Ser His Gly Ala Gin He Ala 20 25 30 Gly Gly Gly Ala Ala Gly Asp Tyr Phe Lys Ser Pro Thr Ser Ala Arg 35 40 45 Thr Leu He Pro Leu Thr Ala Ser Cys Leu Arg Pro Asp Gly Val Phe 50 55 60 Gln Leu Gly Gly Gly Ser Arg Ser Ser Phe Asn Pro Leu Gin Thr Asp 65 70 75 80 Phe Ala Phe His Ala Leu Pro Ser Arg Pro Arg His Gly Gly He Gly 85 90 95 Ser Arg Gin Phe Val Glu Glu Phe Val Pro Ala Val Tyr Leu Asn Pro 100 105 110 Tyr Ser Gly Pro Pro Asp Ser Tyr Pro Asp Gin Phe He Arg His Tyr 115 120 125 Asn Val Tyr Ser Asn Ser Val Ser Gly Tyr Ser 130 135 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 408..1331 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: CCTCATCAAA CAACCCGTGG TGGGCACCAC CCACGTGGAA ATGCCTCGCA ACGAAGTCCT 60 AGAACAACAT CTGACCTCAC ATGGCGCTCA AATCGCGGGC GGAGGCGCTG CGGGCGATTA 120 CTTTAAAAGC CCCACTTCAG CTCGAACCCT TATCCCGCTC ACCGCCTCCT GCTTAAGACC 180 AGATGGAGTC TTTCAACTAG GAGGAGGCTC GCGTTCATCT TTCAACCCCC TGCAAACAGA 240 TTTTGCCTTC CACGCCCTGC CCTCCAGACC GCGCCACGGG GGCATAGGAT CCAGGCAGTT 300 TGTAGAGGAA TTTGTGCCCG CCGTCTACCT CAACCCCTAC TCGGGACCGC CGGACTCTTA 360 TCCGGACCAG TTTATACGCC ACTACAACGT GTACAGCAAC TCTGTGA GCG GTT ATA 416 Ala Val He 1 GCT GAG ATT GTA AGA CTC TCC TAT CTG TCT CTG TGC TGC TTT TCC GCT 464 Ala Glu He Val Arg Leu Ser Tyr Leu Ser Leu Cys Cys Phe Ser Ala 5 10 15 TCA AGC CCC ACA AGC ATG AAG GGG TTT CTG CTC ATC TTC AGC CTG CTT 512 Ser Ser Pro Thr Ser Met Lys Gly Phe Leu Leu He Phe Ser Leu Leu 20 25 30 35 GTG CAT TGT CCC CTA ATT CAT GTT GGG ACC ATT AGC TTC TAT GCT GCA 560 Val His Cys Pro Leu He His Val Gly Thr He Ser Phe Tyr Ala Ala 40 45 50 AGG CCC GGG TCT GAG CCT AAC GCG ACT TAT GTT TGT GAC TAT GGA AGC 608 Arg Pro Gly Ser Glu Pro Asn Ala Thr Tyr Val Cys Asp Tyr Gly Ser 55 60 65 GAG TCA GAT TAC AAC CCC ACC ACG GTT CTG TGG TTG GCT CGA GAG ACC 656 Glu Ser Asp Tyr Asn Pro Thr Thr Val Leu Trp Leu Ala Arg Glu Thr 70 75 80 GAT GGC TCC TGG ATC TCT GTT CTT TTC CGT CAC AAC GGC TCC TCA ACT 704 Asp Gly Ser Trp He Ser Val Leu Phe Arg His Asn Gly Ser Ser Thr 85 90 95 GCA GCC CCC GGG GTC GTC GCG CAC TTT ACT GAC CAC AAC AGC AGC ATT 752 Ala Ala Pro Gly Val Val Ala His Phe Thr Asp His Asn Ser Ser He 100 105 110 115 GTG GTG CCC CAG TAT TAC CTC CTC AAC AAC TCA CTC TCT AAG CTC TGC 800 Val Val Pro Gin Tyr Tyr Leu Leu Asn Asn Ser Leu Ser Lys Leu Cys 120 125 130 TGC TCA TAC CGG CAC AAC GAG CGT TCT CAG TTT ACC TGC AAA CAA GCT 848 Cys Ser Tyr Arg His Asn Glu Arg Ser Gin Phe Thr Cys Lys Gin Ala 135 140 145 GAC GTC CCT ACC TGT CAC GAG CCC GGC AAG CCG CTC ACC CTC CGC GTC 896 Asp Val Pro Thr Cys His Glu Pro Gly Lys Pro Leu Thr Leu Arg Val 150 155 160 TCC CCC GCG CTG GGA ACT GCC CAC CAA GCA GTC ACT TGG TTT TTT CAA 944 Ser Pro Ala Leu Gly Thr Ala His Gin Ala Val Thr Trp Phe Phe Gin 165 170 175 AAT GTA CCC ATA GCT ACT GTT TAC CGA CCT TGG GGC AAT GTA ACT TGG 992 Asn Val Pro He Ala Thr Val Tyr Arg Pro Trp Gly Asn Val Thr Trp 180 185 190 195 TTT TGT CCT CCC TTC ATG TGT ACC TTT AAT GTC AGC CTG AAC TCC CTA 1040 Phe Cys Pro Pro Phe Met Cys Thr Phe Asn Val Ser Leu Asn Ser Leu 200 205 210 CTT ATT TAC AAC TTT TCT GAC AAA ACC GGG GGG CAA TAC ACA GCT CTC 1088 Leu He Tyr Asn Phe Ser Asp Lys Thr Gly Gly Gin Tyr Thr Ala Leu 215 220 225 ATG CAC TCC GGA CCT GCT TCC CTC TTT CAG CTC TTT AAG CCA ACG ACT 1136 Met His Ser Gly Pro Ala Ser Leu Phe Gin Leu Phe Lys Pro Thr Thr 230 235 240 TGT GTC ACC AAG GTG GAG GAC CCG CCG TAT GCC AAC GAC CCG GCC TCG 1184 Cys Val Thr Lys Val Glu Asp Pro Pro Tyr Ala Asn Asp Pro Ala Ser 245 250 255 CCT GTG TGG CGC CCA CTG CTT TTT GCC TTC GTC CTC TGC ACC GGC TGC 1232 Pro Val Trp Arg Pro Leu Leu Phe Ala Phe Val Leu Cys Thr Gly Cys 260 265 270 275 GCG GTG TTG TTA ACC GCC TTC GGT CCA TCG ATT CTA TCC GGT ACC CGA 1280 Ala Val Leu Leu Thr Ala Phe Gly Pro Ser He Leu Ser Gly Thr Arg 280 285 290 AAG CTT ATC TCA GCC CGC TTT TGG AGT CCC GAG CCC TAT ACC ACC CTC 1328 Lys Leu He Ser Ala Arg Phe Trp Ser Pro Glu Pro Tyr Thr Thr Leu 295 300 305 CAC TAACAGTCCC CCCATGGAGC CAGACGGAGT TCATGCCGAG CAGCAGTTTA 1381 His TCCTCAATCA GATTTCCTGC GCCAACACTG CCCTCCAGCG TCAAAGGGAG GAACTAGCTT 1441 CCCTTGTCAT GTTGCATGCC TGTAAGCGTG GCCTCTTTTG TCCAGTCAAA ACTTACAAGC 1501 TCAGCCTCAA CGCCTCGGCC AGCGAGCACA GCCTGCACTT TGAAAAAAGT CCCTCCCGAT 1561 TCACCCTGGT CAACACTCAC GCCGGAGCTT CTGTGCGAGT GGCCCTACAC CACCAGGGAG 1621 CTTCCGGCAG CATCCGCTGT TCCTGTTCCC ACGCCGAGTG CCTCCCCGTC CTCCTCAAGA 1681 CCCTCTGTGC CTTTAACTTT TTAGATTAGC TGAAAGCAAA TATAAAATGG TGTGCTTACC 1741 GTAATTCTGT TTTGACTTGT GTGCTTGATT TCTCCCCCTG CGCCGTAATC CAGTGCCCCT 1801 CTTCAAAACT CTCGTACCCT ATGCGATTCG CATAGGCATA TTTTCTAAAA GCTCTGAAGT 1861 CAACATCACT CTCAAACACT TCTCCGTTGT AGGTTACTTT CATCTACAGA TAAAGTCATC 1921 CACCGGTTAA CATCATGAAG AGAAGTGTGC CCCAGGACTT TAATCTTGTG TATCCGTACA 1981 AGGCTAAGAG GCCCAACATC ATGCCGCCCT TTTTTGACCG CAATGGCTTT GTTGAAAACC 2041 AAGAAGCCAC GCTAGCCATG CTTGTGGAAA AGCCGCTCAC GTTCGACAAG GAAGGTGCGC 2101 TGACCCTGGG CGTCGGACGC GGCATCCGCA TTAACCCCGC GGGGCTTCTG GAGACAAACG 2161 ACCTCGCGTC CGCTGTCTTC CCACCGCTGG CCTCCGATGA GGCCGGCAAC GTCACGCTCA 2221 ACATGTCTGA CGGGCTATAT ACTAAGGACA ACAAGCTAGC TGTCAAAGTA GGTCCCGGGC 2281 TGTCCCTCGA CTCCAATAAT GCTCTCCAGG TCCACACAGG CGACGGGCTC ACGGTAACCG 2341 ATGACAAGGT GTCTCTAAAT ACCCAAGCTC CCCTCTCGAC CACCAGCGCG GGCCTCTCCC 2401 TACTTCTGGG TCCCAGCCTC CACTTAGGTG AGGAGGAACG ACTAACAGTA AACACCGGAG 2461 CGGGCCTCCA AATTAGCAAT AACGCTCTGG CCGTAAAAGT AGGTTCAGGT ATCACCGTAG 2521 ATGCTCAAAA CCAGCTCGCT GCATCCCTGG GGGACGGTCT AGAAAGCAGA GATAATAAAA 2581 CTGTCGTTAA GGCTGGGCCC GGACTTACAA TAACTAATCA AGCTCTTACT GTTGCTACCG 2641 GGAACGGCCT TCAGGTCAAC CCGGAAGGGC AACTGCAGCT AAACATTACT GCCGGTCAGG 2701 GCCTCAACTT TGCAAACAAC AGCCTCGCCG TGGAGCTGGG CTCGGGCCTG CATTTTCCCC 2761 CTGGCCAAAA CCAAGTAAGC CTTTATCCCG GAGATGGAAT AGACATCCGA GATAATAGGG 2821 TGACTGTGCC CGCTGGGCCA GGCCTGAGAA TGCTCAACCA CCAACTTGCC GTAGCTTCCG 2881 GAGACGGTTT AGAAGTCCAC AGCGACACCC TCCGGTTAAA GCTCTCCCAC GGCCTGACAT 2941 TTGAAAATGG CGCCGTACGA GCAAAACTAG GACCAGGACT TGGCACAGAC GACTCTGGTC 3001 GGTCCGTGGT TCGCACAGGT CGAGGACTTA GAGTTGCAAA CGGCCAAGTC CAGATCTTCA 3061 GCGGAAGAGG CACCGCCATC GGCACTGATA GCAGCCTCAC TCTCAACATC CGGGCGCCCC 3121 TACAATTTTC TGGACCCGCC TTGACTGCTA GTTTGCAAGG CAGTGGTCCG ATTACTTACA 3181 ACAGCAACAA TGGCACTTTC GGTCTCTCTA TAGGCCCCGG AATGTGGGTA GACCAAAACA 3241 GACTTCAGGT AAACCCAGGC GCTGGTTTAG TCTTCCAAGG AAACAACCTT GTCCCAAACC 3301 TTGCGGATCC GCTGGCTATT TCCGACAGCA AAATTAGTCT CAGTCTCGGT CCCGGCCTGA 3361 CCCAAGCTTC CAACGCCCTG ACTTTAAGTT TAGGAAACGG GCTTGAATTC TCCAATCAAG 3421 CCGTTGCTAT AAAAGCGGGC CGGGGCTTAC GCTTTGAGTC TTCCTCACAA GCTTTAGAGA 3481 GCAGCCTCAC AGTCGGAAAT GGCTTAACGC TTACCGATAC TGTGATCCGC CCCAACCTAG 3541 GGGACGGCCT AGAGGTCAGA GACAATAAAA TCATTGTTAA GCTGGGCGCG AATCTTCGTT 3601 TTGAAAACGG AGCCGTAACC GCCGGCACCG TTAACCCTTC TGCGCCCGAG GCACCACCAA 3661 CTCTCACTGC AGAACCACCC CTCCGAGCCT CCAACTCCCA TCTTCAACTG TCCCTATCGG 3721 AGGGCTTGGT TGTGCATAAC AACGCCCTTG CTCTCCAACT GGGAGACGGC ATGGAAGTAA 3781 ATCAGCACGG ACTTACTTTA AGAGTAGGCT CGGGTTTGCA AATGCGTGAC GGCATTTTAA 3841 CAGTTACACC CAGCGGCACT CCTATTGAGC CCAGACTGAC TGCCCCACTG ACTCAGACAG 3901 AGAATGGAAT CGGGCTCGCT CTCGGCGCCG GCTTGGAATT AGACGAGAGC GCGCTCCAAG 3961 TAAAAGTTGG GCCCGGCATG CGCCTGAACC CTGTAGAAAA GTATGTAACC CTGCTCCTGG 4021 GTCCTGGCCT TAGTTTTGGG CAGCCGGCCA ACAGGACAAA TTATGATGTG CGCGTTTCTG 4081 TGGAGCCCCC CATGGTTTTC GGACAGCGTG GTCAGCTCAC ATTTTTAGTG GGTCACGGAC 4141 TACACATTCA AAATTCCAAA CTTCAGCTCA ATTTGGGACA AGGCCTCAGA ACTGACCCCG 4201 TCACCAACCA GCTGGAAGTG CCCCTCGGTC AAGGTTTGGA AATTGCAGAC GAATCCCAGG 4261 TTAGGGTTAA ATTGGGCGAT GGCCTGCAGT TTGATTCACA AGCTCGCATC ACTACCGCTC 4321 CTAACATGGT CACTGAAACT CTGTGGACCG GAACAGGCAG TAATGCTAAT GTTACATGGC 4381 GGGGCTACAC TGCCCCCGGC AGCAAACTCT TTTTGAGTCT CACTCGGTTC AGCACTGGTC 4441 TAGTTTTAGG AAACATGACT ATTGACAGCA ATGCATCCTT TGGGCAATAC ATTAACGCGG 4501 GACACGAACA GATCGAATGC TTTATATTGT TGGACAATCA GGGTAACCTA AAAGAAGGAT 4561 CTAACTTGCA AGGCACTTGG GAAGTGAAGA ACAACCCCTC TGCTTCCAAA GCTGCTTTTT 4621 TGCCTTCCAC CGCCCTATAC CCCATCCTCA ACGAAAGCCG AGGGAGTCTT CCTGGAAAAA 4681 ATCTTGTGGG CATGCAAGCC ATACTGGGAG GCGGGGGCAC TTGCACTGTG ATAGCCACCC 4741 TCAATGGCAG ACGCAGCAAC AACTATCCCG CGGGCCAGTC CATAATTTTC GTGTGGCAAG 4801 AATTCAACAC CATAGCCCGC CAACCTCTGA ACCACTCTAC ACTTACTTTT TCTTACTGGA 4861 CTTAAATAAG TTGGAAATAA AGAGTTAAAC TGAATGTTTA AGTGCAACAG ACTTTTATTG 4921 GTTTTGGCTC ACAACAAATT ACAACAGCAT AGACAAGTCA TACCGGTCAA ACAACACAGG 4981 CTCTCGAAAA CGGGCTAACC GCTCCAAGAA TCTGTCACGC AGACGAGCAA GTCCTAAATG 5041 TTTTTTCACT CTCTTCGGGG CCAAGTTCAG CATGTATCGG ATTTTCTGCT TACACCTTT 5100 (2) INFORMATION FOR SEQ ID N0:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 308 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Ala Val He Ala Glu He Val Arg Leu Ser Tyr Leu Ser Leu Cys Cys 1 5 10 15 Phe Ser Ala Ser Ser Pro Thr Ser Met Lys Gly Phe Leu Leu He Phe 20 25 30 Ser Leu Leu Val His Cys Pro Leu He His Val Gly Thr He Ser Phe 35 40 45 Tyr Ala Ala Arg Pro Gly Ser Glu Pro Asn Ala Thr Tyr Val Cys Asp 50 55 60 Tyr Gly Ser Glu Ser Asp Tyr Asn Pro Thr Thr Val Leu Trp Leu Ala 65 70 75 80 Arg Glu Thr Asp Gly Ser Trp He Ser Val Leu Phe Arg His Asn Gly 85 90 95 Ser Ser Thr Ala Ala Pro Gly Val Val Ala His Phe Thr Asp His Asn 100 105 110 Ser Ser He Val Val Pro Gin Tyr Tyr Leu Leu Asn Asn Ser Leu Ser 115 120 125 Lys Leu Cys Cys Ser Tyr Arg His Asn Glu Arg Ser Gin Phe Thr Cys 130 135 140 Lys Gin Ala Asp Val Pro Thr Cys His Glu Pro Gly Lys Pro Leu Thr 145 150 155 160 Leu Arg Val Ser Pro Ala Leu Gly Thr Ala His Gin Ala Val Thr Trp 165 170 175 Phe Phe Gin Asn Val Pro He Ala Thr Val Tyr Arg Pro Trp Gly Asn 180 185 190 Val Thr Trp Phe Cys Pro Pro Phe Met Cys Thr Phe Asn Val Ser Leu 195 200 205 Asn Ser Leu Leu He Tyr Asn Phe Ser Asp Lys Thr Gly Gly Gin Tyr 210 215 220 Thr Ala Leu Met His Ser Gly Pro Ala Ser Leu Phe Gin Leu Phe Lys 225 230 235 240 Pro Thr Thr Cys Val Thr Lys Val Glu Asp Pro Pro Tyr Ala Asn Asp 245 250 255 Pro Ala Ser Pro Val Trp Arg Pro Leu Leu Phe Ala Phe Val Leu Cys 260 265 270 Thr Gly Cys Ala Val Leu Leu Thr Ala Phe Gly Pro Ser He Leu Ser 275 280 285 Gly Thr Arg Lys Leu He Ser Ala Arg Phe Trp Ser Pro Glu Pro Tyr 290 295 300 Thr Thr Leu His 305 (2) INFORMATION FOR SEQ ID N0:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 529..954 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19: CCTCATCAAA CAACCCGTGG TGGGCACCAC CCACGTGGAA ATGCCTCGCA ACGAAGTCCT 60 AGAACAACAT CTGACCTCAC ATGGCGCTCA AATCGCGGGC GGAGGCGCTG CGGGCGATTA 120 CTTTAAAAGC CCCACTTCAG CTCGAACCCT TATCCCGCTC ACCGCCTCCT GCTTAAGACC 180 AGATGGAGTC TTTCAACTAG GAGGAGGCTC GCGTTCATCT TTCAACCCCC TGCAAACAGA 240 TTTTGCCTTC CACGCCCTGC CCTCCAGACC GCGCCACGGG GGCATAGGAT CCAGGCAGTT 300 TGTAGAGGAA TTTGTGCCCG CCGTCTACCT CAACCCCTAC TCGGGACCGC CGGACTCTTA 360 TCCGGACCAG TTTATACGCC ACTACAACGT GTACAGCAAC TCTGTGAGCG GTTATAGCTG 420 AGATTGTAAG ACTCTCCTAT CTGTCTCTGT GCTGCTTTTC CGCTTCAAGC CCCACAAGCA 480 TGAAGGGGTT TCTGCTCATC TTCAGCCTGC TTGTGCATTG TCCCCTAA TTC ATG TTG 537 Phe Met Leu 1 GGA CCA TTA GCT TCT ATG CTG CAA GGC CCG GGT CTG AGC CTA ACG CGA 585 Gly Pro Leu Ala Ser Met Leu Gin Gly Pro Gly Leu Ser Leu Thr Arg 5 10 15 CTT ATG TTT GTG ACT ATG GAA GCG AGT CAG ATT ACA ACC CCA CCA CGG 633 Leu Met Phe Val Thr Met Glu Ala Ser Gin He Thr Thr Pro Pro Arg 20 25 30 35 TTC TGT GGT TGG CTC GAG AGA CCG ATG GCT CCT GGA TCT CTG TTC TTT 681 Phe Cys Gly Trp Leu Glu Arg Pro Met Ala Pro Gly Ser Leu Phe Phe 40 45 50 TCC GTC ACA ACG GCT CCT CAA CTG CAG CCC CCG GGG TCG TCG CGC ACT 729 Ser Val Thr Thr Ala Pro Gin Leu Gin Pro Pro Gly Ser Ser Arg Thr 55 60 65 TTA CTG ACC ACA ACA GCA GCA TTG TGG TGC CCC AGT ATT ACC TCC TCA 777 Leu Leu Thr Thr Thr Ala Ala Leu Trp Cys Pro Ser He Thr Ser Ser 70 75 80 ACA ACT CAC TCT CTA AGC TCT GCT GCT CAT ACC GGC ACA ACG AGC GTT 825 Thr Thr His Ser Leu Ser Ser Ala Ala His Thr Gly Thr Thr Ser Val 85 90 95 CTC AGT TTA CCT GCA AAC AAG CTG ACG TCC CTA CCT GTC ACG AGC CCG 873 Leu Ser Leu Pro Ala Asn Lys Leu Thr Ser Leu Pro Val Thr Ser Pro 100 105 110 115 GCA AGC CGC TCA CCC TCC GCG TCT CCC CCG CGC TGG GAA CTG CCC ACC 921 Ala Ser Arg Ser Pro Ser Ala Ser Pro Pro Arg Trp Glu Leu Pro Thr 120 125 130 AAG CAG TCA CTT GGT TTT TTC AAA ATG TAC CCA TAGCTACTGT TTACCGACCT 974 Lys Gin Ser Leu Gly Phe Phe Lys Met Tyr Pro 135 140 TGGGGCAATG TAACTTGGTT TTGTCCTCCC TTCATGTGTA CCTTTAATGT CAGCCTGAAC 1034 TCCCTACTTA TTTACAACTT TTCTGACAAA ACCGGGGGGC AATACACAGC TCTCATGCAC 1094 TCCGGACCTG CTTCCCTCTT TCAGCTCTTT AAGCCAACGA CTTGTGTCAC CAAGGTGGAG 1154 GACCCGCCGT ATGCCAACGA CCCGGCCTCG CCTGTGTGGC GCCCACTGCT TTTTGCCTTC 1214 GTCCTCTGCA CCGGCTGCGC GGTGTTGTTA ACCGCCTTCG GTCCATCGAT TCTATCCGGT 1274 ACCCGAAAGC TTATCTCAGC CCGCTTTTGG AGTCCCGAGC CCTATACCAC CCTCCACTAA 1334 CAGTCCCCCC ATGGAGCCAG ACGGAGTTCA TGCCGAGCAG CAGTTTATCC TCAATCAGAT 1394 TTCCTGCGCC AACACTGCCC TCCAGCGTCA AAGGGAGGAA CTAGCTTCCC TTGTCATGTT 1454 GCATGCCTGT AAGCGTGGCC TCTTTTGTCC AGTCAAAACT TACAAGCTCA GCCTCAACGC 1514 CTCGGCCAGC GAGCACAGCC TGCACTTTGA AAAAAGTCCC TCCCGATTCA CCCTGGTCAA 1574 CACTCACGCC GGAGCTTCTG TGCGAGTGGC CCTACACCAC CAGGGAGCTT CCGGCAGCAT 1634 CCGCTGTTCC TGTTCCCACG CCGAGTGCCT CCCCGTCCTC CTCAAGACCC TCTGTGCCTT 1694 TAACTTTTTA GATTAGCTGA AAGCAAATAT AAAATGGTGT GCTTACCGTA ATTCTGTTTT 1754 GACTTGTGTG CTTGATTTCT CCCCCTGCGC CGTAATCCAG TGCCCCTCTT CAAAACTCTC 1814 GTACCCTATG CGATTCGCAT AGGCATATTT TCTAAAAGCT CTGAAGTCAA CATCACTCTC 1874 AAACACTTCT CCGTTGTAGG TTACTTTCAT CTACAGATAA AGTCATCCAC CGGTTAACAT 1934 CATGAAGAGA AGTGTGCCCC AGGACTTTAA TCTTGTGTAT CCGTACAAGG CTAAGAGGCC 1994 CAACATCATG CCGCCCTTTT TTGACCGCAA TGGCTTTGTT GAAAACCAAG AAGCCACGCT 2054 AGCCATGCTT GTGGAAAAGC CGCTCACGTT CGACAAGGAA GGTGCGCTGA CCCTGGGCGT 2114 CGGACGCGGC ATCCGCATTA ACCCCGCGGG GCTTCTGGAG ACAAACGACC TCGCGTCCGC 2174 TGTCTTCCCA CCGCTGGCCT CCGATGAGGC CGGCAACGTC ACGCTCAACA TGTCTGACGG 2234 GCTATATACT AAGGACAACA AGCTAGCTGT CAAAGTAGGT CCCGGGCTGT CCCTCGACTC 2294 CAATAATGCT CTCCAGGTCC ACACAGGCGA CGGGCTCACG GTAACCGATG ACAAGGTGTC 2354 TCTAAATACC CAAGCTCCCC TCTCGACCAC CAGCGCGGGC CTCTCCCTAC TTCTGGGTCC 2414 CAGCCTCCAC TTAGGTGAGG AGGAACGACT AACAGTAAAC ACCGGAGCGG GCCTCCAAAT 2474 TAGCAATAAC GCTCTGGCCG TAAAAGTAGG TTCAGGTATC ACCGTAGATG CTCAAAACCA 2534 GCTCGCTGCA TCCCTGGGGG ACGGTCTAGA AAGCAGAGAT AATAAAACTG TCGTTAAGGC 2594 TGGGCCCGGA CTTACAATAA CTAATCAAGC TCTTACTGTT GCTACCGGGA ACGGCCTTCA 2654 GGTCAACCCG GAAGGGCAAC TGCAGCTAAA CATTACTGCC GGTCAGGGCC TCAACTTTGC 2714 AAACAACAGC CTCGCCGTGG AGCTGGGCTC GGGCCTGCAT TTTCCCCCTG GCCAAAACCA 2774 AGTAAGCCTT TATCCCGGAG ATGGAATAGA CATCCGAGAT AATAGGGTGA CTGTGCCCGC 2834 TGGGCCAGGC CTGAGAATGC TCAACCACCA ACTTGCCGTA GCTTCCGGAG ACGGTTTAGA 2894 AGTCCACAGC GACACCCTCC GGTTAAAGCT CTCCCACGGC CTGACATTTG AAAATGGCGC 2954 CGTACGAGCA AAACTAGGAC CAGGACTTGG CACAGACGAC TCTGGTCGGT CCGTGGTTCG 3014 CACAGGTCGA GGACTTAGAG TTGCAAACGG CCAAGTCCAG ATCTTCAGCG GAAGAGGCAC 3074 CGCCATCGGC ACTGATAGCA GCCTCACTCT CAACATCCGG GCGCCCCTAC AATTTTCTGG 3134 ACCCGCCTTG ACTGCTAGTT TGCAAGGCAG TGGTCCGATT ACTTACAACA GCAACAATGG 3194 CACTTTCGGT CTCTCTATAG GCCCCGGAAT GTGGGTAGAC CAAAACAGAC TTCAGGTAAA 3254 CCCAGGCGCT GGTTTAGTCT TCCAAGGAAA CAACCTTGTC CCAAACCTTG CGGATCCGCT 3314 GGCTATTTCC GACAGCAAAA TTAGTCTCAG TCTCGGTCCC GGCCTGACCC AAGCTTCCAA 3374 CGCCCTGACT TTAAGTTTAG GAAACGGGCT TGAATTCTCC AATCAAGCCG TTGCTATAAA 3434 AGCGGGCCGG GGCTTACGCT TTGAGTCTTC CTCACAAGCT TTAGAGAGCA GCCTCACAGT 3494 CGGAAATGGC TTAACGCTTA CCGATACTGT GATCCGCCCC AACCTAGGGG ACGGCCTAGA 3554 GGTCAGAGAC AATAAAATCA TTGTTAAGCT GGGCGCGAAT CTTCGTTTTG AAAACGGAGC 3614 CGTAACCGCC GGCACCGTTA ACCCTTCTGC GCCCGAGGCA CCACCAACTC TCACTGCAGA 3674 ACCACCCCTC CGAGCCTCCA ACTCCCATCT TCAACTGTCC CTATCGGAGG GCTTGGTTGT 3734 GCATAACAAC GCCCTTGCTC TCCAACTGGG AGACGGCATG GAAGTAAATC AGCACGGACT 3794 TACTTTAAGA GTAGGCTCGG GTTTGCAAAT GCGTGACGGC ATTTTAACAG TTACACCCAG 3854 CGGCACTCCT ATTGAGCCCA GACTGACTGC CCCACTGACT CAGACAGAGA ATGGAATCGG 3914 GCTCGCTCTC GGCGCCGGCT TGGAATTAGA CGAGAGCGCG CTCCAAGTAA AAGTTGGGCC 3974 CGGCATGCGC CTGAACCCTG TAGAAAAGTA TGTAACCCTG CTCCTGGGTC CTGGCCTTAG 4034 TTTTGGGCAG CCGGCCAACA GGACAAATTA TGATGTGCGC GTTTCTGTGG AGCCCCCCAT 4094 GGTTTTCGGA CAGCGTGGTC AGCTCACATT TTTAGTGGGT CACGGACTAC ACATTCAAAA 4154 TTCCAAACTT CAGCTCAATT TGGGACAAGG CCTCAGAACT GACCCCGTCA CCAACCAGCT 4214 GGAAGTGCCC CTCGGTCAAG GTTTGGAAAT TGCAGACGAA TCCCAGGTTA GGGTTAAATT 4274 GGGCGATGGC CTGCAGTTTG ATTCACAAGC TCGCATCACT ACCGCTCCTA ACATGGTCAC 4334 TGAAACTCTG TGGACCGGAA CAGGCAGTAA TGCTAATGTT ACATGGCGGG GCTACACTGC 4394 CCCCGGCAGC AAACTCTTTT TGAGTCTCAC TCGGTTCAGC ACTGGTCTAG TTTTAGGAAA 4454 CATGACTATT GACAGCAATG CATCCTTTGG GCAATACATT AACGCGGGAC ACGAACAGAT 4514 CGAATGCTTT ATATTGTTGG ACAATCAGGG TAACCTAAAA GAAGGATCTA ACTTGCAAGG 4574 CACTTGGGAA GTGAAGAACA ACCCCTCTGC TTCCAAAGCT GCTTTTTTGC CTTCCACCGC 4634 CCTATACCCC ATCCTCAACG AAAGCCGAGG GAGTCTTCCT GGAAAAAATC TTGTGGGCAT 4694 GCAAGCCATA CTGGGAGGCG GGGGCACTTG CACTGTGATA GCCACCCTCA ATGGCAGACG 4754 CAGCAACAAC TATCCCGCGG GCCAGTCCAT AATTTTCGTG TGGCAAGAAT TCAACACCAT 4814 AGCCCGCCAA CCTCTGAACC ACTCTACACT TACTTTTTCT TACTGGACTT AAATAAGTTG 4874 GAAATAAAGA GTTAAACTGA ATGTTTAAGT GCAACAGACT TTTATTGGTT TTGGCTCACA 4934 ACAAATTACA ACAGCATAGA CAAGTCATAC CGGTCAAACA ACACAGGCTC TCGAAAACGG 4994 GCTAACCGCT CCAAGAATCT GTCACGCAGA CGAGCAAGTC CTAAATGTTT TTTCACTCTC 5054 TTCGGGGCCA AGTTCAGCAT GTATCGGATT TTCTGCTTAC ACCTTT 5100 (2) INFORMATION FOR SEQ ID N0:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 142 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:20: Phe Met Leu Gly Pro Leu Ala Ser Met Leu Gin Gly Pro Gly Leu Ser 1 5 10 15 Leu Thr Arg Leu Met Phe Val Thr Met Glu Ala Ser Gin He Thr Thr 20 25 30 Pro Pro Arg Phe Cys Gly Trp Leu Glu Arg Pro Met Ala Pro Gly Ser 35 40 45 Leu Phe Phe Ser Val Thr Thr Ala Pro Gin Leu Gin Pro Pro Gly Ser 50 55 60 Ser Arg Thr Leu Leu Thr Thr Thr Ala Ala Leu Trp Cys Pro Ser He 65 70 75 80 Thr Ser Ser Thr Thr His Ser Leu Ser Ser Ala Ala His Thr Gly Thr 85 90 95 Thr Ser Val Leu Ser Leu Pro Ala Asn Lys Leu Thr Ser Leu Pro Val 100 105 110 Thr Ser Pro Ala Ser Arg Ser Pro Ser Ala Ser Pro Pro Arg Trp Glu 115 120 125 Leu Pro Thr Lys Gin Ser Leu Gly Phe Phe Lys Met Tyr Pro 130 135 140 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1246..1707 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: CCTCATCAAA CAACCCGTGG TGGGCACCAC CCACGTGGAA ATGCCTCGCA ACGAAGTCCT 60 AGAACAACAT CTGACCTCAC ATGGCGCTCA AATCGCGGGC GGAGGCGCTG CGGGCGATTA 120 CTTTAAAAGC CCCACTTCAG CTCGAACCCT TATCCCGCTC ACCGCCTCCT GCTTAAGACC 180 AGATGGAGTC TTTCAACTAG GAGGAGGCTC GCGTTCATCT TTCAACCCCC TGCAAACAGA 240 TTTTGCCTTC CACGCCCTGC CCTCCAGACC GCGCCACGGG GGCATAGGAT CCAGGCAGTT 300 TGTAGAGGAA TTTGTGCCCG CCGTCTACCT CAACCCCTAC TCGGGACCGC CGGACTCTTA 360 TCCGGACCAG TTTATACGCC ACTACAACGT GTACAGCAAC TCTGTGAGCG GTTATAGCTG 420 AGATTGTAAG ACTCTCCTAT CTGTCTCTGT GCTGCTTTTC CGCTTCAAGC CCCACAAGCA 480 TGAAGGGGTT TCTGCTCATC TTCAGCCTGC TTGTGCATTG TCCCCTAATT CATGTTGGGA 540 CCATTAGCTT CTATGCTGCA AGGCCCGGGT CTGAGCCTAA CGCGACTTAT GTTTGTGACT 600 ATGGAAGCGA GTCAGATTAC AACCCCACCA CGGTTCTGTG GTTGGCTCGA GAGACCGATG 660 GCTCCTGGAT CTCTGTTCTT TTCCGTCACA ACGGCTCCTC AACTGCAGCC CCCGGGGTCG 720 TCGCGCACTT TACTGACCAC AACAGCAGCA TTGTGGTGCC CCAGTATTAC CTCCTCAACA 780 ACTCACTCTC TAAGCTCTGC TGCTCATACC GGCACAACGA GCGTTCTCAG TTTACCTGCA 840 AACAAGCTGA CGTCCCTACC TGTCACGAGC CCGGCAAGCC GCTCACCCTC CGCGTCTCCC 900 CCGCGCTGGG AACTGCCCAC CAAGCAGTCA CTTGGTTTTT TCAAAATGTA CCCATAGCTA 960 CTGTTTACCG ACCTTGGGGC AATGTAACTT GGTTTTGTCC TCCCTTCATG TGTACCTTTA 1020 ATGTCAGCCT GAACTCCCTA CTTATTTACA ACTTTTCTGA CAAAACCGGG GGGCAATACA 1080 CAGCTCTCAT GCACTCCGGA CCTGCTTCCC TCTTTCAGCT CTTTAAGCCA ACGACTTGTG 1140 TCACCAAGGT GGAGGACCCG CCGTATGCCA ACGACCCGGC CTCGCCTGTG TGGCGCCCAC 1200 TGCTTTTTGC CTTCGTCCTC TGCACCGGCT GCGCGGTGTT GTTAA CCG CCT TCG 1254 Pro Pro Ser 1 GTC CAT CGA TTC TAT CCG GTA CCC GAA AGC TTA TCT CAG CCC GCT TTT 1302 Val His Arg Phe Tyr Pro Val Pro Glu Ser Leu Ser Gin Pro Ala Phe 5 10 15 GGA GTC CCG AGC CCT ATA CCA CCC TCC ACT AAC AGT CCC CCC ATG GAG 1350 Gly Val Pro Ser Pro He Pro Pro Ser Thr Asn Ser Pro Pro Met Glu 20 25 30 35 CCA GAC GGA GTT CAT GCC GAG CAG CAG TTT ATC CTC AAT CAG ATT TCC 1398 Pro Asp Gly Val His Ala Glu Gin Gin Phe He Leu Asn Gin He Ser 40 45 50 TGC GCC AAC ACT GCC CTC CAG CGT CAA AGG GAG GAA CTA GCT TCC CTT 1446 Cys Ala Asn Thr Ala Leu Gin Arg Gin Arg Glu Glu Leu Ala Ser Leu 55 60 65 GTC ATG TTG CAT GCC TGT AAG CGT GGC CTC TTT TGT CCA GTC AAA ACT 1494 Val Met Leu His Ala Cys Lys Arg Gly Leu Phe Cys Pro Val Lys Thr 70 75 80 TAC AAG CTC AGC CTC AAC GCC TCG GCC AGC GAG CAC AGC CTG CAC TTT 1542 Tyr Lys Leu Ser Leu Asn Ala Ser Ala Ser Glu His Ser Leu His Phe 85 90 95 GAA AAA AGT CCC TCC CGA TTC ACC CTG GTC AAC ACT CAC GCC GGA GCT 1590 Glu Lys Ser Pro Ser Arg Phe Thr Leu Val Asn Thr His Ala Gly Ala 100 105 110 115 TCT GTG CGA GTG GCC CTA CAC CAC CAG GGA GCT TCC GGC AGC ATC CGC 1638 Ser Val Arg Val Ala Leu His His Gin Gly Ala Ser Gly Ser He Arg 120 125 130 TGT TCC TGT TCC CAC GCC GAG TGC CTC CCC GTC CTC CTC AAG ACC CTC 1686 Cys Ser Cys Ser His Ala Glu Cys Leu Pro Val Leu Leu Lys Thr Leu 135 140 145 TGT GCC TTT AAC TTT TTA GAT TAGCTGAAAG CAAATATAAA ATGGTGTGCT 1737 Cys Ala Phe Asn Phe Leu Asp 150 TACCGTAATT CTGTTTTGAC TTGTGTGCTT GATTTCTCCC CCTGCGCCGT AATCCAGTGC 1797 CCCTCTTCAA AACTCTCGTA CCCTATGCGA TTCGCATAGG CATATTTTCT AAAAGCTCTG 1857 AAGTCAACAT CACTCTCAAA CACTTCTCCG TTGTAGGTTA CTTTCATCTA CAGATAAAGT 1917 CATCCACCGG TTAACATCAT GAAGAGAAGT GTGCCCCAGG ACTTTAATCT TGTGTATCCG 1977 TACAAGGCTA AGAGGCCCAA CATCATGCCG CCCTTTTTTG ACCGCAATGG CTTTGTTGAA 2037 AACCAAGAAG CCACGCTAGC CATGCTTGTG GAAAAGCCGC TCACGTTCGA CAAGGAAGGT 2097 GCGCTGACCC TGGGCGTCGG ACGCGGCATC CGCATTAACC CCGCGGGGCT TCTGGAGACA 2157 AACGACCTCG CGTCCGCTGT CTTCCCACCG CTGGCCTCCG ATGAGGCCGG CAACGTCACG 2217 CTCAACATGT CTGACGGGCT ATATACTAAG GACAACAAGC TAGCTGTCAA AGTAGGTCCC 2277 GGGCTGTCCC TCGACTCCAA TAATGCTCTC CAGGTCCACA CAGGCGACGG GCTCACGGTA 2337 ACCGATGACA AGGTGTCTCT AAATACCCAA GCTCCCCTCT CGACCACCAG CGCGGGCCTC 2397 TCCCTACTTC TGGGTCCCAG CCTCCACTTA GGTGAGGAGG AACGACTAAC AGTAAACACC 2457 GGAGCGGGCC TCCAAATTAG CAATAACGCT CTGGCCGTAA AAGTAGGTTC AGGTATCACC 2517 GTAGATGCTC AAAACCAGCT CGCTGCATCC CTGGGGGACG GTCTAGAAAG CAGAGATAAT 2577 AAAACTGTCG TTAAGGCTGG GCCCGGACTT ACAATAACTA ATCAAGCTCT TACTGTTGCT 2637 ACCGGGAACG GCCTTCAGGT CAACCCGGAA GGGCAACTGC AGCTAAACAT TACTGCCGGT 2697 CAGGGCCTCA ACTTTGCAAA CAACAGCCTC GCCGTGGAGC TGGGCTCGGG CCTGCATTTT 2757 CCCCCTGGCC AAAACCAAGT AAGCCTTTAT CCCGGAGATG GAATAGACAT CCGAGATAAT 2817 AGGGTGACTG TGCCCGCTGG GCCAGGCCTG AGAATGCTCA ACCACCAACT TGCCGTAGCT 2877 TCCGGAGACG GTTTAGAAGT CCACAGCGAC ACCCTCCGGT TAAAGCTCTC CCACGGCCTG 2937 ACATTTGAAA ATGGCGCCGT ACGAGCAAAA CTAGGACCAG GACTTGGCAC AGACGACTCT 2997 GGTCGGTCCG TGGTTCGCAC AGGTCGAGGA CTTAGAGTTG CAAACGGCCA AGTCCAGATC 3057 TTCAGCGGAA GAGGCACCGC CATCGGCACT GATAGCAGCC TCACTCTCAA CATCCGGGCG 3117 CCCCTACAAT TTTCTGGACC CGCCTTGACT GCTAGTTTGC AAGGCAGTGG TCCGATTACT 3177 TACAACAGCA ACAATGGCAC TTTCGGTCTC TCTATAGGCC CCGGAATGTG GGTAGACCAA 3237 AACAGACTTC AGGTAAACCC AGGCGCTGGT TTAGTCTTCC AAGGAAACAA CCTTGTCCCA 3297 AACCTTGCGG ATCCGCTGGC TATTTCCGAC AGCAAAATTA GTCTCAGTCT CGGTCCCGGC 3357 CTGACCCAAG CTTCCAACGC CCTGACTTTA AGTTTAGGAA ACGGGCTTGA ATTCTCCAAT 3417 CAAGCCGTTG CTATAAAAGC GGGCCGGGGC TTACGCTTTG AGTCTTCCTC ACAAGCTTTA 3477 GAGAGCAGCC TCACAGTCGG AAATGGCTTA ACGCTTACCG ATACTGTGAT CCGCCCCAAC 3537 CTAGGGGACG GCCTAGAGGT CAGAGACAAT AAAATCATTG TTAAGCTGGG CGCGAATCTT 3597 CGTTTTGAAA ACGGAGCCGT AACCGCCGGC ACCGTTAACC CTTCTGCGCC CGAGGCACCA 3657 CCAACTCTCA CTGCAGAACC ACCCCTCCGA GCCTCCAACT CCCATCTTCA ACTGTCCCTA 3717 TCGGAGGGCT TGGTTGTGCA TAACAACGCC CTTGCTCTCC AACTGGGAGA CGGCATGGAA 3777 GTAAATCAGC ACGGACTTAC TTTAAGAGTA GGCTCGGGTT TGCAAATGCG TGACGGCATT 3837 TTAACAGTTA CACCCAGCGG CACTCCTATT GAGCCCAGAC TGACTGCCCC ACTGACTCAG 3897 ACAGAGAATG GAATCGGGCT CGCTCTCGGC GCCGGCTTGG AATTAGACGA GAGCGCGCTC 3957 CAAGTAAAAG TTGGGCCCGG CATGCGCCTG AACCCTGTAG AAAAGTATGT AACCCTGCTC 4017 CTGGGTCCTG GCCTTAGTTT TGGGCAGCCG GCCAACAGGA CAAATTATGA TGTGCGCGTT 4077 TCTGTGGAGC CCCCCATGGT TTTCGGACAG CGTGGTCAGC TCACATTTTT AGTGGGTCAC 4137 GGACTACACA TTCAAAATTC CAAACTTCAG CTCAATTTGG GACAAGGCCT CAGAACTGAC 4197 CCCGTCACCA ACCAGCTGGA AGTGCCCCTC GGTCAAGGTT TGGAAATTGC AGACGAATCC 4257 CAGGTTAGGG TTAAATTGGG CGATGGCCTG CAGTTTGATT CACAAGCTCG CATCACTACC 4317 GCTCCTAACA TGGTCACTGA AACTCTGTGG ACCGGAACAG GCAGTAATGC TAATGTTACA 4377 TGGCGGGGCT ACACTGCCCC CGGCAGCAAA CTCTTTTTGA GTCTCACTCG GTTCAGCACT 4437 GGTCTAGTTT TAGGAAACAT GACTATTGAC AGCAATGCAT CCTTTGGGCA ATACATTAAC 4497 GCGGGACACG AACAGATCGA ATGCTTTATA TTGTTGGACA ATCAGGGTAA CCTAAAAGAA 4557 GGATCTAACT TGCAAGGCAC TTGGGAAGTG AAGAACAACC CCTCTGCTTC CAAAGCTGCT 4617 TTTTTGCCTT CCACCGCCCT ATACCCCATC CTCAACGAAA GCCGAGGGAG TCTTCCTGGA 4677 AAAAATCTTG TGGGCATGCA AGCCATACTG GGAGGCGGGG GCACTTGCAC TGTGATAGCC 4737 ACCCTCAATG GCAGACGCAG CAACAACTAT CCCGCGGGCC AGTCCATAAT TTTCGTGTGG 4797 CAAGAATTCA ACACCATAGC CCGCCAACCT CTGAACCACT CTACACTTAC TTTTTCTTAC 4857 TGGACTTAAA TAAGTTGGAA ATAAAGAGTT AAACTGAATG TTTAAGTGCA ACAGACTTTT 4917 ATTGGTTTTG GCTCACAACA AATTACAACA GCATAGACAA GTCATACCGG TCAAACAACA 4977 CAGGCTCTCG AAAACGGGCT AACCGCTCCA AGAATCTGTC ACGCAGACGA GCAAGTCCTA 5037 AATGTTTTTT CACTCTCTTC GGGGCCAAGT TCAGCATGTA TCGGATTTTC TGCTTACACC 5097 TTT 5100 (2) INFORMATION FOR SEQ ID N0:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 154 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Pro Pro Ser Val His Arg Phe Tyr Pro Val Pro Glu Ser Leu Ser Gin 1 5 10 15 Pro Ala Phe Gly Val Pro Ser Pro He Pro Pro Ser Thr Asn Ser Pro 20 25 30 Pro Met Glu Pro Asp Gly Val His Ala Glu Gin Gin Phe He Leu Asn 35 40 45 Gin He Ser Cys Ala Asn Thr Ala Leu Gin Arg Gin Arg Glu Glu Leu 50 55 60 Ala Ser Leu Val Met Leu His Ala Cys Lys Arg Gly Leu Phe Cys Pro 65 70 75 80 Val Lys Thr Tyr Lys Leu Ser Leu Asn Ala Ser Ala Ser Glu His Ser 85 90 95 Leu His Phe Glu Lys Ser Pro Ser Arg Phe Thr Leu Val Asn Thr His 100 105 110 Ala Gly Ala Ser Val Arg Val Ala Leu His His Gin Gly Ala Ser Gly 115 120 125 Ser He Arg Cys Ser Cys Ser His Ala Glu Cys Leu Pro Val Leu Leu 130 135 140 Lys Thr Leu Cys Ala Phe Asn Phe Leu Asp 145 150 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1439..1702 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23: CCTCATCAAA CAACCCGTGG TGGGCACCAC CCACGTGGAA ATGCCTCGCA ACGAAGTCCT 60 AGAACAACAT CTGACCTCAC ATGGCGCTCA AATCGCGGGC GGAGGCGCTG CGGGCGATTA 120 CTTTAAAAGC CCCACTTCAG CTCGAACCCT TATCCCGCTC ACCGCCTCCT GCTTAAGACC 180 AGATGGAGTC TTTCAACTAG GAGGAGGCTC GCGTTCATCT TTCAACCCCC TGCAAACAGA 240 TTTTGCCTTC CACGCCCTGC CCTCCAGACC GCGCCACGGG GGCATAGGAT CCAGGCAGTT 300 TGTAGAGGAA TTTGTGCCCG CCGTCTACCT CAACCCCTAC TCGGGACCGC CGGACTCTTA 360 TCCGGACCAG TTTATACGCC ACTACAACGT GTACAGCAAC TCTGTGAGCG GTTATAGCTG 420 AGATTGTAAG ACTCTCCTAT CTGTCTCTGT GCTGCTTTTC CGCTTCAAGC CCCACAAGCA 480 TGAAGGGGTT TCTGCTCATC TTCAGCCTGC TTGTGCATTG TCCCCTAATT CATGTTGGGA 540 CCATTAGCTT CTATGCTGCA AGGCCCGGGT CTGAGCCTAA CGCGACTTAT GTTTGTGACT 600 ATGGAAGCGA GTCAGATTAC AACCCCACCA CGGTTCTGTG GTTGGCTCGA GAGACCGATG 660 GCTCCTGGAT CTCTGTTCTT TTCCGTCACA ACGGCTCCTC AACTGCAGCC CCCGGGGTCG 720 TCGCGCACTT TACTGACCAC AACAGCAGCA TTGTGGTGCC CCAGTATTAC CTCCTCAACA 780 ACTCACTCTC TAAGCTCTGC TGCTCATACC GGCACAACGA GCGTTCTCAG TTTACCTGCA 840 AACAAGCTGA CGTCCCTACC TGTCACGAGC CCGGCAAGCC GCTCACCCTC CGCGTCTCCC 900 CCGCGCTGGG AACTGCCCAC CAAGCAGTCA CTTGGTTTTT TCAAAATGTA CCCATAGCTA 960 CTGTTTACCG ACCTTGGGGC AATGTAACTT GGTTTTGTCC TCCCTTCATG TGTACCTTTA 1020 ATGTCAGCCT GAACTCCCTA CTTATTTACA ACTTTTCTGA CAAAACCGGG GGGCAATACA 1080 CAGCTCTCAT GCACTCCGGA CCTGCTTCCC TCTTTCAGCT CTTTAAGCCA ACGACTTGTG 1140 TCACCAAGGT GGAGGACCCG CCGTATGCCA ACGACCCGGC CTCGCCTGTG TGGCGCCCAC 1200 TGCTTTTTGC CTTCGTCCTC TGCACCGGCT GCGCGGTGTT GTTAACCGCC TTCGGTCCAT 1260 CGATTCTATC CGGTACCCGA AAGCTTATCT CAGCCCGCTT TTGGAGTCCC GAGCCCTATA 1320 CCACCCTCCA CTAACAGTCC CCCCATGGAG CCAGACGGAG TTCATGCCGA GCAGCAGTTT 1380 ATCCTCAATC AGATTTCCTG CGCCAACACT GCCCTCCAGC GTCAAAGGGA GGAACTAG 1438 CTT CCC TTG TCA TGT TGC ATG CCT GTA AGC GTG GCC TCT TTT GTC CAG 1486 Leu Pro Leu Ser Cys Cys Met Pro Val Ser Val Ala Ser Phe Val Gin 1 5 10 15 TCA AAA CTT ACA AGC TCA GCC TCA ACG CCT CGG CCA GCG AGC ACA GCC 1534 Ser Lys Leu Thr Ser Ser Ala Ser Thr Pro Arg Pro Ala Ser Thr Ala 20 25 30 TGC ACT TTG AAA AAA GTC CCT CCC GAT TCA CCC TGG TCA ACA CTC ACG 1582 Cys Thr Leu Lys Lys Val Pro Pro Asp Ser Pro Trp Ser Thr Leu Thr 35 40 45 CCG GAG CTT CTG TGC GAG TGG CCC TAC ACC ACC AGG GAG CTT CCG GCA 1630 Pro Glu Leu Leu Cys Glu Trp Pro Tyr Thr Thr Arg Glu Leu Pro Ala 50 55 60 GCA TCC GCT GTT CCT GTT CCC ACG CCG AGT GCC TCC CCG TCC TCC TCA 1678 Ala Ser Ala Val Pro Val Pro Thr Pro Ser Ala Ser Pro Ser Ser Ser 65 70 75 80 AGA CCC TCT GTG CCT TTA ACT TTT TAGATTAGCT GAAAGCAAAT ATAAAATGGT 1732 Arg Pro Ser Val Pro Leu Thr Phe 85 GTGCTTACCG TAATTCTGTT TTGACTTGTG TGCTTGATTT CTCCCCCTGC GCCGTAATCC 1792 AGTGCCCCTC TTCAAAACTC TCGTACCCTA TGCGATTCGC ATAGGCATAT TTTCTAAAAG 1852 CTCTGAAGTC AACATCACTC TCAAACACTT CTCCGTTGTA GGTTACTTTC ATCTACAGAT 1912 AAAGTCATCC ACCGGTTAAC ATCATGAAGA GAAGTGTGCC CCAGGACTTT AATCTTGTGT 1972 ATCCGTACAA GGCTAAGAGG CCCAACATCA TGCCGCCCTT TTTTGACCGC AATGGCTTTG 2032 TTGAAAACCA AGAAGCCACG CTAGCCATGC TTGTGGAAAA GCCGCTCACG TTCGACAAGG 2092 AAGGTGCGCT GACCCTGGGC GTCGGACGCG GCATCCGCAT TAACCCCGCG GGGCTTCTGG 2152 AGACAAACGA CCTCGCGTCC GCTGTCTTCC CACCGCTGGC CTCCGATGAG GCCGGCAACG 2212 TCACGCTCAA CATGTCTGAC GGGCTATATA CTAAGGACAA CAAGCTAGCT STCAAAGTAG 2272 GTCCCGGGCT GTCCCTCGAC TCCAATAATG CTCTCCAGGT CCACACAGGC GACGGGCTCA 2332 CGGTAACCGA TGACAAGGTG TCTCTAAATA CCCAAGCTCC CCTCTCGACC ACCAGCGCGG 2392 GCCTCTCCCT ACTTCTGGGT CCCAGCCTCC ACTTAGGTGA GGAGGAACGA CTAACAGTAA 2452 ACACCGGAGC GGGCCTCCAA ATTAGCAATA ACGCTCTGGC CGTAAAAGTA GGTTCAGGTA 2512 TCACCGTAGA TGCTCAAAAC CAGCTCGCTG CATCCCTGGG GGACGGTCTA GAAAGCAGAG 2572 ATAATAAAAC TGTCGTTAAG GCTGGGCCCG GACTTACAAT AACTAATCAA GCTCTTACTG 2632 TTGCTACCGG GAACGGCCTT CAGGTCAACC CGGAAGGGCA ACTGCAGCTA AACATTACTG 2692 CCGGTCAGGG CCTCAACTTT GCAAACAACA GCCTCGCCGT GGAGCTGGGC TCGGGCCTGC 2752 ATTTTCCCCC TGGCCAAAAC CAAGTAAGCC TTTATCCCGG AGATGGAATA GACATCCGAG 2812 ATAATAGGGT GACTGTGCCC GCTGGGCCAG GCCTGAGAAT GCTCAACCAC CAACTTGCCG 2872 TAGCTTCCGG AGACGGTTTA GAAGTCCACA GCGACACCCT CCGGTTAAAG CTCTCCCACG 2932 GCCTGACATT TGAAAATGGC GCCGTACGAG CAAAACTAGG ACCAGGACTT GGCACAGACG 2992 ACTCTGGTCG GTCCGTGGTT CGCACAGGTC GAGGACTTAG AGTTGCAAAC GGCCAAGTCC 3052 AGATCTTCAG CGGAAGAGGC ACCGCCATCG GCACTGATAG CAGCCTCACT CTCAACATCC 3112 GGGCGCCCCT ACAATTTTCT GGACCCGCCT TGACTGCTAG TTTGCAAGGC AGTGGTCCGA 3172 TTACTTACAA CAGCAACAAT GGCACTTTCG GTCTCTCTAT AGGCCCCGGA ATGTGGGTAG 3232 ACCAAAACAG ACTTCAGGTA AACCCAGGCG CTGGTTTAGT CTTCCAAGGA AACAACCTTG 3292 TCCCAAACCT TGCGGATCCG CTGGCTATTT CCGACAGCAA AATTAGTCTC AGTCTCGGTC 3352 CCGGCCTGAC CCAAGCTTCC AACGCCCTGA CTTTAAGTTT AGGAAACGGG CTTGAATTCT 3412 CCAATCAAGC CGTTGCTATA AAAGCGGGCC GGGGCTTACG CTTTGAGTCT TCCTCACAAG 3472 CTTTAGAGAG CAGCCTCACA GTCGGAAATG GCTTAACGCT TACCGATACT GTGATCCGCC 3532 CCAACCTAGG GGACGGCCTA GAGGTCAGAG ACAATAAAAT CATTGTTAAG CTGGGCGCGA 3592 ATCTTCGTTT TGAAAACGGA GCCGTAACCG CCGGCACCGT TAACCCTTCT GCGCCCGAGG 3652 CACCACCAAC TCTCACTGCA GAACCACCCC TCCGAGCCTC CAACTCCCAT CTTCAACTGT 3712 CCCTATCGGA GGGCTTGGTT GTGCATAACA ACGCCCTTGC TCTCCAACTG GGAGACGGCA 3772 TGGAAGTAAA TCAGCACGGA CTTACTTTAA GAGTAGGCTC GGGTTTGCAA ATGCGTGACG 3832 GCATTTTAAC AGTTACACCC AGCGGCACTC CTATTGAGCC CAGACTGACT GCCCCACTGA 3892 CTCAGACAGA GAATGGAATC GGGCTCGCTC TCGGCGCCGG CTTGGAATTA GACGAGAGCG 3952 CGCTCCAAGT AAAAGTTGGG CCCGGCATGC GCCTGAACCC TGTAGAAAAG TATGTAACCC 4012 TGCTCCTGGG TCCTGGCCTT AGTTTTGGGC AGCCGGCCAA CAGGACAAAT TATGATGTGC 4072 GCGTTTCTGT GGAGCCCCCC ATGGTTTTCG GACAGCGTGG TCAGCTCACA TTTTTAGTGG 4132 GTCACGGACT ACACATTCAA AATTCCAAAC TTCAGCTCAA TTTGGGACAA GGCCTCAGAA 4192 CTGACCCCGT CACCAACCAG CTGGAAGTGC CCCTCGGTCA AGGTTTGGAA ATTGCAGACG 4252 AATCCCAGGT TAGGGTTAAA TTGGGCGATG GCCTGCAGTT TGATTCACAA GCTCGCATCA 4312 CTACCGCTCC TAACATGGTC ACTGAAACTC TGTGGACCGG AACAGGCAGT AATGCTAATG 4372 TTACATGGCG GGGCTACACT GCCCCCGGCA GCAAACTCTT TTTGAGTCTC ACTCGGTTCA 4432 GCACTGGTCT AGTTTTAGGA AACATGACTA TTGACAGCAA TGCATCCTTT GGGCAATACA 4492 TTAACGCGGG ACACGAACAG ATCGAATGCT TTATATTGTT GGACAATCAG GGTAACCTAA 4552 AAGAAGGATC TAACTTGCAA GGCACTTGGG AAGTGAAGAA CAACCCCTCT GCTTCCAAAG 4612 CTGCTTTTTT GCCTTCCACC GCCCTATACC CCATCCTCAA CGAAAGCCGA GGGAGTCTTC 4672 CTGGAAAAAA TCTTGTGGGC ATGCAAGCCA TACTGGGAGG CGGGGGCACT TGCACTGTGA 4732 TAGCCACCCT CAATGGCAGA CGCAGCAACA ACTATCCCGC GGGCCAGTCC ATAATTTTCG 4792 TGTGGCAAGA ATTCAACACC ATAGCCCGCC AACCTCTGAA CCACTCTACA CTTACTTTTT 4852 CTTACTGGAC TTAAATAAGT TGGAAATAAA GAGTTAAACT GAATGTTTAA GTGCAACAGA 4912 CTTTTATTGG TTTTGGCTCA CAACAAATTA CAACAGCATA GACAAGTCAT ACCGGTCAAA 4972 CAACACAGGC TCTCGAAAAC GGGCTAACCG CTCCAAGAAT CTGTCACGCA GACGAGCAAG 5032 TCCTAAATGT TTTTTCACTC TCTTCGGGGC CAAGTTCAGC ATGTATCGGA TTTTCTGCTT 5092 ACACCTTT 5100 (2) INFORMATION FOR SEQ ID N0:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 88 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Leu Pro Leu Ser Cys Cys Met Pro Val Ser Val Ala Ser Phe Val Gin 1 5 10 15 Ser Lys Leu Thr Ser Ser Ala Ser Thr Pro Arg Pro Ala Ser Thr Ala 20 25 30 Cys Thr Leu Lys Lys Val Pro Pro Asp Ser Pro Trp Ser Thr Leu Thr 35 40 45 Pro Glu Leu Leu Cys Glu Trp Pro Tyr Thr Thr Arg Glu Leu Pro Ala 50 55 60 Ala Ser Ala Val Pro Val Pro Thr Pro Ser Ala Ser Pro Ser Ser Ser 65 70 75 80 Arg Pro Ser Val Pro Leu Thr Phe 85 (2) INFORMATION FOR SEQ ID N0:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1915..863 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: CCTCATCAAA CAACCCGTGG TGGGCACCAC CCACGTGGAA ATGCCTCGCA ACGAAGTCCT 60 AGAACAACAT CTGACCTCAC ATGGCGCTCA AATCGCGGGC GGAGGCGCTG CGGGCGATTA 120 CTTTAAAAGC CCCACTTCAG CTCGAACCCT TATCCCGCTC ACCGCCTCCT GCTTAAGACC 180 AGATGGAGTC TTTCAACTAG GAGGAGGCTC GCGTTCATCT TTCAACCCCC TGCAAACAGA 240 TTTTGCCTTC CACGCCCTGC CCTCCAGACC GCGCCACGGG GGCATAGGAT CCAGGCAGTT 300 TGTAGAGGAA TTTGTGCCCG CCGTCTACCT CAACCCCTAC TCGGGACCGC CGGACTCTTA 360 TCCGGACCAG TTTATACGCC ACTACAACGT GTACAGCAAC TCTGTGAGCG GTTATAGCTG 420 AGATTGTAAG ACTCTCCTAT CTGTCTCTGT GCTGCTTTTC CGCTTCAAGC CCCACAAGCA 480 TGAAGGGGTT TCTGCTCATC TTCAGCCTGC TTGTGCATTG TCCCCTAATT CATGTTGGGA 540 CCATTAGCTT CTATGCTGCA AGGCCCGGGT CTGAGCCTAA CGCGACTTAT GTTTGTGACT 600 ATGGAAGCGA GTCAGATTAC AACCCCACCA CGGTTCTGTG GTTGGCTCGA GAGACCGATG 660 GCTCCTGGAT CTCTGTTCTT TTCCGTCACA ACGGCTCCTC AACTGCAGCC CCCGGGGTCG 720 TCGCGCACTT TACTGACCAC AACAGCAGCA TTGTGGTGCC CCAGTATTAC CTCCTCAACA 780 ACTCACTCTC TAAGCTCTGC TGCTCATACC GGCACAACGA GCGTTCTCAG TTTACCTGCA 840 AACAAGCTGA CGTCCCTACC TGTCACGAGC CCGGCAAGCC GCTCACCCTC CGCGTCTCCC 900 CCGCGCTGGG AACTGCCCAC CAAGCAGTCA CTTGGTTTTT TCAAAATGTA CCCATAGCTA 960 CTGTTTACCG ACCTTGGGGC AATGTAACTT GGTTTTGTCC TCCCTTCATG TGTACCTTTA 1020 ATGTCAGCCT GAACTCCCTA CTTATTTACA ACTTTTCTGA CAAAACCGGG GGGCAATACA 1080 CAGCTCTCAT GCACTCCGGA CCTGCTTCCC TCTTTCAGCT CTTTAAGCCA ACGACTTGTG 1140 TCACCAAGGT GGAGGACCCG CCGTATGCCA ACGACCCGGC CTCGCCTGTG TGGCGCCCAC 1200 TGCTTTTTGC CTTCGTCCTC TGCACCGGCT GCGCGGTGTT GTTAACCGCC TTCGGTCCAT 1260 CGATTCTATC CGGTACCCGA AAGCTTATCT CAGCCCGCTT TTGGAGTCCC GAGCCCTATA 1320 CCACCCTCCA CTAACAGTCC CCCCATGGAG CCAGACGGAG TTCATGCCGA GCAGCAGTTT 1380 ATCCTCAATC AGATTTCCTG CGCCAACACT GCCCTCCAGC GTCAAAGGGA GGAACTAGCT 1440 TCCCTTGTCA TGTTGCATGC CTGTAAGCGT GGCCTCTTTT GTCCAGTCAA AACTTACAAG 1500 CTCAGCCTCA ACGCCTCGGC CAGCGAGCAC AGCCTGCACT TTGAAAAAAG TCCCTCCCGA 1560 TTCACCCTGG TCAACACTCA CGCCGGAGCT TCTGTGCGAG TGGCCCTACA CCACCAGGGA 1620 GCTTCCGGCA GCATCCGCTG TTCCTGTTCC CACGCCGAGT GCCTCCCCGT CCTCCTCAAG 1680 ACCCTCTGTG CCTTTAACTT TTTAGATTAG CTGAAAGCAA ATATAAAATG GTGTGCTTAC 1740 CGTAATTCTG TTTTGACTTG TGTGCTTGAT TTCTCCCCCT GCGCCGTAAT CCAGTGCCCC 1800 TCTTCAAAAC TCTCGTACCC TATGCGATTC GCATAGGCAT ATTTTCTAAA AGCTCTGAAG 1860 TCAACATCAC TCTCAAACAC TTCTCCGTTG TAGGTTACTT TCATCTACAG ATAA AGT 1917 Ser 1 CAT CCA CCG GTT AAC ATC ATG AAG AGA AGT GTG CCC CAG GAC TTT AAT 1965 His Pro Pro Val Asn lie Met Lys Arg Ser Val Pro Gin Asp Phe Asn . . 5 10 15 CTT GTG TAT CCG TAC AAG GCT AAG AGG CCC AAC ATC ATG CCG CCC TTT 2013 Leu Val Tyr Pro Tyr Lys Ala Lys Arg Pro Asn He Met Pro Pro Phe 20 25 30 TTT GAC CGC AAT GGC TTT GTT GAA AAC CAA GAA GCC ACG CTA GCC ATG 2061 Phe Asp Arg Asn Gly Phe Val Glu Asn Gin Glu Ala Thr Leu Ala Met 35 40 45 CTT GTG GAA AAG CCG CTC ACG TTC GAC AAG GAA GGT GCG CTG ACC CTG 2109 Leu Val Glu Lys Pro Leu Thr Phe Asp Lys Glu Gly Ala Leu Thr Leu 50 55 60 65 GGC GTC GGA CGC GGC ATC CGC ATT AAC CCC GCG GGG CTT CTG GAG ACA 2157 Gly Val Gly Arg Gly He Arg He Asn Pro Ala Gly Leu Leu Glu Thr 70 75 80 AAC GAC CTC GCG TCC GCT GTC TTC CCA CCG CTG GCC TCC GAT GAG GCC 2205 Asn Asp Leu Ala Ser Ala Val Phe Pro Pro Leu Ala Ser Asp Glu Ala 85 90 95 GGC AAC GTC ACG CTC AAC ATG TCT GAC GGG CTA TAT ACT AAG GAC AAC 2253 Gly Asn Val Thr Leu Asn Met Ser Asp Gly Leu Tyr Thr Lys Asp Asn 100 105 110 AAG CTA GCT GTC AAA GTA GGT CCC GGG CTG TCC CTC GAC TCC AAT AAT 2301 Lys Leu Ala Val Lys Val Gly Pro Gly Leu Ser Leu Asp Ser Asn Asn 115 120 125 GCT CTC CAG GTC CAC ACA GGC GAC GGG CTC ACG GTA ACC GAT GAC AAG 2349 Ala Leu Gin Val His Thr Gly Asp Gly Leu Thr Val Thr Asp Asp Lys 130 135 140 145 GTG TCT CTA AAT ACC CAA GCT CCC CTC TCG ACC ACC AGC GCG GGC CTC 2397 Val Ser Leu Asn Thr Gin Ala Pro Leu Ser Thr Thr Ser Ala Gly Leu 150 155 160 TCC CTA CTT CTG GGT CCC AGC CTC CAC TTA GGT GAG GAG GAA CGA CTA 2445 Ser Leu Leu Leu Gly Pro Ser Leu His Leu Gly Glu Glu Glu Arg Leu 165 170 175 ACA GTA AAC ACC GGA GCG GGC CTC CAA ATT AGC AAT AAC GCT CTG GCC 2493 Thr Val Asn Thr Gly Ala Gly Leu Gin He Ser Asn Asn Ala Leu Ala 180 185 190 GTA AAA GTA GGT TCA GGT ATC ACC GTA GAT GCT CAA AAC CAG CTC GCT 2541 Val Lys Val Gly Ser Gly He Thr Val Asp Ala Gin Asn Gin Leu Ala 195 200 205 GCA TCC CTG GGG GAC GGT CTA GAA AGC AGA GAT AAT AAA ACT GTC GTT 2589 Ala Ser Leu Gly Asp Gly Leu Glu Ser Arg Asp Asn Lys Thr Val Val 210 215 220 225 AAG GCT GGG CCC GGA CTT ACA ATA ACT AAT CAA GCT CTT ACT GTT GCT 2637 Lys Ala Gly Pro Gly Leu Thr He Thr Asn Gin Ala Leu Thr Val Ala 230 235 240 ACC GGG AAC GGC CTT CAG GTC AAC CCG GAA GGG CAA CTG CAG CTA AAC 2685 Thr Gly Asn Gly Leu Gin Val Asn Pro Glu Gly Gin Leu Gin Leu Asn 245 250 255 ATT ACT GCC GGT CAG GGC CTC AAC TTT GCA AAC AAC AGC CTC GCC GTG 2733 He Thr Ala Gly Gin Gly Leu Asn Phe Ala Asn Asn Ser Leu Ala Val 260 265 270 GAG CTG GGC TCG GGC CTG CAT TTT CCC CCT GGC CAA AAC CAA GTA AGC 2781 Glu Leu Gly Ser Gly Leu His Phe Pro Pro Gly Gin Asn Gin Val Ser 275 280 285 CTT TAT CCC GGA GAT GGA ATA GAC ATC CGA GAT AAT AGG GTG ACT GTG 2829 Leu Tyr Pro Gly Asp Gly He Asp He Arg Asp Asn Arg Val Thr Val 290 295 300 305 CCC GCT GGG CCA GGC CTG AGA ATG CTC AAC CAC CAA CTT GCC GTA GCT 2877 Pro Ala Gly Pro Gly Leu Arg Met Leu Asn His Gin Leu Ala Val Ala 310 315 320 TCC GGA GAC GGT TTA GAA GTC CAC AGC GAC ACC CTC CGG TTA AAG CTC 2925 Ser Gly Asp Gly Leu Glu Val His Ser Asp Thr Leu Arg Leu Lys Leu 325 330 335 TCC CAC GGC CTG ACA TTT GAA AAT GGC GCC GTA CGA GCA AAA CTA GGA 2973 Ser His Gly Leu Thr Phe Glu Asn Gly Ala Val Arg Ala Lys Leu Gly 340 345 350 CCA GGA CTT GGC ACA GAC GAC TCT GGT CGG TCC GTG GTT CGC ACA GGT 3021 Pro Gly Leu Gly Thr Asp Asp Ser Gly Arg Ser Val Val Arg Thr Gly 355 360 365 CGA GGA CTT AGA GTT GCA AAC GGC CAA GTC CAG ATC TTC AGC GGA AGA 3069 Arg Gly Leu Arg Val Ala Asn Gly Gin Val Gin He Phe Ser Gly Arg 370 375 380 385 GGC ACC GCC ATC GGC ACT GAT AGC AGC CTC ACT CTC AAC ATC CGG GCG 3117 Gly Thr Ala He Gly Thr Asp Ser Ser Leu Thr Leu Asn He Arg Ala 390 395 400 CCC CTA CAA TTT TCT GGA CCC GCC TTG ACT GCT AGT TTG CAA GGC AGT 3165 Pro Leu Gin Phe Ser Gly Pro Ala Leu Thr Ala Ser Leu Gin Gly Ser 405 410 415 GGT CCG ATT ACT TAC AAC AGC AAC AAT GGC ACT TTC GGT CTC TCT ATA 3213 Gly Pro He Thr Tyr Asn Ser Asn Asn Gly Thr Phe Gly Leu Ser He 420 425 430 GGC CCC GGA ATG TGG GTA GAC CAA AAC AGA CTT CAG GTA AAC CCA GGC 3261 Gly Pro Gly Met Trp Val Asp Gin Asn Arg Leu Gin Val Asn Pro Gly 435 440 445 GCT GGT TTA GTC TTC CAA GGA AAC AAC CTT GTC CCA AAC CTT GCG GAT 3309 Ala Gly Leu Val Phe Gin Gly Asn Asn Leu Val Pro Asn Leu Ala Asp 450 455 460 465 CCG CTG GCT ATT TCC GAC AGC AAA ATT AGT CTC AGT CTC GGT CCC GGC 3357 Pro Leu Ala He Ser Asp Ser Lys He Ser Leu Ser Leu Gly Pro Gly 470 475 480 CTG ACC CAA GCT TCC AAC GCC CTG ACT TTA AGT TTA GGA AAC GGG CTT 3405 Leu Thr Gin Ala Ser Asn Ala Leu Thr Leu Ser Leu Gly Asn Gly Leu 485 490 495 GAA TTC TCC AAT CAA GCC GTT GCT ATA AAA GCG GGC CGG GGC TTA CGC 3453 Glu Phe Ser Asn Gin Ala Val Ala He Lys Ala Gly Arg Gly Leu Arg 500 505 510 TTT GAG TCT TCC TCA CAA GCT TTA GAG AGC AGC CTC ACA GTC GGA AAT 3501 Phe Glu Ser Ser Ser Gin Ala Leu Glu Ser Ser Leu Thr Val Gly Asn 515 520 525 GGC TTA ACG CTT ACC GAT ACT GTG ATC CGC CCC AAC CTA GGG GAC GGC 3549 Gly Leu Thr Leu Thr Asp Thr Val He Arg Pro Asn Leu Gly Asp Gly 530 535 540 545 CTA GAG GTC AGA GAC AAT AAA ATC ATT GTT AAG CTG GGC GCG AAT CTT 3597 Leu Glu Val Arg Asp Asn Lys He He Val Lys Leu Gly Ala Asn Leu 550 555 560 CGT TTT GAA AAC GGA GCC GTA ACC GCC GGC ACC GTT AAC CCT TCT GCG 3645 Arg Phe Glu Asn Gly Ala Val Thr Ala Gly Thr Va Asn Pro Ser Ala 565 570 575 CCC GAG GCA CCA CCA ACT CTC ACT GCA GAA CCA CCC CTC CGA GCC TCC 3693 Pro Glu Ala Pro Pro Thr Leu Thr Ala Glu Pro Pro Leu Arg Ala Ser 580 585 590 AAC TCC CAT CTT CAA CTG TCC CTA TCG GAG GGC TTG GTT GTG CAT AAC 3741 Asn Ser His Leu Gin Leu Ser Leu Ser Glu Gly Leu Val Val His Asn 595 600 605 AAC GCC CTT GCT CTC CAA CTG GGA GAC GGC ATG GAA GTA AAT CAG CAC 3789 Asn Ala Leu Ala Leu Gin Leu Gly Asp Gly Met Glu Val Asn Gin His 610 615 620 625 GGA CTT ACT TTA AGA GTA GGC TCG GGT TTG CAA ATG CGT GAC GGC ATT 3837 Gly Leu Thr Leu Arg Val Gly Ser Gly Leu Gin Met Arg Asp Gly He 630 635 640 TTA ACA GTT ACA CCC AGC GGC ACT CCT ATT GAG CCC AGA CTG ACT GCC 3885 Leu Thr Val Thr Pro Ser Gly Thr Pro He Glu Pro Arg Leu Thr Ala 645 650 655 CCA CTG ACT CAG ACA GAG AAT GGA ATC GGG CTC GCT CTC GGC GCC GGC 3933 Pro Leu Thr Gin Thr Glu Asn Gly He Gly Leu Ala Leu Gly Ala Gly 660 665 670 TTG GAA TTA GAC GAG AGC GCG CTC CAA GTA AAA GTT GGG CCC GGC ATG 3981 Leu Glu Leu Asp Glu Ser Ala Leu Gin Val Lys Val Gly Pro Gly Met 675 680 685 CGC CTG AAC CCT GTA GAA AAG TAT GTA ACC CTG CTC CTG GGT CCT GGC 4029 Arg Leu Asn Pro Val Glu Lys Tyr Val Thr Leu Leu Leu Gly Pro Gly 690 695 700 705 CTT AGT TTT GGG CAG CCG GCC AAC AGG ACA AAT TAT GAT GTG CGC GTT 4077 Leu Ser Phe Gly Gin Pro Ala Asn Arg Thr Asn Tyr Asp Val Arg Val 710 715 720 TCT GTG GAG CCC CCC ATG GTT TTC GGA CAG CGT GGT CAG CTC ACA TTT 4125 Ser Val Glu Pro Pro Met Val Phe Gly Gin Arg Gly Gin Leu Thr Phe 725 730 735 TTA GTG GGT CAC GGA CTA CAC ATT CAA AAT TCC AAA CTT CAG CTC AAT 4173 Leu Val Gly His Gly Leu His He Gin Asn Ser Lys Leu Gin Leu Asn 740 745 750 TTG GGA CAA GGC CTC AGA ACT GAC CCC GTC ACC AAC CAG CTG GAA GTG 4221 Leu Gly Gin Gly Leu Arg Thr Asp Pro Val Thr Asn Gin Leu Glu Val 755 760 765 CCC CTC GGT CAA GGT TTG GAA ATT GCA GAC GAA TCC CAG GTT AGG GTT 4269 Pro Leu Gly Gin Gly Leu Glu He Ala Asp Glu Ser Gin Val Arg Val 770 775 780 785 AAA TTG GGC GAT GGC CTG CAG TTT GAT TCA CAA GCT CGC ATC ACT ACC 4317 Lys Leu Gly Asp Gly Leu Gin Phe Asp Ser Gin Ala Arg He Thr Thr 790 795 800 GCT CCT AAC ATG GTC ACT GAA ACT CTG TGG ACC GGA ACA GGC AGT AAT 4365 Ala Pro Asn Met Val Thr Glu Thr Leu Trp Thr Gly Thr Gly Ser Asn 805 810 815 GCT AAT GTT ACA TGG CGG GGC TAC ACT GCC CCC GGC AGC AAA CTC TTT 4413 Ala Asn Val Thr Trp Arg Gly Tyr Thr Ala Pro Gly Ser Lys Leu Phe 820 825 830 TTG AGT CTC ACT CGG TTC AGC ACT GGT CTA GTT TTA GGA AAC ATG ACT 4461 Leu Ser Leu Thr Arg Phe Ser Thr Gly Leu Val Leu Gly Asn Met Thr 835 840 845 ATT GAC AGC AAT GCA TCC TTT GGG CAA TAC ATT AAC GCG GGA CAC GAA 4509 He Asp Ser Asn Ala Ser Phe Gly Gin Tyr He Asn Ala Gly His Glu 850 855 860 865 CAG ATC GAA TGC TTT ATA TTG TTG GAC AAT CAG GGT AAC CTA AAA GAA 4557 Gin He Glu Cys Phe He Leu Leu Asp Asn Gin Gly Asn Leu Lys Glu 870 875 880 GGA TCT AAC TTG CAA GGC ACT TGG GAA GTG AAG AAC AAC CCC TCT GCT 4605 Gly Ser Asn Leu Gin Gly Thr Trp Glu Val Lys Asn Asn Pro Ser Ala 885 890 895 TCC AAA GCT GCT TTT TTG CCT TCC ACC GCC CTA TAC CCC ATC CTC AAC 4653 Ser Lys Ala Ala Phe Leu Pro Ser Thr Ala Leu Tyr Pro He Leu Asn 900 905 910 GAA AGC CGA GGG AGT CTT CCT GGA AAA AAT CTT GTG GGC ATG CAA GCC 4701 Glu Ser Arg Gly Ser Leu Pro Gly Lys Asn Leu Val Gly Met Gin Ala 915 920 925 ATA CTG GGA GGC GGG GGC ACT TGC ACT GTG ATA GCC ACC CTC AAT GGC 4749 He Leu Gly Gly Gly Gly Thr Cys Thr Val He Ala Thr Leu Asn Gly 930 935 940 945 AGA CGC AGC AAC AAC TAT CCC GCG GGC CAG TCC ATA ATT TTC GTG TGG 4797 Arg Arg Ser Asn Asn Tyr Pro Ala Gly Gin Ser He He Phe Val Trp 950 955 960 CAA GAA TTC AAC ACC ATA GCC CGC CAA CCT CTG AAC CAC TCT ACA CTT 4845 Gin Glu Phe Asn Thr He Ala Arg Gin Pro Leu Asn His Ser Thr Leu 965 970 975 ACT TTT TCT TAC TGG ACT TAAATAAGTT GGAAATAAAG AGTTAAACTG 4893 Thr Phe Ser Tyr Trp Thr 980 AATGTTTAAG TGCAACAGAC TTTTATTGGT TTTGGCTCAC AACAAATTAC AACAGCATAG 4953 ACAAGTCATA CCGGTCAAAC AACACAGGCT CTCGAAAACG GGCTAACCGC TCCAAGAATC 5013 TGTCACGCAG ACGAGCAAGT CCTAAATGTT TTTTCACTCT CTTCGGGGCC AAGTTCAGCA 5073 TGTATCGGAT TTTCTGCTTA CACCTTT 5100 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 983 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Ser His Pro Pro Val Asn He Met Lys Arg Ser Val Pro Gin Asp Phe 1 5 10 15 Asn Leu Val Tyr Pro Tyr Lys Ala Lys Arg Pro Asn He Met Pro Pro 20 25 30 Phe Phe Asp Arg Asn Gly Phe Val Glu Asn Gin Glu Ala Thr Leu Ala 35 40 45 Met Leu Val Glu Lys Pro Leu Thr Phe Asp Lys Glu Gly Ala Leu Thr 50 55 60 Leu Gly Val Gly Arg Gly He Arg He Asn Pro Ala Gly Leu Leu Glu 65 70 75 80 hr Asn Asp Leu Ala Ser Ala Val Phe Pro Pro Leu Ala Ser Asp Glu 85 90 95 Ala Gly Asn Val Thr Leu Asn Met Ser Asp Gly Leu Tyr Thr Lys Asp 100 105 110 Asn Lys Leu Ala Val Lys Val Gly Pro Gly Leu Ser Leu Asp Ser Asn 115 120 125 Asn Ala Leu Gin Val His Thr Gly Asp Gly Leu Thr Val Thr Asp Asp 130 135 140 Lys Val Ser Leu Asn Thr Gin Ala Pro Leu Ser Thr Thr Ser Ala Gly 145 150 155 160 Leu Ser Leu Leu Leu Gly Pro Ser Leu His Leu Gly Glu Glu Glu Arg 165 170 175 Leu Thr Val Asn Thr Gly Ala Gly Leu Gin He Ser Asn Asn Ala Leu 180 185 190 Ala Val Lys Val Gly Ser Gly He Thr Val Asp Ala Gin Asn Gin Leu 195 200 205 Ala Ala Ser Leu Gly Asp Gly Leu Glu Ser Arg Asp Asn Lys Thr Val 210 215 220 Val Lys Ala Gly Pro Gly Leu Thr He Thr Asn Gin Ala Leu Thr Val 225 230 235 240 Ala Thr Gly Asn Gly Leu Gin Val Asn Pro Glu Gly Gin Leu Gin Leu 245 250 255 Asn He Thr Ala Gly Gin Gly Leu Asn Phe Ala Asn Asn Ser Leu Ala 260 265 270 Val Glu Leu Gly Ser Gly Leu His Phe Pro Pro Gly Gin Asn Gin Val 275 280 285 Ser Leu Tyr Pro Gly Asp Gly He Asp He Arg Asp Asn Arg Val Thr 290 295 300 Val Pro Ala Gly Pro Gly Leu Arg Met Leu Asn His Gin Leu Ala Val 305 310 315 320 Ala Ser Gly Asp Gly Leu Glu Val His Ser Asp Thr Leu Arg Leu Lys 325 330 335 Leu Ser His Gly Leu Thr Phe Glu Asn Gly Ala Vat Arg Ala Lys Leu 340 345 350 Gly Pro Gly Leu Gly Thr Asp Asp Ser Gly Arg Ser Val Val Arg Thr 355 360 365 Gly Arg Gly Leu Arg Val Ala Asn Gly Gin Val Gin He Phe Ser Gly 370 375 380 ΛΓ9 Gly Thr Ala He Gly Thr Asp Ser Ser Leu Thr Leu Asn He Arg 385 390 395 400 Ala Pro Leu Gin Phe Ser Gly Pro Ala Leu Thr Ala Ser Leu Gin Gly 405 410 415 Ser Gly Pro He Thr Tyr Asn Ser Asn Asn Gly Thr Phe Gly Leu Ser 420 425 430 He Gly Pro Gly Met Trp Val Asp Gin Asn Arg Leu Gin Val Asn Pro 435 440 445 Gly Ala Gly Leu Val Phe Gin Gly Asn Asn Leu Val Pro Asn Leu Ala 450 455 460 Asp Pro Leu Ala He Ser Asp Ser Lys He Ser Leu Ser Leu Gly Pro 465 470 475 480 Gly Leu Thr Gin Ala Ser Asn Ala Leu Thr Leu Ser Leu Gly Asn Gly 485 490 495 Leu Glu Phe Ser Asn Gin Ala Val Ala He Lys Ala Gly Arg Gly Leu 500 505 510 Arg Phe Glu Ser Ser Ser Gin Ala Leu Glu Ser Ser Leu Thr Val Gly 515 520 525 Asn Gly Leu Thr Leu Thr Asp Thr Val He Arg Pro Asn Leu Gly Asp 530 535 540 Gly Leu Glu Val Arg Asp Asn Lys He He Val Lys Leu Gly Ala Asn 545 550 555 560 Leu Arg Phe Glu Asn Gly Ala Val Thr Ala Gly Thr Val Asn Pro Ser 565 570 575 Ala Pro Glu Ala Pro Pro Thr Leu Thr Ala Glu Pro Pro Leu Arg Ala 580 585 590 Ser Asn Ser His Leu Gin Leu Ser Leu Ser Glu Gly Leu Val Val His 595 600 605 Asn Asn Ala Leu Ala Leu Gin Leu Gly Asp Gly Met Glu Val Asn Gin 610 615 620 His Gly Leu Thr Leu Arg Val Gly Ser Gly Leu Gin Met Arg Asp Gly 625 630 635 640 He Leu Thr Val Thr Pro Ser Gly Thr Pro He Glu Pro Arg Leu Thr 645 650 655 Ala Pro Leu Thr Gin Thr Glu Asn Gly He Gly Leu Ala Leu Gly Ala 660 665 670 Gly Leu Glu Leu Asp Glu Ser Ala Leu Gin Val Lys Val Gly Pro Gly 675 680 685 Met Arg Leu Asn Pro Val Glu Lys Tyr Val Thr Leu Leu Leu Gly Pro 690 695 700 Gly Leu Ser Phe Gly Gin Pro Ala Asn Arg Thr Asn Tyr Asp Val Arg 705 710 715 720 Val Ser Val Glu Pro Pro Met Val Phe Gly Gin Arg Gly Gin Leu Thr 725 730 735 Phe Leu Val Gly His Gly Leu His He Gin Asn Ser Lys Leu Gin Leu 740 745 750 Asn Leu Gly Gin Gly Leu Arg Thr Asp Pro Val Thr Asn Gin Leu Glu 755 760 765 Val Pro Leu Gly Gin Gly Leu Glu He Ala Asp Glu Ser Gin Val Arg 770 775 780 Val Lys Leu Gly Asp Gly Leu Gin Phe Asp Ser Gin Ala Arg He Thr 785 790 795 800 Thr Ala Pro Asn Met Val Thr Glu Thr Leu Trp Thr Gly Thr Gly Ser 805 810 815 Asn Ala Asn Val Thr Trp Arg Gly Tyr Thr Ala Pro Gly Ser Lys Leu 820 825 830 Phe Leu Ser Leu Thr Arg Phe Ser Thr Gly Leu Val Leu Gly Asn Met 835 840 845 Thr He Asp Ser Asn Ala Ser Phe Gly Gin Tyr He Asn Ala Gly His 850 855 860 Glu Gin He Glu Cys Phe He Leu Leu Asp Asn Gin Gly Asn Leu Lys 865 870 875 880 Glu Gly Ser Asn Leu Gin Gly Thr Trp Glu Val Lys Asn Asn Pro Ser 885 890 895 Ala Ser Lys Ala Ala Phe Leu Pro Ser Thr Ala Leu Tyr Pro He Leu 900 905 910 Asn Glu Ser Arg Gly Ser Leu Pro Gly Lys Asn Leu Val Gly Met Gin 915 920 925 Ala He Leu Gly Gly Gly Gly Thr Cys Thr Val He Ala Thr Leu Asn 930 935 940 Gly Arg Arg Ser Asn Asn Tyr Pro Ala Gly Gin Ser He He Phe Val 945 950 955 960 Trp Gin Glu Phe Asn Thr He Ala Arg Gin Pro Leu Asn His Ser Thr 965 970 975 Leu Thr Phe Ser Tyr Trp Thr 980 (2) INFORMATION FOR SEQ ID N0:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 227 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i i ) MOLECULE TYPE: protein (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:27: Met Ser Lys Glu He Pro Thr Pro Tyr Met Trp Ser Tyr Gin Pro Gin 1 5 10 15 Met Gly Leu Ala Ala Gly Ala Ala Gin Asp Tyr Ser Thr Arg He Asn 20 25 30 Tyr Met Ser Ala Gly Pro His Met He Ser Arg Val Asn Gly He Arg 35 40 45 Ala His Arg Asn Arg He Leu Leu Glu Gin Ala Ala He Thr Thr Thr 50 55 60 Pro Arg Asn Asn Leu Asn Pro Arg Ser Trp Pro Ala Ala Leu Val Tyr 65 70 75 80 Gin Glu Ser Pro Ala Pro Thr Thr Val Val Leu Pro Arg Asp Ala Gin 85 90 95 Ala Glu Val Gin Met Thr Asn Ser Gly Ala Gin Leu Ala Gly Gly Phe 100 105 110 Arg His Arg Val Arg Ser Pro Gly Gin Gly He Thr His Leu Lys He 115 120 125 Arg Gly Arg Gly He Gin Leu Asn Asp Glu Ser Val Ser Ser Ser Leu 130 135 140 Gly Leu Arg Pro Asp Gly Thr Phe Gin He Gly Gly Ala Gly Arg Ser 145 150 155 160 Ser Phe Thr Pro Arg Gin Ala He Leu Thr Leu Gin Thr Ser Ser Ser 165 170 175 Glu Pro Arg Ser Gly Gly He Gly Thr Leu Gin Phe He Glu Glu Phe 180 185 190 Val Pro Ser Val Tyr Phe Asn Pro Phe Ser Gly Pro Pro Gly His Tyr 195 200 205 Pro Asp Gin Phe He Pro Asn Phe Asp Ala Val Lys Asp Ser Ala Asp 210 215 220 Gly Tyr Asp 225 (2) INFORMATION FOR SEQ ID N0:28: d " ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 128 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Met Thr Asp Thr Leu Asp Leu Glu Met Asp Gly He He Thr Glu Gin 1 5 10 15 Arg Leu Leu Glu Arg Arg Arg Ala Ala Ala Glu Gin Gin Arg Met Asn 20 25 30 Gin Glu Leu Gin Asp Met Val Asn Leu His Gin Cys Lys Arg Gly He 35 40 45 Phe Cys Leu Val Lys Gin Ala Lys Val Thr Tyr Asp Ser Asn Thr Thr 50 55 60 Gly His Arg Leu Ser Tyr Lys Leu Pro Thr Lys Arg Gin Lys Leu Val 65 70 75 80 Val Met Val Gly Glu Lys Pro He Thr He Thr Gin His Ser Val Glu 85 90 95 Thr Glu Gly Cys He His Ser Pro Cys Gin Gly Pro Glu Asp Leu Cys 100 105 110 Thr Leu He Lys Thr Leu Cys Gly Leu Lys Asp Leu He Pro Phe Asn 115 120 125 (2) INFORMATION FOR SEQ ID N0:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 582 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro 1 5 10 15 Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro 20 25 30 Phe Val Ser Pro Asn Gly Phe Gin Glu Ser Pro Pro Gly Val Leu Ser 35 40 45 Leu Arg Val Ser Glu Pro Leu Asp Thr Ser His Gly Met Leu Ala Leu 50 55 60 Lys Met Gly Ser Gly Leu Thr Leu Asp Lys Ala Gly Asn Leu Thr Ser 65 70 75 80 Gin Asn Val Thr Thr Val Thr Gin Pro Leu Lys Lys Thr Lys Ser Asn 85 90 95 He Ser Leu Asp Thr Ser Ala Pro Leu Thr He Thr Ser Gly Ala Leu 100 105 110 Thr Val Ala Thr Thr Ala Pro Leu He Val Thr Ser Gly Ala Leu Ser 115 120 125 Val Gin Ser Gin Ala Pro Leu Thr Val Gin Asp Ser Lys Leu Ser He 130 135 140 Ala Thr Lys Gly Pro He Thr Val Ser Asp Gly Lys Leu Ala Leu Gin 145 150 155 160 Thr Ser Ala Pro Leu Ser Gly Ser Asp Ser Asp Thr Leu Thr Val Thr 165 170 175 Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly He Asn Met 180 185 190 Glu Asp Pro He Tyr Val Asn Asn Gly Lys He Gly He Lys He Ser 195 200 205 Gly Pro Leu Gin Val Ala Gin Asn Ser Asp Thr Leu Thr Val Val Thr 210 215 220 Gly Pro Gly Val Thr Val Glu Gin Asn Ser Leu Arg Thr Lys Val Ala 225 230 235 240 Gly Ala He Gly Tyr Asp Ser Ser Asn Asn Met Glu He Lys Thr Gly 245 250 255 Gly Gly Met Arg He Asn Asn Asn Leu Leu He Leu Asp Val Asp Tyr 260 265 270 Pro Phe Asp Ala Gin Thr Lys Leu Arg Leu Lys Leu Gly Gin Gly Pro 275 280 285 Leu Tyr He Asn Ala Ser His Asn Leu Asp He Asn Tyr Asn Arg Gly 290 295 300 Leu Tyr Leu Phe Asn Ala Ser Asn Asn Thr Lys Lys Leu Glu Vat Ser 305 310 315 320 He Lys Lys Ser Ser Gly Leu Asn Phe Asp Asn Thr Ala He Ala He 325 330 335 Asn Ala Gly Lys Gly Leu Glu Phe Asp Thr Asn Thr Ser Glu Ser Pro 340 345 350 Asp He Asn Pro He Lys Thr Lys He Gly Ser Gly He Asp Tyr Asn 355 360 365 Glu Asn Gly Ala Met He Thr Lys Leu Gly Ala Gly Leu Ser Phe Asp 370 375 380 Asn Ser Gly Ala He Thr He Gly Asn Lys Asn Asp Asp Lys Leu Thr 385 390 395 400 Leu Trp Thr Thr Pro Asp Pro Ser Pro Asn Cys Arg He His Ser Asp 405 410 415 Asn Asp Cys Lys Phe Thr Leu Val Leu Thr Lys Cys Gly Ser Gin Val 420 425 430 Leu Ala Thr Val Ala Ala Leu Ala Val Ser Gly Asp Leu Ser Ser Met 435 440 445 Thr Gly Thr Val Ala Ser Val Ser He Phe Leu Arg Phe Asp Gin Asn 450 455 460 Gly Val Leu Met Glu Asn Ser Ser Leu Lys Lys His Tyr Trp Asn Phe 465 470 475 480 Arg Asn Gly Asn Ser Thr Asn Ala Asn Pro Tyr Thr Asn Ala Val Gly 485 490 495 Phe Met Pro Asn Leu Leu Ala Tyr Pro Lys Thr Gin Ser Gin Thr Ala 500 505 510 Lys Asn Asn He Val Ser Gin Val Tyr Leu His Gly Asp Lys Thr Lys 515 520 525 Pro Met He Leu Thr He Thr Leu Asn Gly Thr Ser Glu Ser Thr Glu 530 535 540 Thr Ser Glu Val Ser Thr Tyr Ser Met Ser Phe Thr Trp Ser Trp Glu 545 550 555 560 Ser Gly Lys Tyr Thr Thr Glu Thr Phe Ala Thr Asn Ser Tyr Thr Phe 565 570 575 Ser Tyr He Ala Gin Glu 580 (2) INFORMATION FOR SEQ ID N0:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /note= "This position is X2." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /note= "This position is X13." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /note= "This position is X2." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Cys Xaa Cys Xaa Cys Xaa Cys 1 5 (2) INFORMATION FOR SEQ ID N0:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0:31: Gin Ser Ser Xaa Ser Thr Ser 1 5 (2) INFORMATION FOR SEQ ID N0:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0:32: Pro Leu Leu Phe Ala Phe Val Leu Cys Thr Gly Cys Ala Val Leu Leu 1 5 10 15 Thr Ala Phe Gly Pro Ser He Leu Ser Gly Thr 20 25 (2) INFORMATION FOR SEQ ID N0:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 57 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Glu Glu Val Thr Ser His Phe Phe Leu Asp Cys Pro Glu Asp Pro Ser 1 5 10 15 Arg Glu Cys Ser Ser Cys Gly Phe His Gin Ala Gin Ser Gly He Pro 20 25 30 Gly He Met Cys Ser Leu Cys Tyr Met Arg Gin Thr Tyr His Cys He 35 40 45 Tyr Ser Pro Val Ser Glu Glu Glu Met 50 55 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:34: Val Asp Leu Glu Cys His Glu Val Leu Pro Pro Ser 1 5 10

Claims: Claims 1. A live recombinant bovine adenovirus vector (BAV) system selected from the group consisting of: (a) a system wherein part or all of the El gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof; (b) a system wherein a part or all of the E3 gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof; and (c) a system wherein part or all of the El gene region and part or all of the E3 gene region are deleted and a heterologous nucleotide sequence encoding a foreign gene or fragment thereof is inserted into at least one of the deletions. 2. The BAV system of claim 1 which is a bovine adenovirus type 3. 3. The BAV system of claim 1 wherein (a) a recombinant BAV wherein part or all of the El gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof. 4. The BAV system of claim 1 wherein (b) a recombinant BAV wherein a part or all of the E3 gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof. 5. The BAV system of claim 1 wherein the foreign nucleotide sequence is with or without the control of an exogenous promoter. 6. The BAV system of claim 1 wherein (c) a system wherein part or all of the El gene region and part or all of the E3 gene region are deleted and a heterologous nucleotide sequence encoding a foreign gene or fragment thereof is inserted into at least one of the deletions. 7. A recombinant vector system comprising the entire BAV genome and a plasmid capable of generating a recombinant virus by in vivo recombination following cotransfection of a suitable cell line comprising the entire BAV genome representing the wild-type BAV genome and a plasmid comprising an adenovirus left end nucleotide sequences containing the ElA gene region or a plasmid comprising adenovirus right end sequences containing the E3 gene region, the plasmid with a heterologous nucleotide sequence encoding a foreign gene or fragment thereof substituted for part or all of the El and/or E3 gene regions, respectively. 8. A recombinant bovine adenovirus vector system comprising two plasmids capable of generating a recombinant virus by in vivo recombination following cotransfection of a cell line comprising (1) a first plasmid comprising the entire BAV genome except for a deletion of part or all of the El and/or E3 gene regions, and (2) a second plasmid comprising BAV left or right end nucleotide sequences containing the El or E3 gene regions, respectively, having a heterologous nucleotide sequence encoding a foreign gene or fragment thereof inserted for the deletion of a part or all of the El or E3 gene regions. .9. A live viable recombinant bovine adenovirus (BAV) comprising a deletion of part or all of the El gene region, a deletion of part or all of the E3 gene region or deletion of both, and inserted into at least one deletion a heterologous nucleotide sequence coding for a polypeptide or an antigenic determinant produced by a disease causing organism. 10. A live viable recombinant bovine adenovirus (BAV) for producing an immune response in a mammalian host comprising: (1) a live bovine adenovirus (BAV) modified to contain a heterologous nucleotide sequence coding for a polypeptide or an antigenic determinant corresponding to the desired immune response in association with or without (2) an effective promoter for said nucleotide sequence to provide expression of said antigenic determinant in immunogenic non-pathogenic quantities. 11. A live recombinant bovine adenovirus expression system comprising a deletion of all or part of the El gene region or all or part of the E3 gene region, or both deletions and inserted in at least one deletion a heterologous nucleotide sequence coding for a foreign gene or fragment thereof under control of an expression promoter with or without one or more polyadenylation signal. 12. A recombinant mammalian cell line comprising bovine adenovirus (BAV) El gene region, said recombinant cell line thereby capable of allowing replication therein of a bovine adenovirus comprising an El deletion which may or may not be replaced by a heterologous or homologous nucleotide sequence encoding a foreign gene or fragment thereof. 13. The cell line of claim 12 which is a bovine cell line. 14. The recombinant mammalian cell line of claim 12 wherein the heterologous or homologous nucleotide sequence encoding the foreign gene or fragment thereof is selected from the group consisting of a bovine adenovirus (BAV) El polypeptide, , a BAV El-associated polypeptide, a growth factor, a cellular receptor or other cellular polypeptide. 15. A recombinant mammalian cell line comprising bovine adenovirus El genes, said recombinant cell line thereby capable of allowing DNA- mediated transfection to generate a recombinant bovine adenovirus (BAV) selected from the group consisting of: (a) a recombinant BAV wherein part or all of the El gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof, (b) a recombinant BAV wherein part or all of the E3 gene region is replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof, (c) a recombinant BAV wherein part or all of the El gene region and part or all of the E3 gene region are deleted and inserted into at least one deletion a heterologous nucleotide sequence encoding a foreign gene or fragment thereof, (d) a recombinant BAV wherein part or all of the El gene region and/or part or all of the E3 gene region are deleted and inserted into at least one deletion a heterologous nucleotide sequence encoding more than one foreign gene or fragment thereof to produce a recombinant fusion protein, and (e) a mutant BAV wherein part or all of the El gene region and/or part or all of the E3 gene region are deleted. 16. A method of preparing a recombinant polypeptide or fragment thereof which comprises: (1) infecting the mammalian cell line of claim 12, with a recombinant bovine adenovirus comprising a deletion of part or all of the El gene region and/or part or all of the E3 gene region and inserted into at least one deletion a heterologous nucleotide sequence encoding the polypeptide or fragment thereof, (2) replicating the recombinant virus in a recombinant cell line under conditions to provide for expression of the polypeptide, and (3) recovering the recombinant polypeptide or antigenic fragment thereof. 17. A method of isolating a polypeptide which comprises: (1) replicating a recombinant mammalian cell line of claim 12 under conditions to provide for expression of the polypeptide, and (2) recovering the polypeptide or fragment thereof. 18. A method for eliciting an immune response in a mammalian host to protect against an infection comprising: administering a vaccine composition comprising a live recombinant BAV of claim 1 wherein the foreign gene or fragment encodes an antigen with or without a pharmaceutically acceptable carrier. 19. A method for eliciting an immune response in a mammalian host to protect against an infection comprising: administering a vaccine comprising a recombinant polypeptide or fragment thereof prepared by a method of claim 16 with or without a pharmaceutically acceptable carrier. 20. A vaccine for protecting a mammalian host against infection comprising a live recombinant adenovirus of claim 1 wherein the foreign gene or fragment encodes an antigen with or without a pharmaceutically acceptable carrier. 21. A vaccine for protecting a mammalian host against infection comprising a recombinant antigen prepared by a method of claim 16 with or without a pharmaceutically acceptable carrier. 22. A mutant bovine adenovirus (BAV) comprising a deletion of part or all of El and/or a deletion of part or all of E3. 23. A method for providing gene therapy to a mammal in need thereof to control a gene deficiency which comprises administering to said mammal a live recombinant bovine adenovirus containing a foreign nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in the target organ or tissue.

Inventors: BABIUK LORNE A, GRAHAM FRANK L, MITTAL SURESH K, PREVEC LUDVIK, BABIUK, LORNE, A., GRAHAM, FRANK, L., MITTAL, SURESH, K., PREVEC, LUDVIK
Applicants: UNIV SASKATCHEWAN, UNIVERSITY OF SASKATCHEWAN
Application year: 1994
Main classification: C12N15
IPC codes: A61K48, C07K14, C12N7, C12N15